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ABSTRACT 
Intermittent hypoxia (IH) is a major pathophysiological manifestation of 
obstructive sleep apnea (OSA). Previous studies have implicated IH in mediating 
many pathophysiological outcomes associated with OSA. Only few studies have 
examined IH-induced alterations to central signaling pathways important in 
cardiovascular and metabolic phenotypes associated with OSA. This thesis 
employed a rodent model of IH to examine changes to molecular neural pathways 
associated with metabolic and cardiovascular pathophysiological outcomes of OSA. 
Acute IH induces a specific negative body energy balance phenotype. This is 
concomitant to a reduction in body weight and food intake, with an elevation in food 
conversion efficiency. Increased plasma leptin concentrations also occur 
immediately following acute IH, which is mirrored by increased activation of leptin-
signaling and satiety-inducing molecules within the arcuate nucleus of the 
hypothalamus (ARC). The effects observed on body energy balance following acute 
IH are attenuated in the homozygous leptin-deficient KILO rat, suggesting the 
importance of elevated leptin in mediating the body energy balance responses 
following acute IH. Over chronic IH exposure, rats have a complex metabolic 
phenotype, which includes a reduction in body weight and body fat mass. 
Throughout the chronic period of exposure, animals develop a resistance to the 
hormone leptin, the primary hallmark for the development of obesity. This is 
concomitant to increased food intake and fat-standardized plasma leptin 
concentrations. Within ARC, leptin-associated signaling pathways are not activated, 
and there is less protein content of satiety-inducing proteins. There is also more 
protein of a negative regulator of leptin signaling in ARC following chronic IH. 
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Chronic IH also elevates resting blood pressure and reduces baroreceptor reflex 
gain, which are associated with reduced neuroplasticity markers within the nucleus 
of the solitary tract. Some of the changes observed over acute IH in these markers 
are leptin-dependent, as they are abolished in the leptin-deficient KILO rat. Leptin 
appears to interact at the major sensory site for IH, the carotid body, with the renin-
angiotensin system, as blockers captopril and losartan inhibit IH-induced alterations 
to leptin signaling molecules. This thesis shows potential mechanisms by which IH 
can induce cardiovascular and metabolic phenotypes observed in OSA patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
 
KEYWORDS 
Intermittent hypoxia 
Leptin 
Body energy balance 
Peripheral chemoreceptor reflex 
Neuroplasticity 
 v 
 
CO-AUTHORSHIP 
Chapters 3 and 5 of this thesis use leptin-deficient KILO rats produced and provided 
in part by Dr. A McCoy from Sigma Advanced Genetic Engineering Labs (St. Louis, 
MO, USA).  
In Chapter 3, Dr. D. Jones provided the wild-type Sprague-Dawley rats, as well as 
editorial review of the manuscript.  
In Chapter 6 of this thesis, S. Messenger performed some of the western blots in 
captopril-treated carotid bodies and provided editorial review of the manuscript. 
All other experiments conducted as part of this thesis were performed by Jason 
Moreau under the supervision of Dr. John Ciriello at the University of Western 
Ontario. 
  
  
 vi 
 
 
 
 
 
 
 
This thesis is dedicated to  
Paul Douglas Moreau and Diane Lynn Moreau 
 
 
 
Your love and support knows no bounds.  
I couldn’t have done this without you. 
 
 
 
 
 
 vii 
 
ACKNOWLEDGEMENTS 
It has been a remarkable journey completing my Ph.D. over the last number 
of years here at Western. Graduate school is not for the faint of heart, and may be 
best suited for those who are willing to go somewhat crazy. Nonetheless, my time in 
the Department of Physiology and Pharmacology has been filled with a lion’s share 
of extremes: ups and downs. I am a better person and scholar for it. It is now that I 
would like to express my utmost thanks to some of the people that have helped me 
complete this journey. 
 First, I would like to acknowledge my supervisor Dr. John Ciriello. You took a 
chance on a third-year Physiology student that was completely unsure of his future 
direction. You exposed me to an experience that changed my life, and honed my 
future. You invested time, energy and probably some of your sanity guiding and 
supporting me. Importantly, you provided me a framework to allow my mind to 
wander and for me to experiment with new ideas. I attribute my sense of scientific 
wonderment and curiosity to this framework. When I wandered too far, you reined 
me in and showed me how to “put the puck in the net”. You have provided me with 
more opportunities to develop my career than any other person in my life, and for 
this simple fact, I am indebted to you. I would also like to acknowledge the role you 
have played in my life as a role model. Frankly, I respect you as both a professor 
(and all that the title entails), but also as a person, and have often looked to you for 
personal guidance, which you have masterfully provided. I can’t imagine having 
traveled along this journey without you. 
 viii 
 
 Second, I must give my many thanks to my advisory committee members, 
past and present. Drs. Dan Hardy, Doug Jones, Morris Karmazyn, Peter Ossenkopp 
and Andy Watson, you have provided me with excellent feedback throughout the 
course of my studies. You have refined my communication skills – there is a 
difference between increased and more – and elevated my knowledge about data 
presentation and analysis. On a more personal note, I have had many excellent 
private meetings with each one of you, and have always had solace knowing that I 
can reach out to my committee should problems arise. You are all excellent 
researchers, and I could only hope to, one day, attain your level of knowledge and 
professionalism. 
 To the former and ongoing members of the Ciriello Lab, I thank you for your 
support. Waseem, we have been down a long road together every step of the way, 
and it’s been a pleasure. Scott, you are a great researcher and a good friend, just 
don’t ask me to move any Flammables cabinets. Megan, you always brought a smile 
to my face, especially on bright-shirt Fridays during the miserable winter months we 
shared together in the lab. To the other Ciriello Lab students, volunteers and 
research associates: thank you for being a pleasure to teach and for providing me 
the opportunity to share the pleasure of research with you. 
 To family, thank you for sticking with me through the thick and thin of 
graduate school. You know better than most about the struggles and successes I 
have experienced throughout this journey, and I am forever grateful for your love 
and support. Mom and Dad, you have been my biggest fans and advocates since 
always, and all that you gave me during this experience has been nothing short of 
 ix 
 
miraculous. You have provided me with constant feedback, always telling me how 
proud you are of my accomplishments, but I feel like I could never emote quite how 
much your support and love meant to me, so I begin by dedicating this thesis to you. 
Kate and Dan, you have always been there to listen to my complaints and bragging, 
usually followed by playful mockery. It’s grounded me and kept me focused on my 
goals. “MOREAU” will go on the spine of this thesis, and I feel like that is suiting 
considering its completion was as much dependent on my family as it was on me.  
 To my friends, I can finally tell you I am done. It turns out I won’t be in school 
forever, after all. Thank you for your support and polite head-nodding when I talked 
about my work. I guess now all I have left to do is buy that island. 
 Finally, to Elyse, you have been closest to me during this journey. You have 
been my traveling companion. Your love and support has provided me with the 
motivation and clarity to succeed within the Ph.D. program. I could not have 
completed the writing of this thesis without your daily support and words of 
encouragement. You have always taught me that ambition to succeed is nice, but 
you have to be happy in your life outside of work as well. For the last 8 years, you 
have provided me with much of that outside happiness, and I know you will be the 
source of it for my future endeavours. 
 x 
 
TABLE OF CONTENTS 
ABSTRACT .......................................................................................................... ii 
KEYWORDS ........................................................................................................ iv 
CO-AUTHORSHIP ............................................................................................... v 
DEDICATION ....................................................................................................... vi 
ACKNOWLEDGEMENTS .................................................................................... vii 
TABLE OF CONTENTS ....................................................................................... x 
LIST OF TABLES ................................................................................................ xxi 
LIST OF FIGURES ............................................................................................... xxii 
LIST OF ABBREVIATIONS ................................................................................. xxiv 
CHAPTER 1: INTRODUCTION AND BACKGROUND ........................................ 1 
1. INTRODUCTION .................................................................................. 2 
1.1 OBSTRUCTIVE SLEEP APNEA ..................................................... 2 
1.1.1   Disease description .............................................................. 2 
1.1.2   Diagnosis and treatment of OSA .......................................... 3 
1.1.3   Prevalence of OSA ............................................................... 5 
1.1.4   Comorbidities of OSA ........................................................... 5 
1.1.4.1 Cardiovascular comorbidities ................................... 6 
1.1.4.1.1 Systemic hypertension ................................ 6 
1.1.4.1.2 Pulmonary hypertension ............................. 6 
 xi 
 
1.1.4.1.3 Cardiac Arrhythmias ................................... 7 
1.1.4.1.4 Stroke ......................................................... 8 
 1.1.4.2 Metabolic comorbidities ............................................ 8 
1.1.4.2.1 Obesity........................................................ 8 
1.1.4.2.2 Metabolic syndrome .................................... 9 
1.1.4.2.3 Insulin resistance ........................................ 10 
1.1.4.2.4 Dyslipidemia ............................................... 10  
1.1.4.3 Neurocognitive comorbidities ................................... 11 
1.1.5 Intermittent hypoxia as a model for OSA ................................ 12 
1.2 HYPOXIA-SENSING AND THE CARDIOVASCULAR SYSTEM ......... 13 
 1.2.1 Peripheral arterial chemoreceptors ........................................ 13 
 1.2.2 Chemoreceptor reflex and the sympathetic nervous  
system ............................................................................................. 14 
 1.2.3 Intermittent hypoxia and cardiorespiratory reflexes ................ 15 
 1.2.3.1 Effect on peripheral chemoreceptor reflex ................ 15 
 1.2.3.2 Effect on arterial baroreceptor reflex ........................ 17 
 1.3 HYPOXIA AND BODY ENERGY BALANCE ....................................... 18 
 1.3.1 Cellular energy responses to hypoxia .................................... 18 
1.3.1.1 Hypoxia-inducible factor 1 ........................................ 19 
1.3.1.2 Generation of ATP .................................................... 19 
1.3.2 Organism energy responses to hypoxia ................................. 21 
 xii 
 
 1.3.2.1 Body weight and food intake .................................... 21 
1.3.2.2 Lipid metabolism....................................................... 21 
1.3.2.3 Glucose metabolism ................................................. 22 
1.4 LEPTIN SIGNALING ............................................................................ 23 
1.4.1 Leptin and its receptors .......................................................... 23 
1.4.2 Regulation of leptin secretion ................................................. 25 
1.4.3 Leptin-related signaling pathways .......................................... 27 
1.4.4 Leptin and energy balance ..................................................... 28 
 1.4.4.1 Food intake ............................................................... 28 
 1.4.4.2 Energy expenditure .................................................. 31 
1.4.5 Leptin and sympathetic nervous activity ................................. 32 
1.4.6 Leptin and neuroplasticity....................................................... 33 
1.4.7 Leptin resistance .................................................................... 35 
1.5 HYPOTHESIS AND OBJECTIVES ...................................................... 37 
 1.5.1 Hypothesis ............................................................................. 37 
 1.5.2 Objectives .............................................................................. 37 
1.6 REFERENCES .................................................................................... 39 
CHAPTER 2: EFFECTS OF ACUTE INTERMITTENT HYPOXIA ON ENERGY 
BALANCE AND HYPOTHALAMIC FEEDING PATHWAYS ............................... 60 
2. CHAPTER 2 ......................................................................................... 61 
 
 xiii 
 
2.1 CHAPTER SUMMARY ........................................................................ 61 
2.2 INTRODUCTION ................................................................................. 62 
2.3 METHODS AND MATERIAL ............................................................... 64 
2.3.1 Animals .................................................................................. 64 
2.3.2 Groups ................................................................................... 64 
2.3.3 IH or Norm exposure .............................................................. 65 
2.3.4 Measures of body weight, food intake and water intake ......... 65 
2.3.5 Locomotion assay .................................................................. 66 
2.3.6 Blood glucose measurement .................................................. 66 
2.3.7 Plasma collection and enzyme immunoassays ...................... 67 
2.3.8 Tissue collection and preparation ........................................... 67 
2.3.9 Western blots ......................................................................... 68 
2.3.10 Immunohistochemistry ......................................................... 70 
2.3.11 Immunofluorescence ............................................................ 71 
2.3.12 Antibodies ............................................................................ 72 
2.3.13 Statistics and analysis .......................................................... 73 
2.4 RESULTS ............................................................................................ 74 
2.4.1 Body weight, adipose tissue mass, food and fluid intake  
and locomotion after acute IH ......................................................... 75 
2.4.2 Plasma leptin, adiponectin and leptin:adiponectin ratio  
are  altered by acute IH ................................................................... 77 
 xiv 
 
2.4.3 Adipose tissue content of leptin and adiponectin protein is  
altered as a result of acute IH exposure .......................................... 82 
2.4.4 IH exposure alters signals associated with leptin signaling    
within ARC ...................................................................................... 82 
2.4.5 Acute IH activates POMC-containing neurons and  
increases POMC within ARC .......................................................... 85 
2.5 DISCUSSION ...................................................................................... 90 
2.6 FOOTNOTES ...................................................................................... 95 
2.7 REFERENCES .................................................................................... 96 
CHAPTER 3: ACUTE INTERMITTENT HYPOXIA DOES NOT ALTER  
ENERGY BALANCE IN THE LEPTIN-DEFICIENT KILO RAT............................ 101 
3. CHAPTER 3 ........................................................................................... 102 
3.1 CHAPTER SUMMARY ........................................................................ 102 
3.2 INTRODUCTION ................................................................................. 103 
3.3 METHODS AND MATERIAL ............................................................... 105 
3.3.1 Animals and study design ...................................................... 105 
3.3.2 IH and normoxic exposures .................................................... 105 
3.3.3 Measures of body weight, food intake and water intake ......... 106 
3.3.4 Locomotion assay .................................................................. 106 
3.3.5 Plasma collection and enzyme immunoassays ...................... 107 
3.3.6 Tissue collection and preparation ........................................... 107 
3.3.7 Western blots ......................................................................... 108 
 xv 
 
3.3.8 Antibodies .............................................................................. 109 
3.3.9 Statistics and analysis ............................................................ 110 
3.4 RESULTS ............................................................................................ 111 
3.4.1 Food and water intake ............................................................ 111 
3.4.2 Food conversion efficiency ..................................................... 111 
3.4.3 Body weight changes ............................................................. 114 
3.4.4 Fat pad mass ......................................................................... 115 
3.4.5 Locomotion ............................................................................. 118 
3.4.6 Plasma leptin concentration ................................................... 118 
3.4.7 Plasma angiotensin II concentration ...................................... 121 
3.4.8 ARC leptin signaling molecules .............................................. 121 
3.5 DISCUSSION ...................................................................................... 127 
3.6 FOOTNOTES ...................................................................................... 130 
3.7 REFERENCES .................................................................................... 131 
CHAPTER 4: CHRONIC INTERMITTENT HYPOXIA INDUCES LEPTIN 
RESISTANCE ...................................................................................................... 133 
4. CHAPTER 4 ........................................................................................... 134 
4.1 CHAPTER SUMMARY ........................................................................ 134 
4.2 INTRODUCTION ................................................................................. 136 
4.3 METHODS AND MATERIAL ............................................................... 138 
4.3.1 Animals .................................................................................. 138 
 xvi 
 
4.3.2 CIH and normoxic exposures ................................................. 138 
4.3.3 Measurement of body weight, food and water intake ............. 139 
4.3.4 Locomotion assay .................................................................. 139 
4.3.5 Leptin resistance assay .......................................................... 140 
4.3.6 Plasma collection and enzyme immunoassays ...................... 140 
4.3.7 Tissue collection and preparation ........................................... 141 
4.3.8 Western blots ......................................................................... 142 
4.3.9 Antibodies .............................................................................. 143 
4.3.10 Statistics and analysis .......................................................... 144 
4.4 RESULTS ............................................................................................ 145 
4.4.1 Body weight changes ............................................................. 145 
4.4.2 Fat pad mass changes ........................................................... 146 
4.4.3 Food intake ............................................................................ 149 
4.4.4 Food conversion efficiency ..................................................... 149 
4.4.5 Locomotion changes .............................................................. 150 
4.4.6 Plasma leptin concentrations ................................................. 150 
4.4.7 Leptin resistance induced by CIH ........................................... 150 
4.4.8 Protein expression of leptin receptors after CIH ..................... 153 
4.4.9 Proteins associated with leptin signaling within the ARC ....... 153 
4.4.10 Protein markers associated with leptin resistance in ARC ... 158 
 xvii 
 
4.5 DISCUSSION ...................................................................................... 163 
4.6 FOOTNOTES ...................................................................................... 169 
4.7 REFERENCES .................................................................................... 170 
CHAPTER 5: INTERMITTENT HYPOXIA INDUCES CHANGES IN  
PROTEIN EXPRESSION OF NEUROPLASTICITY MARKERS IN THE  
NUCLEUS OF THE SOLITARY TRACT .............................................................. 174 
5. CHAPTER 5 ........................................................................................... 175 
5.1 CHAPTER SUMMARY ........................................................................ 175 
5.2 INTRODUCTION ................................................................................. 177 
5.3 METHODS AND MATERIAL ............................................................... 179 
5.3.1 Animals .................................................................................. 179 
5.3.2 IH or normoxic exposure ........................................................ 179 
5.3.3 Hemodynamic recordings....................................................... 180 
5.3.4 Tissue collection and preparation ........................................... 180 
5.3.5 Western blots ......................................................................... 181 
5.3.6 Antibodies .............................................................................. 182 
5.3.7 Statistics and analysis ............................................................ 182 
5.4 RESULTS ............................................................................................ 184 
5.4.1 AP following exposure to IH ................................................... 184 
5.4.2 BDNF protein expression in NTS following IH ........................ 184 
5.4.3 TrkB protein expression in NTS following IH .......................... 185 
 xviii 
 
5.4.4 Synaptophysin protein expression in NTS following IH .......... 189 
5.4.5 GAP-43 protein expression in NTS following IH ..................... 192 
 5.4.6 Changes in neuroplastic markers in NTS of KILO rats      
following IH ..................................................................................... 192 
5.5 DISCUSSION ...................................................................................... 200 
5.6 FOOTNOTES ...................................................................................... 204 
5.7 REFERENCES .................................................................................... 205 
CHAPTER 6: EFFECTS OF ANGIOTENSIN II ON LEPTIN AND      
DOWNSTREAM LEPTIN SIGNALIN IN THE CAROTID BODY DURING        
ACUTE INTERMITTENT HYPOXIA ..................................................................... 209 
6. CHAPTER 6 ........................................................................................... 210 
6.1 CHAPTER SUMMARY ........................................................................ 210 
6.2 INTRODUCTION ................................................................................. 212 
6.3 METHODS AND MATERIAL ............................................................... 216 
6.3.1 General animal procedures .................................................... 216 
6.3.2 Angiotensin converting enzyme inhibition .............................. 216 
6.3.3 Selective blockade of AT1R .................................................... 217 
6.3.4 Induction of IH ........................................................................ 217 
6.3.5 Plasma collection and immunoassays ................................... 217 
6.3.6 Carotid body protein extracts and immunoblot analysis ......... 218 
6.3.7 Immunofluorescence .............................................................. 220 
6.3.8 Statistical analysis .................................................................. 222 
 xix 
 
6.4 RESULTS ............................................................................................ 223 
6.4.1 Plasma ANG II and leptin levels following captopril and     
losartan treatment ........................................................................... 223 
6.4.2 Leptin, Ob-Rb and AT1R co-expression in carotid body ......... 223 
6.4.3 Effect of IH on AT1R and AT2R in carotid body ...................... 228 
6.4.4 Effect of IH in animals treated with captopril or losartan  
on leptin within the carotid body ...................................................... 228 
6.4.5 Effect of IH on OB-Rb and Ob-R100 protein expression  
within the carotid body following captopril or losartan treatment ..... 233 
6.4.6 Effect of captopril or losartan on STAT3, pSTAT3,  
SOCS3 and pERK1/2 in the carotid body after IH ........................... 239 
6.5 DISCUSSION ...................................................................................... 251 
6.6 FOOTNOTES ...................................................................................... 257 
6.7 REFERENCES .................................................................................... 258 
CHAPTER 7: SUMMARY AND CONCLUSIONS ................................................ 264 
7. CHAPTER 7 ........................................................................................... 265 
7.1 SUMMARY OF MAJOR FINDINGS ..................................................... 265 
7.2 LIMITATIONS AND FUTURE STUDIES .............................................. 268 
7.3 SIGNIFICANCE OF RESEARCH AND CONCLUSIONS ..................... 271 
7.4 REFERENCES .................................................................................... 275 
APPENDIX ........................................................................................................... 276 
APPENDIX 1 ANIMAL USE PROTOCOL APPROVAL ........................................ 277 
 xx 
 
CURRICULUM VITAE .......................................................................................... 278 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 xxi 
 
LIST OF TABLES 
Table 6.1 Effect of captopril or losartan treatment on ANGII receptors and          
leptin signaling molecules in the carotid body following IH ................................... 234 
  
 xxii 
 
LIST OF FIGURES 
Figure 1.1 Relevant leptin signaling pathways ..................................................... 29 
Figure 2.1 Changes in body weight and fat mass following IH............................. 75 
Figure 2.2 Changes in food intake and locomotion following IH .......................... 78 
Figure 2.3 Changes in plasma hormones in response to IH ................................ 80 
Figure 2.4 Adipose adipokine protein content following IH .................................. 83 
Figure 2.5 ObR related intracellular pathways activated following IH .................. 86 
Figure 2.6 ARC POMC-containing cell activation following IH ............................. 88 
Figure 3.1 Energy intake and utilization in KILO rats following IH........................ 112 
Figure 3.2 Body weight in KILO rats exposed to IH ............................................. 116 
Figure 3.3 Fat pad mass and locomotion in KILO rats following IH ..................... 119 
Figure 3.4 Plasma hormone concentrations in KILO rats exposed to IH ............. 122 
Figure 3.5 Leptin signaling molecules in ARC of KILO rats exposed to IH .......... 125 
Figure 4.1 Effect of CIH on body weight changes and fat pad mass ................... 147 
Figure 4.2 Changes in food intake and energy expenditure following CIH .......... 151 
Figure 4.3 CIH induces resistance to leptin ......................................................... 154 
Figure 4.4 Effect of CIH on ObR in ARC .............................................................. 156 
Figure 4.5 Leptin signaling proteins in ARC following CIH ................................... 159 
Figure 4.6 Effect of CIH on negative regulators of leptin signaling in ARC .......... 161 
Figure 5.1 Effect of IH on hemodynamic variables .............................................. 185 
 xxiii 
 
Figure 5.2 NTS expression of BDNF following IH ................................................ 187 
Figure 5.3 NTS expression of TrkB isoforms following IH .................................... 190 
Figure 5.4 NTS expression of synaptophysin following IH ................................... 193 
Figure 5.5 NTS expression of GAP-43 following IH ............................................. 195 
Figure 5.6 Effect of IH in KILO rats on neuroplastic markers in NTS ................... 198 
Figure 6.1 Change in plasma levels of ANG II and leptin following IH ................. 224 
Figure 6.2 Leptin and AT1R in glomus cells in the carotid body ........................... 226 
Figure 6.3 Effect of IH on AT1R and AT2R within carotid body ............................ 229 
Figure 6.4 Carotid body leptin protein following IH .............................................. 231 
Figure 6.5 ObR isoforms following Capt in carotid body ...................................... 235 
Figure 6.6 ObR isoforms following Capt: IH vs. normoxic groups ........................ 237 
Figure 6.7 Changes in STAT3 following Capt ...................................................... 241 
Figure 6.8 Changes in STAT3 following Capt: IH vs. normoxic groups ............... 243 
Figure 6.9 Changes in SOCS3 following IH and Capt treatment ......................... 245 
Figure 6.10 Changes in ERK1/2 following Capt ................................................... 247 
Figure 6.11 Changes in ERK1/2 following Capt: IH vs. normoxic groups ............ 249  
 xxiv 
 
LIST OF ABBREVIATIONS 
α-MSH  α-melanocyte stimulating hormone 
ACE   angiotensin I converting enzyme 
AgRP   agouti-related peptide 
AHI   apnea-hypopnea Index 
ANG II  angiotensin II 
AP   arterial pressure 
ARC   arcuate nucleus of the hypothalamus 
AT1R   angiotensin II type 1 receptor    
AT2R   angiotensin II type 2 receptor 
BDNF   brain-derived neurotrophic factor 
BMI   body mass index 
Capt   captopril 
CART   cocaine- and amphetamine-related transcript 
CIH   chronic intermittent hypoxia 
CPAP   continuous positive airway pressure 
CRH   corticotrophin releasing hormone 
CSF   cerebrospinal fluid page 
ECL   enhanced chemiluminescence 
ERK1/2  extracellular signal-regulated kinase 1/2 
 xxv 
 
Fra-1   immediate early gene Fra-1 
FRA-1/2  immediate early gene protein products FRA-1/2 
GAP-43  growth-associated protein 43  
GAPDH   glyceraldehyde 3-phosphate dehydrogenase 
gp145   long form TrkB neurotropic receptor  
gp95   short form TrkB neurotropic receptor 
HIF-1   hypoxia-inducible factor 1 
HR   heart rate 
HRE   hypoxia response element 
HRP    horseradish peroxidase 
IH   intermittent hypoxia 
JAK2   janus kinase 2 
KILO   homozygous leptin-deficient rats 
Los   losartan 
MAPK   mitogen-activated protein kinase 
NMDA  N-methyl-D-aspartate 
NPY   neuropeptide Y 
NTS   nucleus of the solitary tract 
ObR   leptin receptor 
ObR100  100 kDa short-form leptin receptor  
 xxvi 
 
ObRA, C-D, F short form leptin receptors 
ObRB   long form leptin receptor 
ObRE   soluble/secreted leptin receptor 
OSA   obstructive sleep apnea 
PBS   phosphate-buffered saline 
pERK1/2   phosphorylated ERK1/2  
POMC  pro-opiomelanocortin 
pSTAT3   phosphorylated STAT3 
PTP1B  protein tyrosine phosphatase 1B 
RAS   renin-angiotensin system 
ROS   reactive oxygen species 
RVLM   rostral ventrolateral medulla 
SDS   sodium dodecyl sulfate 
sLTF   sensory long-term facilitation 
SOCS3  suppressor of cytokine signaling 3 
STAT3  signal transducer and activator of transcription 3  
TBST   tris-buffered saline + tween-20 
TrkB   tropomyosin receptor kinase B 
VLM   ventrolateral medulla  
WT   wild type control rats  
1 
 
CHAPTER 1 
 
INTRODUCTION AND BACKGROUND 
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1. INTRODUCTION 
This thesis focuses on consequences of intermittent hypoxia, a major 
pathophysiological manifestation of obstructive sleep apnea. In particular, 
alterations to energy balance, and the cardiovascular system were assessed. In 
addition to these physiological changes, associated neural pathways were 
evaluated for alterations that may serve as determinants in mediating these 
changes. The first chapter will provide 1) an overview of obstructive sleep apnea, 
2) current understanding and mechanisms of hypoxia in body energy balance 
and cardiovascular disease, and 3) an overview of the leptin hormonal system as 
it pertains to body energy and cardiovascular systems. 
 
1.1  OBSTRUCTIVE SLEEP APNEA 
 
1.1.1 Disease description 
Obstructive sleep apnea (OSA) is a chronic, progressive disease. OSA 
patients experience episodic partial (apnea) or complete (hypopnea) closure of 
the upper airway during sleep (Dempsey et al., 2010). These closures prevent 
appropriate air flow into and out of the lungs, despite respiratory effort. As a 
result, alveolar partial pressure of oxygen is reduced, leading to a hypoxic state 
during the airway closure. This, in turn, causes a reduction in blood-oxygen 
pressure and hypoxemia. The overall effect of these repeated closures during 
sleep is a state of intermittent hypoxia (IH) and intermittent hypoxemia.  These 
events and their resultant IH lead to arousals, disrupting sleep architecture and 
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elevating activity of the autonomic nervous system above normal levels. 
Resulting from the reductions in gas exchange across the blood-gas barrier, 
hypercapnea is also commonly observed in patients with OSA. Likewise, 
intrathoracic reductions in pressure are observed as an individual struggles to 
breathe without success. 
 The first reports of OSA come from British physicians in the 1870s, who 
described individuals having “fruitless contractions of the inspiratory and 
expiratory muscles against glottis obstruction… during sleep” (Lavie, 2003). It 
was not until the 1960s that OSA was described in obese subjects experiencing 
arousals resulting from episodic airway obstruction (Gastaut et al., 1966). These 
results brought to light the concept that obesity, sleepiness, sleep disruption and 
nocturnal airway obstruction may be linked.  
 
1.1.2 Diagnosis and treatment of OSA 
OSA is diagnosed following overnight observation and polysomnography. 
Determinations of the number of apneic or hypopneic events per hour are 
calculated, representing the Apnea-Hypopnea Index (AHI). A patient with an AHI 
greater than five is considered to have a mild form of OSA, while those with an 
AHI greater than 30 are considered to have severe OSA. Significant reductions 
blood-oxygen saturation have also been described as important markers for 
OSA, with a measure of time below 90% blood-oxygen saturation being utilized 
to identify susceptibility to cardiovascular events (Nieto et al., 2000). 
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OSA is primarily treated using continuous positive airway pressure 
(CPAP) devices, since CPAP is highly effective at reducing apneic events and 
pathophysiology associated with OSA (Faccenda et al., 2001; Jenkinson et al., 
1999). That said, there is still a considerable problem with adherence among 
individuals using CPAP, despite the association between daytime sleepiness and 
severity of OSA with the likelihood of using the CPAP system (Hoy et al., 1997).  
Alternative treatments for OSA include surgery, particularly for individuals 
with anatomical-related disposition to apnea. The most common surgical 
intervention for OSA is the uvulopalatopharyngoplasty, which is not necessarily 
recommended for OSA patients without anatomical dispositions to apnea, since 
less than half of individuals treated in this way have AHI reduced to less than 20 
events per hour.  
Oral appliances are another major form of treatment for patients with OSA. 
The devices used are generally either mandibular advancement devices or 
tongue retainers, which prevent the collapse of the upper airway (Ferguson et al., 
1996, 1997). Certainly these devices have their place in the treatment of mild-to-
moderate cases of OSA, and are more effective than surgical interventions, 
though they are generally less effective than CPAP (American Academy of Sleep 
Medicine Task Force, 1999). 
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1.1.3 Prevalence of OSA 
The Wisconsin Sleep Cohort, a study involving 602 middle-aged (30-60 
years old) subjects, found the proportion of males and females with OSA to be 
24% and 9%, respectively. Despite this prevalence, only 4% of males and 2% of 
females experience daytime somnolence, although having an AHI >5, suggesting 
a significant under-diagnosis of the disease (Young et al., 1993). More recently, it 
was estimated that 17% of this same age-group in the United States suffered 
from at least mild sleep apnea, and approximately 6% suffered from at least 
moderate sleep apnea, and 41-58% of the burden of sleep apnea was due to 
excess body weight (Young et al., 2005). Interestingly, countries such as Brazil 
and some Asian countries have higher prevalence of OSA, despite lower 
prevalence of obesity (Ip et al., 2001; Sharma and Ahluwalia, 2010). 
Nonetheless, obesity is a major risk factor for the development of OSA, as an 
increase of 6 kg/m2 on the body mass index (BMI) scale results in an increased 
risk of OSA by 4-times (Young et al., 1993). It is estimated that 70% of OSA 
patients suffer from obesity (Malhotra and White, 2002). 
 
1.1.4 Comorbidities of OSA  
While obesity is a major risk factor for the development of OSA, there are 
many other comorbidities of OSA. There are three major categories of OSA 
comorbidities: cardiovascular, metabolic and neurocognitive. 
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1.1.4.1 Cardiovascular comorbidities 
1.1.4.1.1 Systemic Hypertension 
Blood pressure in normal individuals is reduced during sleep, compared to 
normal waking pressures. This “dipping” is not observed in many patients with 
OSA, attributable to vasoconstriction during the apneic period (Golbin et al., 
2008). An event-associated increase in both systolic and diastolic blood pressure 
was observed in the Sleep Heart Health Study, which involved more than 6000 
patients (Nieto et al., 2000). Likewise, Lavie and colleagues (2000) showed a 
one percent increased risk of hypertension for every increase of one unit on the 
AHI scale. The Wisconsin Sleep Cohort, a prospective study, determined an 
event-associated increase in hypertension at four years follow-up, even after 
accounting for known confounders. Other studies have not displayed a significant 
effect of OSA on blood pressure, especially when BMI is taken into 
consideration. However, OSA is considered by many to be a major risk factor for 
the development of secondary hypertension (Bradley and Floras, 2009; 
Chobanian et al., 2003). Likewise, use of CPAP is able to reduce blood pressure 
and sympathetic activity in patients (Dimsdale et al., 2000; Haentjens et al., 
2007).  
 
1.1.4.1.2 Pulmonary Hypertension 
Pulmonary hypertension is diagnosed following right heart catheterization 
measurement of pulmonary arterial pressure of greater than 25 mmHg.  The 
pathophysiology of pulmonary hypertension in OSA could be explained by the 
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fact that chronic respiratory diseases that induce hypoxia appear to remodel the 
pulmonary arteries (Presberg et al., 2003). Pulmonary hypertension prevalence 
in patients with OSA has been estimated at 41%, when adjusted for confounding 
variables, including BMI (Sajkov et al., 1994). CPAP reduces pulmonary arterial 
blood pressure (Arias et al., 2006). 
 
1.1.4.1.3 Cardiac Arrhythmias 
In the cross-sectional Sleep Heart Health Study, severe OSA patients had 
four times the frequency of having atrial fibrillation, when adjusted for 
confounders, including BMI. OSA patients had three-times the frequency of 
having nonsustained ventricular tachycardias when adjusted for confounders 
(Mehra et al., 2006). Bradyarrhythmias are also found in patients with OSA, and 
it has been shown that CPAP use can reduce this difference (Guilleminault et al., 
1983).  
Cardiovascular mortality is elevated in men and women with severe OSA 
and mortality can be reduced by implementation of CPAP (Marin et al., 2005; 
Campos-Rodriguez et al., 2012). This may be due to alterations in the timing of 
severe cardiac events, as it has been shown that these are more likely to occur 
during sleep hours of patients with OSA, while it is more frequent in the morning 
for normal people (Gami et al., 2005). 
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1.1.4.1.4 Stroke 
In a prospective study by Redline and colleagues (2010) stemming from 
the Sleep Heart Health Study, it was shown that moderate-to-severe OSA is 
associated with a three-fold risk of stroke over an eight year period. This 
association is supported by findings of the Wisconsin Sleep Cohort, which shows 
moderate-to-severe OSA is a significant risk factor for stroke (Arzt et al., 2005), 
and this may be associated with the severity of the disease (Yaggi et al., 2005). 
Interestingly, the development and progression of OSA may be bidirectionally 
associated with incident stroke, as apneas are associated with decreased blood 
flow following stroke, which may induce thrombosis (Netzer et al., 1998). CPAP 
therapy has beneficial effects in decreasing mortality in OSA patients with stroke 
(Martinez-Garcia et al., 2009). 
 
1.1.4.2 Metabolic comorbidities 
 
1.1.4.2.1 Obesity 
Obesity is an energy balance disease, resulting from a chronic state of 
positive energy balance, such that energy consumed is not adequately utilized. 
Excess calories are stored in adipose tissue depots located throughout the body. 
A concomitant increase in lean mass is also observed, resulting in significant 
weight gain and elevation of body mass index (BMI; Williams and Fruhbeck, 
2009). OSA is associated with obesity, as previously mentioned and illustrated by 
the fact that obese patients with OSA that undergo bariatric surgery have 
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improvements in OSA parameters such as oxygen saturation and sleep 
disturbances (Haines et al., 2007). Similar results have been obtained in studies 
using sibutramine-induced weight loss (Sutherland et al., 2011). Patients 
diagnosed with OSA appear to have trouble losing excess weight when 
compared to non-apneics with the same level of obesity. Likewise, patients with 
OSA tend to gain weight over the course of their disease (Phillips et al., 1999). 
As a result, it is clear that a bidirectional relationship exists between obesity and 
OSA, though this has not received much scientific study. 
 
1.1.4.2.2 Metabolic syndrome 
The metabolic syndrome is a cluster of metabolic pathophysiologies that 
include obesity, insulin resistance, hypertension and dyslipidemia. The criteria by 
which individuals are diagnosed with the metabolic syndrome include specific 
cut-offs of specific measures that fall under the umbrella of the pathophysiologies 
mentioned above, including altered cholesterols, elevated blood pressure and 
triglycerides, glucose intolerance, and elevated BMI (American Medical 
Association, 2001). Current guidelines suggest that a patient experience any 
combination of three of these issues, and obesity is not a requirement for 
diagnosis. It is estimated that the prevalence of the metabolic syndrome in 
developed countries is 23% (Ford et al., 2002).   
 Studies have emerged examining a potential relationship between OSA 
and the metabolic syndrome. OSA was found to be associated with specific 
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criteria of the metabolic syndrome, and the syndrome itself, with an odds ratio of 
around 9 (Coughlin et al., 2004). The severity of OSA may also predict the 
number of criteria of the metabolic syndrome (Lam et al., 2006). Interestingly, 
OSA is associated with a worse metabolic profile of individuals who were not 
obese, and associated with the presence of the metabolic syndrome (Kono et al., 
2007). 
 
1.1.4.2.3 Insulin resistance 
Insulin resistance is a hallmark manifestation of the metabolic syndrome, 
and type II diabetes mellitus. The prevalence of OSA within type II diabetics is 
estimated at 23%, and OSA is correlated with type II diabetes, regardless of 
appropriate confounders such as BMI, age and neck size (West et al., 2006). The 
use of CPAP in modulating glycemia has only provided weak, observational 
evidence to support a role of OSA treatment in improving hyperglycemia (Babu et 
al., 2005; Hassaballa et al., 2005). The Wisconsin Sleep Cohort failed to show 
provide an increased incidence of diabetes in OSA patients after adjustment at 
follow-up, and so a causal role for OSA in diabetes is not able to be made 
(Reichmuth et al., 2005). 
 
1.1.4.2.4 Dyslipidemia 
Many studies have observed associations between OSA and poor lipid 
profiles. The Sleep Heart Health Study, for example, showed a significant 
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negative association between OSA severity and high-density lipoprotein levels, 
whereas a significant positive association was observed between OSA severity 
and circulating triglyceride concentrations when adjusted for confounders 
(Newman et al., 2001). Other studies have shown similar effects in patients 
matched by BMI (McNicholas et al., 2007; Coughlin et al., 2004). Despite this, 
CPAP intervention studies have failed to show convincing significant 
improvement in cholesterol or triglyceride levels (Coughlin et al., 2007; Robinson 
et al., 2004). 
 
1.1.4.3 Neurocognitive comorbidities 
One of the primary symptoms of OSA is excessive daytime somnolence. 
This experience of increased sleepiness is associated with a variety of cognitive 
deficits including decreased alertness, reduced psychomotor speed and impaired 
executive function (Beebe et al., 2003). These abnormalities result in increased 
risk of automobile accidents and a significant reduction in the perceived quality of 
life (Beebe et al., 2003). A loss of gray matter has been observed in OSA 
patients, associated with these symptoms, an effect which can be altered by 
CPAP use (Canessa et al., 2011; Thomas et al., 2012). Interestingly, the use of 
CPAP appears to have greater beneficial effect on these variables in children, 
compared with adults (Sanchez et al., 2009; Ferini et al., 2003; Marcus et al., 
2012; Gurubhagavatula, 2010). 
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1.1.5 Intermittent hypoxia as a model for OSA 
Animal models employing IH have been used for the study of mechanistic 
effects of OSA-induced IH since 1992 (Fletcher et al., 1992). There are two major 
types of rodent IH models: sleep-dependent and sleep-independent IH. Sleep-
dependent IH relies on the presence of sleep for the induction of the model and 
requires significant physiological measurement, including 
electroencephalography and electromyography (Tagaito et al., 2001). This model 
is expensive, time-consuming, low-throughput, and rarely employed. 
  The second, more commonly used IH model is sleep-independent. 
Reductions in available oxygen and a subsequent return to normoxia are applied 
to the animal as many as 60 times per hour, with oxygen nadirs ranging from as 
low as 3% to as high as 10% (Polotsky et al., 2006; Veasey et al., 2004; Gozal et 
al., 2001; Peng et al., 2003). Specific experimental conditions vary widely 
between research groups. Exposure to these conditions is typically during the 
sleep-cycle of the animal, and has been shown to correlate well with oxygen 
saturation values observed in patients with OSA (Jun et al., 2010; Louis and 
Punjabi, 2009). Recently, sleep-independent models of IH have been employed 
(Louis and Punjabi, 2009). 
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1.2  HYPOXIA-SENSING AND THE CARDIOVASCULAR SYSTEM 
 
1.2.1 Peripheral arterial chemoreceptors 
Within the body, hypoxia is primarily sensed by peripheral arterial 
chemoreceptors. These specialized tissues are made up of type I glomus cells 
and type II sustentacular cells within the carotid and aortic bodies. These small 
pieces of tissue are located near the carotid bifurcation and aortic arch. Glomus 
cells are specialized receptors that are hypoxia-sensitive and release a number 
of neurotransmitters in response to altered O2 and CO2/H
+ homeostasis 
(Gonzalez et al., 1994). Sustentacular cells are supportive in nature, and don’t 
appear to have a function related to hypoxia-sensing. Changes in altered blood 
gas homeostasis activate glomus cells, causing the release of excitatory 
neurotransmitters onto the terminals of the carotid sinus branch of the 
glossopharyngeal nerve (Gonzalez et al., 1994; Nurse, 2010; Lopez-Barneo, 
2003). The subsequent neuronal activity results in activation of cardiorespiratory 
reflexes within the brainstem to alter blood gases to appropriate levels. Activation 
of the arterial chemoreceptors initiates what is known as the peripheral 
chemoreceptor reflex, resulting in an elevation of phrenic motor output to the 
diaphragm, and both sympathetic and parasympathetic efferent branches of the 
autonomic nervous system, with a resulting elevation in ventilation and blood 
pressure, and paradoxical bradycardia (Alsberge et al., 1988; Kumar, 2009). 
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1.2.2 Chemoreceptor reflex activation of the sympathetic nervous system 
Much of the evidence indicating the neural structures underlying the 
sympathetic responses to peripheral chemoreceptor reflex activation has been 
acquired in anaesthetized animal preparations. Nonetheless, activation of the 
peripheral chemoreceptor reflex induces phrenic nerve discharge and 
sympathetic nerve activity to the heart and blood vessels following specific 
activation of the carotid bodies or hypoxia (Koshiya et al., 1993; Koshiya and 
Guyenet, 1996a). This activation is eliminated following denervation of the carotid 
bodies (Koshiya and Guyenet, 1996a). The sensory component of the carotid 
chemoreceptor reflex begins with the release of excitatory neurotransmitter onto 
the afferents of the carotid sinus nerve, resulting in activation of the nucleus of 
the solitary tract (NTS). The NTS is the primary site of the termination of 
cardiorespiratory reflexes originating in the aortic and carotid bodies (Ciriello, 
1994), and contains neurons that are activated by chemoreceptor stimulation and 
project to the rostral ventrolateral medulla (RVLM; Koshiya and Guyenet, 1996b; 
Ciriello and Moreau, 2013). It is believed these NTS-RVLM neurons are 
independent of baroreceptor input and respiratory entrainment, regardless of the 
activity of the chemoreceptor reflex (Koshiya and Guyenet, 1996b).  The 
sympathetic outflow from the activation of the chemoreceptor reflex originates as 
signals from the pre-sympathetic neurons of the RVLM, perhaps due to activation 
of these NTS-RVLM neurons. The recruitment of a given subset of these neurons 
will alter the tissue to which sympathetic tone will be changed by activating 
specific sympathetic pre-ganglionic neurons of the spinal cord (Dampney, 1994). 
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How these neurons are recruited to mediate an elevation in sympathetic tone is 
still a matter of controversy (Guyenet, 2000). Increases in hypoxia-related 
sympathetic activity will cause vasoconstriction (Hudson et al., 2011) and a 
release of catecholamines from the adrenal medulla (Prabhakar et al., 2012). 
 
1.2.3 Intermittent hypoxia and cardiorespiratory reflexes 
 
1.2.3.1 Effect on peripheral chemoreceptor reflex 
Individual bouts of short-term hypoxia are observed during IH, which 
activate the peripheral chemoreceptor reflex in the same way as continuous 
hypoxia mentioned above, though with a reduced ventilatory response 
(Prabhakar et al., 2005; Reeves et al., 2003). In fact, a potentiation of the 
chemoreceptor reflex due to sensory long-term facilitation (sLTF) of the 
chemoreceptors has been identified in animals exposed to IH (Prabhakar et al., 
2005; Prabhakar et al., 2009), but not sustained hypoxia (Baker and Mitchell, 
1999; 2000). Likewise, acute IH alters expression of glutamatergic receptors 
within the dorsocaudal brainstem (containing the NTS region), whereas 
sustained hypoxia does not (Reeves et al., 2003). This sLTF is concomitant to an 
elevation of sympathetic nervous tone and blood pressure following acute IH in 
both rats (Dick et al., 2007; Xing and Pilowsky, 2010; Mandel and Schreihofer, 
2009) and humans (Leuenberger et al., 2005). Even after acute exposure to IH, 
this increased sympathetic activity persists following the discontinuation of 
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hypoxia (Fuller et al., 2000), though the increased blood pressure was transient 
(Leuenberger et al., 2005).  
Chronic IH (CIH), like acute IH, has significant cardiovascular 
consequences. Long-lasting elevations in resting blood pressure and 
sympathetic activity are found in animals (Zoccal et al., 2007, 2008; Bao et al., 
1997) and humans (Tamisier et al., 2011) following CIH. These changes in blood 
pressure are likely mediated by a combination of the sympathetic nervous 
system (Fletcher et al., 1992b), and vascular factors such as angiotensin II (Ang 
II), catecholamines and vasopressin (Foster et al., 2010; Bao et al., 1997; 
Fletcher et al., 1999; Fernandes et al., 2005). 
 The role of the peripheral chemoreceptor reflex in mediating the CIH-
induced blood pressure effects are highlighted by the fact that denervation of the 
carotid sinus nerve prior to exposure to CIH in rats, eliminates the cardiovascular 
alterations observed (Fletcher et al., 1992a). Meanwhile, the autonomic 
alterations observed following hypoxia are eliminated when chemoreceptors are 
inhibited by hyperoxia (Querido et al., 2010). 
CIH potentiates the sympathetic response to additional bouts of hypoxia. 
In studies assessing the afferent signaling from the carotid bodies, previous 
exposure to CIH, but not normoxia, caused an increased cellular response (Peng 
and Prabhakar, 2004; Rey et al., 2004). A similar effect was observed for efferent 
sympathetic responses to hypoxia (Huang et al., 2009; Greenberg et al., 1999). 
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At least some of this response is mediated by an alteration in central responses 
within NTS (Kline, 2010). 
 
1.2.3.2 Effect on arterial baroreceptor reflex 
In opposition to the peripheral chemoreceptor reflex, activation of the 
arterial baroreceptor reflex causes a reduction in sympathetic tone and blood 
pressure. The baroreceptors are located within the walls of the vasculature of the 
carotid sinus and the aortic arch and send neural projections into the NTS 
(Ciriello, 1983; Davies and Kalla, 1981), which projects to the caudal VLM. 
Activation of the baroreceptor reflex causes an inhibition of the RVLM via 
monosynaptic connections from the caudal VLM (Agarwal and Calaresu, 1991; 
Agarwal et al., 1990).  
During IH, the baroreceptor reflex would activate to buffer the elevation in 
blood pressure. In animals with experimental peripheral chemoreceptor activation 
using potassium cyanide, baroreceptors become activated following the initial 
rise in blood pressure, resulting in a biphasic response that includes subsequent 
hypotension and bradycardia (Braga et al., 2008).  
Given that animals and humans exposed to CIH develop hypertension, it 
may be concluded that the baroreceptor reflex is inhibited or desensitized 
following long-term IH exposure. In the short-term, IH resets the baroreceptor 
reflex to operate at higher levels of blood pressure and sympathetic tone, not 
changing the sensitivity of the reflex (Monahan et al., 2006), independent of 
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changes to ventilatory responses (Halliwill et al., 2003). However, following CIH, 
desensitization of the baroreceptor reflex may also occur (Gu et al., 2007; Lai et 
al., 2006). 
 
1.3  HYPOXIA AND BODY ENERGY BALANCE 
Hypoxia induces, above all else, a state of negative energy balance. This 
occurs initially at the level of the mitochondria, reducing the capacity for oxidative 
phosphorylation, and thus production of ATP. The response to this reduction in 
energy production is manifested by the release of macromolecules from 
appropriate storage sites, likely mediated by the sympathetic nervous system, 
resulting in a reduction in body weight. 
 
1.3.1 Cellular energy responses to hypoxia 
Cells are sensitive to alterations in available oxygen concentrations within 
their environment. Given the role of oxygen in energy production through 
mitochondrial oxidative phosphorylation, it is not surprising that cells are able to 
alter both the supply and demand of oxygen within their interstitium through 
various mechanisms including augmented glycolytic and reduced oxidative 
phosphorylation pathways.  
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1.3.1.1 Hypoxia-inducible factor 1 
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein made up of α 
and β protein subunits. HIF-1β is a constitutively expressed protein that does not 
have activity independent of HIF-1α and isn’t affected by oxygen tension. In 
contrast, HIF-1α is the primary activator of the HIF-1 complex (Wang et al., 
1995). HIF-1α has domains for binding to HIF-1β, an oxygen-sensitive core and a 
DNA-binding domain for regulation of transcriptional promoters or enhancers 
containing a hypoxia-responsive element (Jiang et al., 1997). During normoxia, 
oxygen binds to the oxygen-sensitive core, resulting in hydroxylation, 
ubiquitination and subsequent degradation of HIF-1α. During hypoxia, there is 
less oxygen to bind to the oxygen-sensitive core, and HIF-1α is free to 
translocate to the nucleus to associate with HIF-1β, forming HIF-1. The 
heterodimer HIF-1 binds to regulators of genes, which are deemed to be 
hypoxia-responsive (Chandel, 2010).  
  
1.3.1.2 Generation of ATP 
During hypoxic insults, mitochondria reduce their uptake of oxygen 
thereby limiting their production of ATP, and increasing anaerobic ATP 
production. This is done to avoid forming anoxic cellular conditions, which may 
ultimately lead to cell death.   
HIF-1 acts as a “switch” to augment the translocation and activity of 
glucose transporters in the cell membrane, increasing the influx of glucose for the 
20 
 
use in so-called fermentative pathways (Gleadle et al., 1997; Maxwell et al., 
1997). The production of ATP by these pathways is oxygen-independent and 
less efficient at producing ATP than oxidative phosphorylation. Despite this, cells 
can maintain glycolytic production of ATP at nearly the same level due to an 
elevated capacity for glucose transport and an increase in glycolytic enzymes, 
mediated by HIF-1 (Gleadle et al., 1997; Maxwell et al., 1997; Mathupala et al., 
2001; Semenza et al., 1994, 1996). 
The shunting of pyruvate and other necessary co-factors of oxidative 
phosphorylation away from the mitochondria and into glycolytic pathways 
prevents an elevation in reactive oxygen species associated with inefficient 
electron transport chain activity (Weideman and Johnson, 2008). The enzymes 
important in these effects are regulated by HIF-1 (Kim et al., 2006; Papandreou 
et al., 2006).  
Reactive oxygen species production has also been shown to occur 
following the reoxygenation events observed in IH. The increase in available 
oxygen within tissues following a return to normoxia not only provides the 
substrate for the production of reactive oxygen species, but also may alter the 
antioxidant capacity of cells (Singh et al., 2001), leading to lipid peroxidation, 
formation of reactive nitrogen species and oxidative stress (Row et al., 2003; Xu 
et al., 2004) 
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1.3.2 Organism energy responses to hypoxia 
1.3.2.1 Body weight and food intake 
It has been largely reported that hypoxia of both a continuous and 
intermittent nature causes an acute reduction in body weight (Westerterp-
Plantenga et al., 1999; Martinez et al., 2008). Interestingly, this effect in 
sustained hypoxia is mirrored by a reduction in food intake, when locomotion, 
stress and temperature are taken into consideration. Alterations in food intake 
were concomitant with an increase in the number of meals taken per day. 
Subjects of this study indicated they felt hungry, but did not have the drive to 
consume food, an effect observed during altitude sickness. This imbalance in 
body energetics is currently without a potential mechanism, but has been 
suggested to be the result of elevated plasma leptin concentrations (Tschop et 
al., 1998). Ratios of the consumption of specific macronutrients do not appear to 
be affected by chronic hypoxia (Westerterp et al., 1992; Westerterp et al., 1994; 
Westerterp et al., 1996). Currently, there are no studies examining food 
consumption and body energy balance during intermittent hypoxic exposure, 
though losses in body weight have been reported (Martinez et al., 2008; Ling et 
al., 2008; Drager et al., 2011). 
 
1.3.2.2 Lipid metabolism 
In normal and atherosclerosis-prone animals, chronic IH increases total 
cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein and 
triglycerides, effects which are amplified by the level of the hypoxic stimulus (Jun 
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et al., 2010; Li et al., 2005; Li et al., 2007). In support of these findings, increased 
lipid synthesis pathways of the liver have been shown to be altered (Li et al., 
2005; Li et al., 2007; Savransky et al., 2007; Li et al., 2007), an effect which 
mimics acute exposure to hypoxia (Piguet et al., 2009). Likewise, this effect may 
be mediated partially by HIF-1 (Li et al., 2006).  
In addition to elevated production of lipids, IH has been shown to induce 
lipolysis, releasing free fatty acids from adipose tissue, likely through activation of 
the sympathetic nervous system (Jun et al., 2010; Jaworski et al., 2007; Lafontan 
and Langin, 2009; Zechner et al., 2009). Chronic IH has been shown to induce 
liver enzymes and liver injury in rodents (Savransky et al., 2007), as well as 
cause the release of pro-inflammatory cytokines (Savransky et al., 2007). 
 
1.3.2.3 Glucose metabolism 
IH is capable of producing an acute insulin resistance in lean mice, and 
potentiating that found within obese leptin-deficient mice (Iiyori et al., 2007; 
Polotsky et al., 2003). As well, in human IH models, these effects have been 
observed without increasing the circulating level of leptin (Louis and Punjabi, 
2009). These effects could be mediated by changes in lipid production within the 
liver, or by increased sympathetic tone leading to lipolysis and ultimately an 
increase in free fatty acids. Free fatty acids have been shown to reduce glucose 
uptake by inhibition of insulin pathways within skeletal muscle (Delarue and 
Magnan, 2007; Kim et al., 2001). Meanwhile, glycogen is released from, and 
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glucose uptake is reduced, in muscle. Elevated hepatic gluconeogenesis and 
hyposecretion of insulin may also be mediated by the sympathetic nervous 
activation following IH. Additional mechanisms mediating insulin resistance in IH 
include inflammation (Cai et al., 2005; Yuan et al., 2001) and corticosteroid 
release (Yokoe et al., 2008; Morton, 2010). 
 
1.4  LEPTIN SIGNALING 
 
1.4.1 Leptin and its receptors 
The hormone leptin is produced from the ob gene, located on 
chromosome 6 of mice and chromosome 7 in humans. The genes are 84% 
homologous, containing 3 exons. Leptin is produced as a non-glycosylated 
protein made up of 167 amino acids, including a 21 amino acid signal peptide 
(Auwerx and Staels, 1998). The protein contains 4-alpha helices, each of which 
is 5-6 turns long, connected by lengthy crossover linkages, similar to cytokines 
like ciliary neurotrophic factor and leukemia inhibitory factor. A single disulphide 
bridge exists between cysteines 96 and 146, which appears to be crucial for the 
proper folding and receptor binding of leptin (Zhang et al., 1997). Two major 
types of mutations occur, which affect the ob gene: a non-sense mutation 
producing a premature stop codon; and a mutation within the gene promoter, 
inhibiting transcription altogether (Halaas et al., 1995).  
Leptin exerts its physiological responses through the leptin receptor 
(ObR). ObR contains a single transmembrane spanning region, and is located on 
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chromosome 1 in humans. The receptor protein belongs to the class-1 cytokine 
receptor family (Tartaglia et al., 1995). ObR can be alternatively spliced to form 
several receptor isoforms (ObRA-F), which share common extracellular and 
transmembrane domains, though a variable intracellular domains. These 
receptors can be classified as short-form (ObRA, C-D, and F), long-form (ObRB), 
or soluble/secreted (ObRE) (Wang et al., 1998; Lee et al., 1996; Tartaglia et al., 
1995). The long-form, ObRB, contains intracellular motifs for the binding and 
activation of janus kinases (JAK) and signal transducers and activators of 
transcription (STAT; the so-called JAK/STAT pathway will be discussed in 
section 1.4.4).  
The various isoforms of ObR have unique roles in leptin signaling and 
secretion. ObRB mediates most of the intracellular signaling associated with 
leptin binding to the extracellular motifs. ObRA, containing a short intracellular 
motif, is important for the movement of leptin across membrane barriers, 
including the blood-brain barrier and from the cerebrospinal fluid into brain 
parenchyma (Tartaglia et al., 1995; Mercer et al., 1996; Fei et al., 1997; Bjorbaek 
et al., 1998; Hileman et al., 2000). The ObRE soluble leptin receptor is important 
for modulation of circulating leptin and its secretion from adipocytes (Ge et al., 
2002; Huang et al., 2001; Lammer et al., 2001; Yang et al., 2004).  
1.4.2 Regulation of leptin secretion 
The hormone leptin is produced by many tissues in the body, including 
adipose tissue, heart, carotid bodies, brain and gonads. Primarily, white adipose 
tissue is the major site of production of leptin. White adipose tissue is found 
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throughout the body in major depots, including the visceral, subcutaneous, 
retroperitoneal and epididymal fat pads. Each fat pad releases different amounts 
of leptin, with the epididymal pad releasing the most (approximately 10 ng/10 
million cells) in rats. In humans, the subcutaneous fat pad releases the most 
leptin (Zheng et al., 1996; Arner, 2001). The average circulating level of leptin in 
normal adults is 3-5 ng/ml, though this value can be much higher (8-90 ng/ml) in 
obese individuals (Shek et al., 1998; Klein et al., 2004). Initially, it was held that 
leptin secretion was proportional to the level of white adipose tissue within an 
individual. The white adipose tissue produces, stores and secretes leptin. The 
amount of leptin from rough endoplasmic reticulum to golgi to secretory vesicles 
of adipocytes increases, suggestive of a concentration of leptin prior to its 
release. Basally, leptin is produced and secreted into the interstitium of adipose 
tissue to maintain a set leptin concentration within and outside of the adipocyte 
(Cammisotto and Bendayan, 2007).  
Leptin secretion is strongly linked to circadian rhythm: its plasma 
concentration is lowest in the morning and highest in the middle of the night 
(Licinio et al., 1997; Mastronardi et al., 2000; Nagatani et al., 2000). Post-
prandial elevations in insulin have also been described as an important factor for 
leptin secretion, though this occurs long after mealtime, suggestive of a long-
term, not short-term role of leptin in energy balance (Koopmans et al., 1998; 
Lynch et al., 2006). 
The stimulation of leptin secretion from the adipose appears to be 
calcium-independent (Cammisotto and Bukowiecki, 2004), though leptin 
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synthesis is dependent on the presence of glucose (Whitehead et al., 2001). This 
effect is likely mediated by alterations in ATP (Mizuno et al., 1996; Mueller et al., 
1998). Insulin, within the physiological range, is sufficient to increase the 
secretion of leptin, which is potentiated by the presence of amino acids such as 
leucine (Cammisotto and Bukowiecki, 2002; Cammisotto et al., 2005; Lynch et 
al., 2006). The post-prandial insulinemic response, and subsequent glucose-
dependent induction of ATP may explain the rise in adipocyte ATP following food 
consumption (Thompson, 1996; Lynch et al., 2006). Glucocorticoids have been 
shown to increase leptin release from adipose tissue, likely through alterations in 
transcription of the protein (De Vos et al., 1995; Bradley and Cheatham, 1999). 
Intriguingly, plasma fatty acids do not alter leptin production or secretion, 
though lipolysis significantly attenuates leptin release (Cammisotto et al., 2003). 
This is likely due to the role of catecholamines in lipolysis, as exercise, cold 
exposure and adrenergic stimulation all inhibit leptin secretion, and are lipolytic 
events associated with cyclic adenosine monophosphate signaling (Bramlett et 
al., 1999; Rayner and Trayhurn, 2001; Gettys et al., 1996).  
Hypoxia is also an important regulator of leptin secretion. Recently, a 
hypoxia-response element (HRE) was discovered in the 5’ flanking region of the 
human ob gene. It was also shown that leptin transcription was increased 
following hypoxic exposure (Ambrosini et al., 2002). This increase in leptin 
transcription was induced by HIF-1α/β binding to the HRE domain of the leptin 
promoter (Ambrosini et al., 2002; Grosfeld et al., 2002). 
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1.4.3 Leptin-related signaling pathways 
Given that ObR is homologous to class I cytokine receptors, it is likely that 
ObR activity will resemble that of other cytokines. Like other cytokine receptors, 
ObRB activates JAK/STAT pathways. Upon leptin binding, JAK2 
autophosphorylates ObRB on specific tyrosine residues (Kloek et al., 2002; 
White et al., 1997; Banks et al., 2000). When phosphorylated at Tyr1138, ObRB 
recruits signal transducer and activator of transcription 3 (STAT3), resulting in 
phosphorylation of tyrosines on STAT3, resulting in homodimerization and 
translocation of pSTAT3 to the nucleus (White et al., 1997; Banks et al., 2000; 
Vaisse et al., 1996). Activated STAT3 acts as a transcription factor, and can 
activate the transcriptional activity of genes associated with leptin signaling 
including pro-opiomelanocortin (POMC), immediate early genes and suppressor 
of cytokine signaling 3 (SOCS3) (Banks et al., 2000; Munzberg et al., 2003; 
Bates et al., 2003). In addition to the activation of the JAK2/STAT3 pathways, 
extracellular signal-regulated kinase 1/2 is also phosphorylated, though this may 
be done directly by JAK2, instead of ObRB (Banks et al., 2000)   SOCS3 acts as 
an important negative feedback regulator of ObRB activation, inhibiting the 
phosphorylation of JAK2, and thus ObRB and  extracellular signal-related kinase 
1/2 (ERK1/2). SOCS3 may accumulate following the chronic activation of ObRB 
(Anubhuti and Arora, 2008). Protein tyrosine phosphatase 1B (PTP1B) is also an 
important regulator of leptin receptor activity, and has been shown to inhibit JAK2 
phosphorylation (Sahu, 2004; Bjorbaeck and Kahn, 2004; Zabolotny et al., 2002; 
Kaszubska et al., 2002; Cook and Unger, 2002; Figure 1.1). Interestingly, some 
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have shown that ObRA has the capacity to phosphorylate JAK2, though it is 
unable to induce STAT3 activation (given that the crucial phospho-Tyr1138 is 
absent in ObRA), suggestive of a potential activation of ERK1/2 by ObRA 
(Bjorbaek et al., 1997; Ghilardi et al., 1996). 
 
1.4.4 Leptin and energy balance 
 
1.4.4.1 Food intake 
Leptin has many sites of action throughout the body, though the brain is 
the primary site for its major physiological effect to reduce food intake. 
Hypothalamic sites of leptin action have drawn particular interest from the 
scientific community, primary of which is the arcuate nucleus of the 
hypothalamus (ARC). Within this region exist specific populations of neurons that 
respond to leptin and contain ObRB. Neuronal cell bodies expressing POMC are 
found within this region (Elias et al., 1998; Korner et al., 1999). POMC is cleaved 
within these neurons by prohormone convertases to produce alternative 
cleavage products that may regulate the autonomic and anorectic effects of 
leptin, including the production of α-melanocyte stimulating hormone (α-MSH). 
By acting through the  
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Figure 1.1 Relevant leptin signaling pathways. 
Graphical representation of signaling pathways associated with the binding of 
leptin to the long-form (ObRB) of its receptor. Upon leptin binding, JAK2 
becomes phosphorylated, resulting in the phosphorylation of ObRB at Tyr1138, 
which causes the phosphorylation and homodimerization of STAT3. pSTAT3 
translocates to the nucleus to regulate the transcription of genes and ultimately 
their protein products including immediate early gene product Fra-1/2, POMC 
and SOCS3. SOCS3 will cause inhibition of the activation of the leptin receptor 
through inhibition of JAK2, which can also be regulated by PTP1B. ERK1/2 may 
also be phosphorylated by activation of ObRB. Arrows indicate activation, 
blunted lines indicate inhibition. 
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melanocortin 3/4 receptor (Schwartz et al., 2000), this peptide is able to reduce 
food intake. The Pomc gene is transcribed as a result of leptin, which can also 
drive the production of other anorexigenic proteins such as cocaine- and 
amphetamine-related transcript (CART) and corticotrophin releasing hormone 
(CRH; Arora and Anubhuti, 2006). Specific sets of neurons within ARC express 
POMC and CART together, are activated by leptin and induce satiety. Specific 
deletion of ObRB from these neurons causes hyperphagia and obesity (Dhillon et 
al., 2006; Balthasar et al., 2004). Leptin acting within the ARC also inhibits and 
reduces the production of orexigenic factors, including neuropeptide Y (NPY) and 
agouti-related peptide (AgRP) (Elmquist et al., 1998; Baskin et al., 1999; 
Erickson et al., 1996). 
In non-ARC regions of the brain, leptin acts through ObRB to mediate 
reductions in homeostatic food intake. Some of these regions include the 
ventromedial hypothalamus (Dhillon et al., 2006) and NTS (Hayes et al., 2009). 
Hedonic food intake has also been shown to be reduced by leptin through the 
dopaminergic mesolimbic system, namely the ventral tegmental area and 
accumbens nucleus (Leinninger et al., 2011; Hommel et al., 2006; Fulton et al., 
2006).  
 
1.4.4.2 Energy expenditure 
Although leptin is primarily known for its effects on satiety and food intake, 
leptin is best described as a hormone that causes a shift to negative body energy 
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balance, as it is able to increase energy utilization. Leptin increases energy 
expenditure through three major mechanisms: 1) increased metabolism (Dieguez 
et al., 2011); 2) increased locomotion (Mendoza et al., 2011); and 3) increased 
thermogenesis (Scarpace et al., 1998).  
 
1.4.5 Leptin and sympathetic nervous activity 
Leptin acts to augment the sympathetic nervous activity in part to 
complete its negative feedback loop with energy balance. That is, release of 
leptin due to energy intake will cause the activation of the sympathetic nervous 
system, which will cause lipolysis in white adipose tissue, thermogenesis in 
brown adipose tissue and elevated metabolic activity within the liver and skeletal 
muscles. These physiological mechanisms will cause net energy expenditure. 
Given that leptin acts in many homeostatic systems, the increase in 
sympathetic tone by leptin also regulates many physiological functions. Bone 
resorption, for example, has recently been shown to be regulated by the effect of 
leptin on the sympathetic nervous system (Eleftriou et al., 2005). Likewise, leptin 
is able to increase sympathetic nervous activity to the kidney and arterial 
vasculature to cause an increase in blood pressure (Mark et al., 2009). These 
effects may be caused by an inhibition of the baroreceptor reflex (Ciriello, 2013a, 
b; Arnold et al., 2009). Injections of leptin into the ARC increases sympathetic 
effects on the hindlimb and kidney, as well as the brown adipose tissue 
(Rahmouni and Morgan, 2007; Montaro et al., 2005). The role of leptin in ARC on 
33 
 
sympathetic outflow to both kidney and cardiovascular system appears to be 
dependent on the melanocortin system (do Camo et al., 2011; Morgan et al., 
2008). 
 
1.4.6 Leptin and neuroplasticity 
Recent advances in the understanding of neuroplasticity in response to 
hormones such as leptin have provided a novel mediator of homeostatic 
functions such as food intake and sympathetic tone. Plastic alterations within 
specific brain regions such as ARC (McNay et al., 2013) and NTS (Kline, 2008) 
have demonstrated that these regions undergo dynamic regulation of function, 
neural morphology and synaptogenesis. 
The role leptin may play in neuroplasticity and synaptic plasticity has only 
recently come to light. Leptin receptor has been localized to, not only somato-
dendritic regions of neurons, but also axonal processes and synapses (Shanley 
et al., 2002). Animals deficient in leptin have electrophysiological deficits in long-
term potentiation and long-term depression, both of which are important 
functional outcomes of neuroplasticity (Li et al., 2002). In vivo, leptin induces 
long-term potentiation (Wayner et al., 2004), which is dependent on N-methyl-D-
aspartate (NMDA) receptor function (Collingridge et al., 1983). Leptin augments 
NMDA receptor signaling, increasing intracellular calcium influx (Shanley et al., 
2001; Harvey et al., 2005). Likewise, there is a crucial role for GluN2 subunit of 
NMDA receptors in mediating the excitatory transmission of leptin (Moult and 
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Harvey, 2011). It appears that in adult life, the neuroplastic effect of leptin on 
synaptic strength is mediated by phosphoinositide-3 kinase, whereas at younger 
points of development this effect is likely due to ERK1/2 (Moult and Harvey, 
2011).  
 In addition to the functional neuroplasticity associated with leptin, there are 
also significant morphological remodelling events that have been shown to occur, 
which likely contribute to the overall ability of leptin to modulate neuroplasticity 
(Maletic-Savatic et al., 1999). Leptin is able to increase the density and motility of 
dendrites, and alter the actin cytoskeleton (O’Malley et al., 2005, 2007; Ning et 
al., 2006). Both of these alterations are important for neurite outgrowth, as well 
as synaptogenesis (Fiala et al., 1998; Munno and Syed, 2003). Such alterations 
have been shown to be related to changes in growth-associated protein 43 
(GAP-43) and the synaptic marker synaptophysin (Bottner et al., 2013; 
Routtenberg, 1985). These morphological alterations are mirrored in activity-
dependent neuroplasticity (Fukazawa et al., 2003).  
 Neurotrophic factors such as brain-derived neurotrophic factor (BDNF) 
and its receptor tropomyosin receptor kinase B (TrkB) have recently been 
implicated in the satiety-inducing effects of leptin in both the hypothalamus and 
NTS (Liao et al., 2012; Spaeth et al., 2013). It appears these neuroplastic 
effectors exist downstream from the leptin receptor, and may be necessary for 
leptin to exert its effect (Liao et al., 2012). 
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1.4.7 Leptin resistance 
When leptin was first discovered in 1994, it was believed the satiety-
inducing hormone would act to resolve positive body energy balance syndromes 
like obesity. However, the finding of hyperleptinemia, as opposed to 
hypoleptinemia, in obese subjects suggested otherwise. An increase in hormone 
concentration with a reduction in its effect is suggestive of a resistance to that 
hormone, as seen with insulin in type II diabetes mellitus (Friedman, 2010). 
Application of leptin to obese mice have varying sensitivities to the hormone, with 
the leptin-deficient ob/ob mouse being the most sensitive and the leptin-receptor 
mutated db/db being the least sensitive (Halaas et al, 1997). This effect is 
mirrored in humans, where obese leptin-deficient people are sensitive to leptin, 
while most other forms of obesity are leptin-resistant. Primary leptin-deficiency in 
human populations is extremely rare (Farooqi et al., 1999), but secondary leptin-
deficiency is slightly more common, arising from lipodystrophy and hypothalamic 
amenorrhea. In all cases, administration of recombinant leptin was able to 
resolve many resulting neuroendocrine, reproductive and metabolic issues 
(Farooqi et al., 1999; Oral et al., 2002; Welt et al., 2004). 
The mechanisms associated with leptin resistance are not completely 
understood. As is found with insulin resistance, many changes in leptin signaling 
and transport systems may accumulate to mediate the resistant state. 
Hyperleptinemia associated with leptin resistance may play an important role as 
both a cause and result of the pathophysiology, given that overexpression of 
leptin within the brain induces leptin resistance, and blockade of leptin receptors 
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in obese animals exaggerates diet-induced obesity (Scarpace and Zhang, 2007). 
The resistance to leptin may be the result of decreased transport across the 
blood-brain barrier (Katsin et al., 1999; Banks et al., 2002; Burguera et al., 2000; 
Dube et al., 2000), and obese humans have a reduced cerebrospinal fluid-serum 
ratio of leptin despite concomitant hyperleptinemia (Caro et al., 1996; Schwartz 
et al., 1996).  
A reduction in downstream signaling of leptin within ARC may also play an 
important role in leptin resistance, either at the level of the receptor availability, 
reduced post-receptor activities, or by augmented negative feedback at the 
receptor (Friedman et al., 2010; Mark, 2013). 
Despite this reduced leptin effect on satiety, thus causing positive energy 
balance, it has been noted that the sympathetic effects of leptin are maintained 
during leptin resistance (Rahmouni et al., 2002; Correira et al., 2002). This has 
given rise to the concept of a selective leptin resistance in obesity, and has 
recently garnered attention as a contributor to obesity-related hypertension (Kuo 
et al., 2001). The selective nature of leptin resistance is poorly understood, but 
may be the result of alternative signaling mechanisms in sympathetic-related 
neurons and brain regions following leptin binding (Mark, 2013). 
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1.5  HYPOTHESIS AND OBJECTIVES 
 
1.5.1 Hypothesis 
We hypothesize that IH in rats will lead to metabolic and hypertensive 
cardiovascular phenotypes, which will be associated with alterations in brain 
regions known to regulate body energy balance and the cardiovascular system. 
This thesis will focus largely on manipulations of various hormones released in 
response to IH, and how they may mediate or affect the phenotypes observed.  
 
1.5.2 Objectives 
The major objectives of this thesis are as follows: 
1) characterize the body energy balance phenotype that may be associated 
with both short- and long-term IH and its concomitant alterations in 
hormonal release; 
 
2) determine alterations in the ARC of animals exposed to short- and long-
term IH that may be associated with body energy balance and the role 
leptin signaling may play in mediating these effects; 
 
3) measure cardiovascular alterations, including baroreceptor reflex function, 
following short- and long-term IH, which may be associated with 
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alterations in neuroplasticity within NTS, and the role leptin may play in the 
short-term changes, and 
 
4) determine the role of angiotensin II in modulating leptin release and 
signaling in the carotid body following IH. 
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2. CHAPTER 2 
2.1 CHAPTER SUMMARY 
This study was done to investigate the effects of acute intermittent hypoxia (IH) 
on metabolic factors associated with energy balance and body weight, and on 
hypothalamic satiety-inducing pathways. Adult male Sprague-Dawley rats were 
exposed to either 8h IH or normoxic control conditions. Food intake, locomotion 
and body weights were examined after IH. Additionally, plasma levels of leptin, 
adiponectin corticosterone, insulin and blood glucose were measured following 
exposure to IH. Furthermore, adipose tissue was removed and analyzed for 
leptin and adiponectin content. Finally, the hypothalamic arcuate nucleus (ARC) 
was assessed for alterations in protein signaling associated with satiety. IH 
reduced body weight, food intake and active cycle locomotion without altering 
adipose tissue mass. Leptin protein content was reduced while adiponectin 
content was elevated in adipose tissue after IH. Plasma concentration of leptin 
was significantly increased while adiponectin decreased after IH. No changes 
were found in plasma corticosterone, insulin and blood glucose. In ARC, 
phosphorylation of signal transducer and activator of transcription-3 and pro-
opiomelanocortin (POMC) expression were elevated. In addition, POMC-
expressing neurons were activated as determined by immediate early gene FRA-
1/2 expression. Finally, ERK1/2 and its phosphorylation were reduced in 
response to IH. These data suggest that IH induces significant alterations to body 
energy balance through changes in the secretion of leptin which exert effects on 
satiety-inducing pathways within the hypothalamus. 
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2.2 INTRODUCTION 
While white adipose tissue is the major storage site for triglycerides in the 
body, this organ also appears to play a role in endocrine function, partly through 
the production and release of a class of hormones known as adipokines. 
Adipokines are used by the body to provide information regarding energy 
balance, which in turn may influence thermogenic activity, food intake and 
glucose homeostasis (Ahima and Osel, 2008).  Leptin, a 16 kDa hormone 
produced by the ob gene (Halaas et al., 1995), is an adipokine that functions as a 
satiety-inducing hormone. The primary site of secretion of leptin into the 
bloodstream is the white adipose tissue, and this secretion generally occurs 
directly in relationship to the white adipose tissue mass (Maffei et al., 1995). 
However, the release of leptin into the circulation can be altered by a number of 
different stimuli, including hypoxia (Reinke et al., 2011; Sherry et al., 2009) and 
acute intermittent hypoxia (IH) (Messenger et al., 2012). Hypoxia elevates leptin 
production and release from white adipose tissue in both in vitro (Grosfield et al., 
2002) and in vivo (Sherry et al., 2009). Similarly, acute IH has been shown to 
increase the circulating levels of leptin (Messenger et al., 2012). Although the 
functional role of this upregulation of the leptinergic system is unknown, it may be 
involved in the regulation of the sympathetic nervous system activity (Mark et al., 
2009; Ciriello and Moreau, 2012), and this may be mediated partly through its 
effects on hypothalamic neurons (Harlan et al., 2011). Leptin not only reduces 
food intake largely by acting on pro-opiomelanocortin (POMC) neurons of the 
arcuate nucleus (ARC; Hill et al., 2008), but these POMC neurons may also 
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affect blood glucose levels (Berglund et al., 2012; Shi et al., 2008). Leptin binds 
to POMC neurons through the long-form leptin receptor (Ob-Rb), resulting in the 
homodimerization and phosphorylation of signal transducer and activator of 
transcription-3 (STAT3; Calvino et al., 2012). Phosphorylated STAT3 (pSTAT3) 
translocates to the nucleus of these neurons and alters gene transcription of 
various targets including Pomc and immediate early genes (Bousquet et al., 
2000).    
As adipose tissue is responsive to hypoxia, and that many factors 
produced by adipose tissue are related to energy balance, this study was done to 
determine whether acute 8 h IH altered the signaling of the adipose, resulting in 
alterations in energy balance. 
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2.3 METHODS AND MATERIAL 
2.3.1 Animals 
Adult, male Sprague-Dawley rats (320 – 400 g: n = 48) were purchased from 
Charles River Canada and housed singly at a temperature of 22°C and 60% 
relative humidity with access to food and water available ad libitum, except 
during the acute 8 h IH or normoxic (Norm) exposure, in 12h light/dark cycle 
conditions. Animals were handled in accordance with the guidelines set forth by 
the Canadian Council on Animal Care and the Animal Use Committee at the 
University of Western Ontario. 
 
2.3.2 Groups  
Animals were divided into different subsets: the first subset (n=7 per condition) 
was used to determine physiological measures including food and water intake 
and body weight changes; the second subset (n=7 per condition) was used for 
active cycle locomotion studies; the third subset (n=7 per condition) was used for 
immediate sacrifice following exposure, from which plasma samples (used for 
hormone analysis), blood glucose, adipose tissue and brains were removed; the 
final subset of animals (n=3 per condition) were perfused immediately following 
exposure, and were used for immunohistochemistry and immunofluorescence.  
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2.3.3 IH or Norm exposure 
Animals were exposed to 8 h (0900-1700) of acute IH or Norm during their sleep 
cycle, as previously described (Messenger et al., 2012). In brief, animals were 
placed in a chamber (35 L volume) consisting of four separate animal tubes (10 
cm diameter by 35 cm length) and a zero-pressure escape valve. For IH-exposed 
animals, a computer that regulated solenoid valves altered the input of N2 or 
room air to generate IH and Norm conditions. The gases were pushed through 
the system using fans and passed through a mixing chamber prior to entering the 
animal tubes. Flows of N2 and room air were set to be equal, requiring the same 
amount of time to drop from 21% to 6.5% O2, as required returning to 21% from 
6.5% O2. Animals were exposed to 80s hypoxia (6.5% O2) followed by 120s 
normoxia. The levels of O2 and CO2 were monitored by sensors on the chamber, 
which relayed information back to the computer to ensure proper cycling. 
Conditions within the chamber were isobaric (770 ± 11 mmHg) and eucapnic 
(<0.1% CO2). Norm animals were exposed to identical chambers with only room 
air input during cycling. No alterations in sleep duration or locomotion were 
observed between IH or Norm animals during exposure.  
 
2.3.4 Measures of body weight, food intake and water intake 
Animals were weighed immediately before and after IH or Norm exposure. These 
values were used to calculate body weight changes during the IH or Norm 
exposure period and 24 h body weight change. Additionally, food and water 
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intake measurements were recorded for the 16 h period immediately following 
exposure  
 
2.3.5 Locomotion assay 
In a subset (n=7 per group), immediately following acute IH or Norm exposure, 
animals were placed in home cages with ad libitum access to food and water. 
Thirty minutes into the dark (active) cycle (1930h), animals were placed into large 
cages (60 cm x 40 cm) with a floor 4x5 grid system in the dark (red light on). 
Animals were acclimatized for 10 min to the testing cage. Over a five-minute 
period, the number of crosses of a line by an animal was determined by two 
independent, blinded observers to determine horizontal locomotion. At the same 
time, vertical locomotion was determined by the number of rearing events. An 
average value was then calculated from these two observers for both horizontal 
and vertical locomotion. These animals were not used for determination of food 
or water intake. 
 
2.3.6 Blood glucose measurement  
Immediately following exposure conscious animals had blood glucose measured 
three times using an Accu-Check Aviva glucometer (Roche Diagnostics Canada; 
Laval, QC) from a tail vein puncture.   
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2.3.7 Plasma collection and enzyme immunoassays  
Subgroups of rats exposed to IH (n=7) or Norm (n=7) were immediately 
sacrificed under equithesin anaesthesia [0.3 ml/100 g b.w.; i.p. (2.88 mg/100 g 
b.w. sodium pentobarbital; 12.79 mg/100 g b.w. chloral hydrate; 6.37 mg/100 g 
b.w. MgSO4; 0.12 ml/100 g b.w. propylene glycol; 0.03 ml/100 g b.w. ethanol)] 
immediately following exposure. Blood samples were collected by cardiac 
puncture in the presence of 7% ethylenediaminetetraacetic acid at a volume of 
10 µl/ml blood. This blood was immediately centrifuged at 10 000 RPM for 10 min 
at 4 °C to isolate the aqueous plasma. This aqueous plasma phase was removed 
and stored frozen at -80 °C until analyzed for hormone content. Plasma samples 
were analyzed using enzyme immunoassays for rat leptin (sensitivity: 67.2 pg/ml; 
Enzo Life Sciences; Farmingdale, NY), adiponectin (sensitivity: 0.12 ng/ml; 
Phoenix Pharmaceuticals; Burlingame, CA), corticosterone (sensitivity: 26.99 
pg/ml; Enzo Life Sciences; Farmingdale, NY) and insulin (sensitivity: 0.12 ng/ml; 
Alpco Diagnostics; Salem, NH), according to manufacturer instructions. Enzyme 
immunoassay plates were read on a SpectraMax M5 plate reader using SoftMax 
Pro v.5 microplate analysis software (Molecular Devices; Sunnyvale, CA).   
 
2.3.8 Tissue collection and preparation 
Immediately after exposure to IH (n=7) or Norm (n=7), additional subgroups of 
the animals were sacrificed under equithesin anaesthesia and the brain and 
retroperitoneal fat pad were removed and frozen at -80 °C until analyzed. Brains 
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were sectioned at 100 µm in a cryostat (Bright Instruments; Cambridgeshire, UK) 
until ARC was identified using cytoarchitectural landmarks and a rat brain atlas 
(Paxinos and Watson, 1986). Using a circular 1 mm (internal diameter) 
micropunch tool, bilateral punches of ARC were made to a depth of 0.5 mm and 
the frozen tissue was then homogenized in cold radioimmunoprecipitation assay 
buffer (50 mM Tris, 150 mM NaCl, 1% Triton-X 100, 0.25% sodium deoxycholate, 
1 mM NaF, 1 mM sodium orthovanadate, 25 mM β-glycerophosphate) with 
protease inhibitor cocktail (Roche Applied Science; Laval, QC) by an electric 
homogenizer (VWR International; Radnor, PA). Homogenates were then 
sonicated over three passages for 15s each on ice (55%; Sonic Dimembrator 
Model 150; Fisher Scientific). Samples were then rotated for 10 min at 4 °C and 
centrifuged at 4°C for 20 min at 14 000 RPM. Adipose tissue samples were taken 
while frozen and processed using the same procedure. Protein content of 
homogenates was quantified using the Bio-Rad Dc protein assay kit (Bio-Rad 
Laboratories; Hercules, CA). Protein samples were added to 25% LDS sample 
buffer and 10% reducing buffer (Life Technologies; Burlington, ON) and water to 
a standard protein concentration of 1.67 mg/ml.  
 
2.3.9 Western blots  
Electrophoresis was carried out using a 10% discontinuous polyacrylamide Bis-
Tris gel (Life Technologies; Burlington, ON), followed by standard protein 
immunoblotting techniques. For each animal, 25 µg of protein of each sample 
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was loaded. Electrophoresis was carried out at 200 V and terminated when the 
dye front reached the bottom of the gel. Proteins were transferred to a 
polyvinylidene fluoride membrane using a wet transfer method in the presence of 
methanol and  SDS (50 mM Tris, 40 mM glycine, 0.3% SDS, 20% methanol) and 
wet transfer apparatus (Mini Trans-Blot Electrophoretic Transfer Cell; Bio- Rad 
Laboratories; Hercules, CA) at 100 V for 2 h. After transfer, the membrane was 
washed in Tris-buffered saline + Tween-20 (TBST; 20 mM Tris, 0.5 M NaCl, 
0.1% Tween-20; pH 8.0) blocked for 1 h with 5% skim milk made in TBST buffer 
at room temperature. The membrane was then incubated with primary antibodies 
diluted in skim milk over night at 4 °C.  The following day, the membrane was 
washed with TBST before being incubated with horseradish peroxidase-
conjugated secondary antibodies-specific to the appropriate host of the primary 
antibody being analyzed, for 1 h at room temperature. For detection, the 
membrane was washed with TBST, followed by distilled water and then detected 
using a horseradish peroxidase substrate ECL chemiluminescence system 
(Luminata Forte, EMD Millipore; Billerica, MA). Blots were visualized using a 
VersaDoc imaging system (Bio-Rad Laboratories; Hercules, CA) and analyzed 
using ImageLab v.3.0 (Bio-Rad Laboratories; Hercules, CA). All comparisons 
presented were made within the same blot. 
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2.3.10 Immunohistochemistry 
Immediately following acute IH (n=3) or Norm (n=3) exposure, rats were deeply 
anesthetized with equithesin and perfused transcardially with 200-300 ml 0.9% 
physiological saline, followed by 450 ml of 4% paraformaldehyde in 0.1 M 
phosphate-buffered saline (PBS; pH 7.4).  Brains were removed and placed 
overnight in fixative at 4ºC.  Brains were then gradually dehydrated through a 
series of alcohols, and placed in xylene followed by paraffin wax. Serial, 
transverse sections (6 µm) through the region of ARC were cut on a microtome, 
mounted on double-gelatinized microscope slides and placed on a slide warmer. 
Tissue sections were later de-paraffinized in xylene and rehydrated using graded 
alcohol solutions. Sections were equilibrated using three 20 min washes of PBS 
(pH 7.4), and then underwent an antigen-retrieval protocol using a citrate buffer 
(10 mM sodium citrate, 0.05% Tween; pH 6.0) heated to 90-95ºC in a microwave 
for 15 min (von Boguslawsky, 1994). Slides were rinsed and endogenous 
peroxidase activity was inhibited by exposing the sections to a 1% hydrogen 
peroxide solution for 10 min.  Sections were washed in PBS and allowed to 
incubate overnight at 22ºC in primary polyclonal rabbit anti-rat POMC antibody in 
PBS/0.3% Triton-X 100 and 4% normal goat serum. The sections were rinsed in 
PBS and exposed to goat anti-rabbit IgG for 1 h, followed by 75 min in ABC Elite 
Kit reagent (Vector Laboratories; Burlingame, CA).  Following three rinses in 
PBS, the sections were immersed for 5 min in a solution of 0.05% 3,3’-
diaminobenzidine containing 0.01% hydrogen peroxide, resulting in a red-
brownish reaction product. The sections then underwent a similar protocol, but 
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using an overnight incubation in primary polyclonal rabbit anti-rat FRA-1/2 
antibody, after an avidin-biotin block (Vector Laboratories; Burlingame, CA). 
FRA-1/2 was detected using a solution of 0.05% 3,3’-diaminobenzidine 
containing 0.015% hydrogen peroxide and 0.05% nickel ammonium sulphate in 
PBS, resulting in a dense, black reaction product. Sections were rinsed and 
coverslipped. Some adjacent tissue sections were rehydrated, stained with 
thionin and cover-slipped for identification of cytoarchitectonic boundaries. 
Controls for immunoreactivity included forebrain brainstem sections processed 
following the omission of the primary antibody or preadsorption of the primary 
antibody with the appropriate antigen (Messenger et al., 2012). Under these 
conditions no POMC or FRA-1/2 immunoreactivity was demonstrated. 
Cells containing POMC- and FRA-1/2-like immunoreactivity were identified 
on sections through the region of ARC using bright-field microscopy (Letiz 
Diaplan), and digital images were obtained with a Nikon DS-Fil camera and NIS 
Elements Basic Research 3.0 software (Nikon Canada, Mississauga, ON, 
Canada). Cell counts of POMC-containing neurons co-expressing FRA-1/2-like 
immunoreactivity were determined by two independent, blinded observers and 
averaged to calculate a final value for each animal. 
 
2.3.11 Immunofluorescence 
Immunofluorescence was performed in a similar manner as described above for 
immunohistochemistry, except paraffin-embedded sections through the region of 
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ARC were exposed to specific antibodies for POMC and FRA-1/2 overnight, 
exposed to either biotinylated secondary antibody, and then exposed to 
streptavidin-linked Texas Red (1:100; GE Healthcare; Buckinghamshire, UK) or 
Alexa-488-linked secondary antibodies.  
 Cells containing POMC- and FRA-1/2-like immunofluorescence were 
identified throughout the region of ARC using a microscope fitted with various 
filters to detect Texas Red and Alexa-488. Digital images were obtained with a 
Nikon DS-Fi1 camera and NIS Elements Basic Research 3.0 Software 
(Messenger et al., 2012).  
 
2.3.12 Antibodies 
For western blots the following antibodies were used: rabbit anti-β-actin-HRP 
(1:50 000; A3854, Sigma-Aldrich; St. Louis MO), rabbit anti-GAPDH (1:2500; sc-
25778, Santa Cruz Biotechnology; Santa Cruz, CA), rabbit anti-leptin (1:1000; sc-
843, Santa Cruz Biotechnology; Santa Cruz, CA), chicken anti-ObRB (1:10 000; 
CH14104, Neuromics; Edina, MN), rabbit anti-FRA-1/2 (1:2000; sc-605, Santa 
Cruz Biotechnology; Santa Cruz, CA), rabbit anti-STAT3 (1:2000; #9132, Cell 
Signaling; Boston, MA), rabbit anti-pSTAT3 (Tyr705) (1:1000; #9131, Cell 
Signaling; Boston, MA), rabbit anti-ERK1/2 (1:2000; #9102, Cell Signaling; 
Boston, MA), rabbit anti-pERK1/2 (Thr 202/Tyr204) (1:1000; #9101, Cell 
Signaling; Boston, MA), rabbit anti-adiponectin (1:5000; AB3267P, Millipore; 
Billerica, MA), rabbit anti-POMC (1:2000; RayBiotech; Norcross GA), donkey 
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anti-rabbit IgG-HRP (1:10 000; 711-035-152, Jackson Immunoresearch; West 
Grove, PA), donkey anti-chicken IgY-HRP (1:10 000; 703-035-155, Jackson 
Immunoresearch; West Grove, PA). For immunohistochemistry and 
immunofluorescence the following antibodies were used: rabbit anti-POMC (1:10 
000; H-029-030, Phoenix Pharmaceuticals; Burlingame, CA), rabbit anti-FRA-1/2 
(1:1000; sc-253, Santa Cruz Biotechnology; Santa Cruz, CA), goat anti-rabbit 
IgG-biotin (1:500; BA-1000, Vector Laboratories; Burlingame, CA) goat anti-
rabbit IgG-Alexa-488 (1:200; 711-545-152, Jackson Immunoresearch; West 
Grove, PA). 
 
2.3.13 Statistics and analysis 
Differences between acute IH and Norm groups were determined by unpaired, 
two-tailed Student t-test, and a p-value < 0.05 was taken to indicate statistical 
significance. All values are expressed as mean ± standard error. All bar charts 
were made using GraphPad Prism v.5 graphing software (GraphPad Software; 
La Jolla, CA). 
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2.4 RESULTS 
2.4.1 Body weight, adipose tissue mass, food and fluid intake and 
locomotion after acute IH 
Animals in acute IH and Norm groups did not differ in starting body weight (365 ± 
9 g and 366 ± 10 g, respectively). Animals immediately after exposure to acute 8 
h IH had significantly (p < 0.01) greater body weight loss (-28 ± 2 g) compared to 
those exposed to Norm conditions (-13 ± 1 g). However, these differences in 
body weight change 24 h after the initiation of the exposure were reversed as 
animals exposed to acute IH (-5 ± 3 g) were not different from animals that were 
exposed to Norm conditions (1 ± 3 g). No changes were found in retroperitoneal 
(IH, 4.6 ± 1.2 g; Norm, 5.0 ± 1.1 g) or epididymal (IH, 2.8 ± 0.7 g; Norm, 3.2 ± 0.9 
g) adipose tissue mass (Fig 2.1).  
Despite the overnight body weight regain, food intake was significantly 
lower (p < 0.01) in acute IH animals (total food intake, 21.1 ± 2.1 g/16 h; food 
intake normalized to body weight, 5.9 ± 0.5 g/100 g body weight/16 h) compared 
to animals exposed to Norm conditions (total food intake, 35.4 ± 5.5 g/16 h; food 
intake normalized to body weight, 9.4 ± 1.3 g/100 g body weight/16 h). Water 
intake was not altered in response to acute IH exposure (total water intake, 42.6 
± 3.5 ml/16 h; water intake normalized to body weight, 12.0 ± 0.8 ml/100 g body 
weight/16 h) compared to Norm conditions (total water intake, 39.5 ± 7.0 ml/16 h; 
water intake normalized to body weight, 10.5 ± 1.9 ml/100 g body weight/16h).  
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Figure 2.1 Changes in body weight and fat mass following IH. 
Acute IH causes a greater reduction in body weight compared to Norm 
conditions, independent of alterations in adipose tissue mass. (a), line graph 
indicating significant (p<0.01) body weight loss as a result of the IH compared to 
Norm. This body weight loss is normalized 24h after the initiation of IH, and is not 
different from Norm. Bar graphs showing (b) retroperitoneal and (c) epididymal 
adipose tissue mass were not different following IH exposure compared to Norm 
animals. Data shown are means ± SEM. *, p<0.05.  n = 7-11 per group. 
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Animals exposed to acute IH had significantly (p < 0.05) reduced 
horizontal locomotion (IH, 88.5 ± 4.1 line crossings/5 min; Norm, 115 ± 9.7 line 
crossings/5 min). In contrast, vertical locomotion (IH, 28.0 ± 2.6 rearings/5 min) 
compared to Norm (32 ± 3.4 rearings/5 min) were not different. These data are 
summarized in Figure 2.2.  
 
2.4.2 Plasma leptin, adiponectin and leptin:adiponectin ratio are altered by 
acute IH 
Plasma leptin concentrations in animals exposed to acute IH (10.0 ± 1.3 ng/ml) 
were significantly (p < 0.05) greater than in animals exposed to Norm conditions 
(3.2 ± 1.3 ng/ml) immediately following exposure. Plasma adiponectin 
concentration was significantly (p < 0.05) less in acute IH compared to Norm 
exposure (2.2 ± 0.1 µg/ml and 2.6 ± 0.1 µg/ml, respectively). The ratio of the 
concentration of leptin to adiponectin in the plasma of the IH group was 
significantly (p < 0.01) higher than in the Norm group (0.0045 ± 0.0008 and 
0.0012 ± 0.0003, respectively). Plasma corticosterone concentrations were not 
changed by acute IH compared to Norm control (4.8 ± 1.2 ng/ml and 5.3 ± 1.1 
ng/ml, respectively). Similarly, plasma insulin concentrations were unchanged in 
the acute IH group compared to Norm conditions (6.4 ± 0.8 ng/ml and 7.2 ± 0.6 
ng/ml, respectively). Furthermore, blood glucose levels immediately following 
acute IH or Norm exposure were not different from each other (8.2 ± 1.0 mmol/L 
and 7.9 ± 1.3 mmol/L, respectively). These data are summarized in Figure 2.3.  
78 
 
 
 
 
 
 
Figure 2.2 Changes in food intake and locomotion following IH. 
Acute IH results in reduced food intake and locomotion compared to Norm 
conditions. Bar graphs indicating overnight food intake (a), standard food intake 
(b), water intake (c), standard water intake (d), horizontal locomotion measure 
(e), and vertical locomotion measure (f) between IH and Norm animals. Data 
shown are means ± SEM. *, p<0.05. n = 11 per group. 
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Figure 2.3 Changes in plasma hormones in response to IH. 
Plasma hormones are altered after acute IH. Bar graphs showing plasma levels 
of leptin (a), adiponectin (b), leptin:adiponectin ratio of plasma concentrations (c), 
corticosterone (d), insulin (e), and blood glucose (f) immediately after IH or Norm 
exposure. Data shown are means ± SEM. *, p<0.05. n = 7 per group. 
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2.4.3 Adipose tissue content of leptin and adiponectin protein is altered as 
a result of acute IH exposure 
As summarized in Figure 2.4, retroperitoneal adipose tissue displayed reduced (p 
< 0.01) expression levels of leptin protein after acute IH exposure compared to 
Norm animals (0.01 ± 0.01 and 0.28 ± 0.05, respectively). On the other hand, the 
protein expression of adiponectin in this tissue was significantly (p < 0.05) 
elevated between acute IH and Norm conditions (0.11 ± 0.02 and 0.05 ± 0.01, 
respectively).  
 
2.4.4 IH exposure alters signals associated with leptin signaling within ARC 
Within ARC, acute IH exposure increased the expression of phosphorylation of 
STAT3 protein approximately 8-fold (p < 0.001) over Norm (0.86 ± 0.05 and 0.11 
± 0.05, respectively) without changing total STAT3 protein expression (0.32 ± 
0.06 and 0.34 ± 0.05, respectively). A significant (p < 0.05) decrease in the total 
amount of ERK1/2 protein expression was also detected in ARC of acute IH 
exposed animals compared to Norm control (0.41 ± 0.08 and 0.56 ± 0.02, 
respectively). In addition, the expression level of phosphorylation of ERK1/2 
protein was reduced between IH and Norm conditions when compared to total 
ERK1/2 (1.05 ± 0.09 and 1.41 ± 0.13, respectively) and compared to β-actin 
(0.42 ± 0.07 and 0.79 ± 0.08, respectively). On the other hand, acute IH did not 
alter SOCS3 protein expression in ARC, compared to Norm (0.45 ± 0.07 and 
0.38 ± 0.08). Additionally, acute IH did not induce an alteration in the expression  
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Figure 2.4 Adipose adipokine protein content following IH. 
Adipose tissue protein content of leptin and adiponectin are altered by acute IH 
exposure. Bar graphs and representative blots indicating a reduction in 
retroperitoneal adipose tissue protein content of leptin (a) and an increase in 
adiponectin (b) protein content relative to GAPDH protein loading control, after IH 
compared to Norm. Data shown are means ± SEM. *, p<0.05. n = 7 per group. 
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of the Ob-Rb protein compared to Norm control (0.32 ± 0.03 and 0.41 ± 0.05, 
respectively). These data are summarized in Figure 2.5. 
 
2.4.5 Acute IH activates POMC-containing neurons and increases POMC 
protein within ARC 
Exposure of animals to acute IH increased the number of POMC-like 
immunoreactive neurons that also expressed the immediate early gene product 
FRA-1/2 compared to Norm animals (15.1 ± 2.2% and 2.3 ± 2.5%, respectively) 
within ARC (Fig. 2.6). The expression of POMC protein within ARC was 
significantly (p < 0.01) elevated in animals exposed to IH compared to Norm 
(0.21 ± 0.07 and 0.08 ± 0.02, respectively; Fig. 2.6). 
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Figure 2.5 ObR related intracellular pathways activated following IH 
Acute IH activates specific long-form leptin receptor (Ob-Rb)-related intracellular 
pathways in ARC. Bar charts and representative blots indicating relative protein 
content of phosphorylated STAT3 (a), phosphorylated ERK1/2 (b), SOCS3 (c) 
and Ob-Rb (d) within ARC of animals exposed to IH or Norm conditions. These 
values are expressed as a ratio to total β-actin protein. Data shown are means ± 
SEM. *, p<0.05. n=7 per group. 
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Figure 2.6 ARC POMC-containing cell activation following IH.  
Acute IH increases activation of POMC-containing cells and POMC protein 
content in ARC.  Photomicrographs of ARC indicating POMC-containing cells 
(brown), which display FRA-1/2 (black), a marker of neuronal activation, in both 
IH (a-b) and Norm conditions (c). Calibration marks represents 50 µm. (b) High-
magnification image of inset in (a). (d) Immunofluorescent image of ARC 
following exposure to IH. Note that POMC immunoreactivity is shown with green 
fluorescent marker and FRA 1/2 immunoreactivity with Texas red fluorescent 
marker. In both (b) and (d) large open arrows indicate cells that contain both 
POMC- and FRA-1/2-like immunoreactivities, while small open arrows show 
example of Fra-1/2 only labelled cells and the small arrow shows examples of 
POMC only labelled cells. (e), shows a bar chart summary of the proportion of 
ARC POMC-containing cells that also express FRA-1/2-like immunoreactivity. (f), 
bar chart and representative blots indicating the relative protein content of POMC 
within ARC in IH and Norm animals. These values are expressed as a ratio to 
total β-actin protein. Data shown are means ± SEM. *, p<0.05. n = 3 per group 
for immunohistochemistry; n = 7 per group for western blot analysis.   
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2.5 DISCUSSION 
This study has demonstrated that acute IH results in significant alterations 
in several variables associated with energy balance, adipokine release and 
activation of hypothalamic satiety signals. IH reduced body weight, active cycle 
food intake, and locomotion. These changes after IH were concomitant with a 
rise in plasma leptin and a reduction in plasma adiponectin, while adipose tissue 
had less leptin and more adiponectin protein expression after acute IH exposure. 
In ARC, acute IH induced phosphorylation of STAT3, reduced total ERK1/2 and 
phosphorylated ERK1/2, but did not significantly affect Ob-Rb or its negative 
regulator, SOCS3. Acute IH also induced activation, as determined by immediate 
early gene product FRA-1/2, of POMC-containing neurons of ARC and increased 
the protein expression of POMC in ARC. Taken together these suggest that IH 
induces significant alterations to body energy balance through changes in the 
secretion of leptin which exerts effects on satiety-inducing pathways within the 
hypothalamus.  
 The 8 h exposure to IH reduced body weight compared to Norm animals. 
However, by the following morning (16 h after IH), body weight change was 
found not to be different between the two groups. Unexpectedly, this body weight 
re-gain occurred despite a reduction in overnight food intake. Although the 
mechanism responsible for this re-gain in body weight is not clear, it is possible 
that the reduction in active cycle locomotion in IH-exposed animals may have 
contributed as a result of decreased energy expenditure. The regain of body 
weight in acute IH-exposed animals may be the result of alterations in 
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metabolism, as studies in rabbits have suggested that intermittent hypobaric 
hypoxia may lower circulating levels of thyroid hormones (Sawhney and 
Malhotra, 1990). Additionally, the reduction in food intake after acute IH was 
likely associated with the increased plasma leptin concentration, which occurred 
despite the lack of change in retroperitoneal or epididymal adipose tissue depot 
mass. It is known that leptin is correlated with adipose tissue content (Maffei et 
al., 1995). However, it has been reported that under certain pathophysiological 
challenges this balance can be altered (Kim and Scarpace, 2003). In this study, 
IH was a sufficient stimulus to elevate plasma leptin concentration and this may 
have accounted for the overnight reduction in food intake observed in these 
animals. Therefore, the actions and secretion of leptin appear to be independent 
of body weight changes induced by IH, while appearing inherently associated 
with IH. Taken together, these data can be interpreted to indicate that following 
acute IH, leptin may induce a state of satiety. As previously suggested, this may 
occur regardless of nutritional status (Levin et al., 1996; Rentsch et al., 1995). 
This finding is in contrast with reduced plasma concentration of leptin in 
individuals exposed to altitude-related hypoxia (Woolcott et al., 2002; Zaccaria et 
al., 2004). However, our findings occur following IH, rather than continuous 
hypoxia and under normobaric conditions, which may account for this difference. 
Consistent with this suggestion, it has been reported that IH can increase 
circulating leptin concentrations in mice (Li et al., 2005). It has been suggested 
that some IH models can induce sleep deprivation (Gozal et al., 2001). Sleep 
deprivation has been reported to reduce body weight and energy expenditure 
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(Vetrivelan et al., 2012), and a reduction (Vetrivelan et al., 2012) or no change 
(Bodosi et al., 2004) in leptin levels, with no changes in food intake (Barf et al., 
2010; Vetrivelan et al., 2012). In humans, sleep deprivation has been shown to 
increase hunger and reduce leptin levels (Brondel et al., 2010; Spiegel et al., 
2004). As well, corticosterone levels in the acute IH-exposed rats was not 
significantly different from Norm-exposed animals, if IH induced sleep deprivation 
in these animals, it would be expected that corticosterone levels would higher 
than controls (Tartar et al., 2009). Taken together, these data would suggest that 
it was unlikely that sleep deprivation played a significant role in the leptin-feeding 
responses observed in this study during acute IH.     
Adipose tissue leptin content was found to be less in acute IH conditions. 
This, coupled with the finding of elevated plasma leptin concentrations, suggests 
an increase in the secretion of the adipokine by adipose tissue. Adipocytes have 
been demonstrated to increase their secretion of leptin in response to hypoxia 
(Famulla et al., 2012), and IH caused a sustained hypoxia in adipose tissue 
(Reinke et al., 2011). Taken together, these findings suggest that adipose tissue 
hypoxia resulting after acute IH in this study may have increased the release of 
leptin from adipocytes. Conversely, adiponectin had a lower circulating level, 
though an increased amount of the protein was found within adipocytes. This is 
consistent with previous studies showing that hypoxia causes a reduction in 
adipocyte secretion of the adipokine (Famulla et al., 2012). The changes in 
circulating levels of adipokines as seen in this study, induces a higher 
leptin:adiponectin ratio, perhaps as a result of altered adipocyte secretion as a 
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result of IH. An increase in leptin:adiponectin ratio is a commonly used measure 
associated with cardiometabolic disease (Satoh et al., 2004; Kotani et al., 2005). 
The alterations observed in circulating adipokine concentrations, as seen during 
IH in this study, are consistent with those found in individuals suffering from 
obesity (Dagogo-Jack et al., 1996) and obstructive sleep apnea (Hargens et al., 
2013), of which IH is a major component. 
Leptin action in ARC reduces food intake through activation of intracellular 
signaling pathways associated with Ob-Rb (Peters et al., 2007; Scarpace et al., 
2007). The primary pathway associated with leptin’s satiety-inducing effects is 
the phosphorylation of STAT3 in the rat (Ladyman and Grattan, 2004). 
Homodimerization of pSTAT3 results in translocation of the transcription factor to 
the nucleus of the affected cell. This induces transcription of several genes, such 
as Pomc and immediate early genes, including Fra-1 (Bousquet et al., 2000). Our 
results show that after acute IH, POMC protein content within ARC increases. 
This finding is supported by the observations of increased Pomc mRNA in 
response to leptin (Mizuno et al., 1998). The effect of leptin on specific neurons 
within ARC is thought to be dependent on the phenotype of the neurons within 
this region. Leptin has been shown to increase the firing rate of POMC-
containing neurons (Cowley et al., 2001; Wang et al., 2008), while inhibiting the 
activity of neurons expressing neuropeptide Y (van den Top et al., 2004; Wang et 
al., 2008). Increased POMC in the hypothalamus induces hypophagia (Zhang et 
al., 2011), and we have found that acute IH induces both an increase in ARC 
POMC, as well as hypophagia. Our findings show that the IH leads to activation 
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of POMC-containing neurons within this region as it was found that a larger 
number of POMC neurons in ARC expressed the immediate early gene product 
FRA-1/2. The finding of increased FRA-1/2 expression in cells has been used to 
indicate alterations in neuronal activity, including depolarization under a variety of 
conditions, including IH (Messenger et al., 2012). These findings are further 
supported by the observation of transcriptional upregulation of satiety genes 
within the hypothalamus following chronic IH (Volgin and Kubin, 2006). 
 In summary, acute IH results in reductions in body weight, food intake and 
locomotion, and can alter the release of adipokines that regulate food intake from 
adipose tissue. Intracellular signaling pathways that are normally associated with 
satiety signaling were elevated in response to IH and this likely lead to the 
increased activity of POMC-containing neurons within ARC. These findings 
suggest that acute IH may result in altered body energy balance possibly through 
activation of hypothalamic pathways.  
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CHAPTER 3 
 
ACUTE INTERMITTENT HYPOXIA DOES NOT ALTER ENERGY 
BALANCE IN THE LEPTIN-DEFICIENT KILO RAT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been submitted for publication to Brain Research 
BRES-D-13-01522, November 16, 2013. 
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3. CHAPTER 3 
3.1 CHAPTER SUMMARY 
Intermittent hypoxia (IH) is a major pathophysiological consequence of 
obstructive sleep apnea. Recently it has been described that acute IH results in 
complex alterations in body energy balance, induced leptin secretion and 
concomitant alterations in feeding pathways within the hypothalamus. To 
determine the role of leptin on these changes, leptin-deficient KILO rats were 
exposed to IH or normoxic control conditions. Body weights, consumatory and 
locomotor behaviours and hypothalamic alterations were assessed immediately 
following exposures. IH failed to alter measures of body weight, fat pad mass, 
food intake, locomotor activity, and the plasma concentration of angiotensin II. 
Plasma leptin concentration was undetectable by enzyme immunoassay. Within 
the arcuate nucleus of the hypothalamus, no changes were observed in 
phosphorylated signal transducer and activator of transcription 3, pro-
opiomelanocortin, long- or short-form leptin receptor, suppressor of cytokine 
signaling 3, nor within phosphorylated extracellular signal-regulated kinase ½. 
This study suggests that leptin plays an essential role in mediating the alterations 
observed in body energy balance and hypothalamic activity following IH 
compared to normoxic controls. Whether this effect is due to a lack of leptin 
directly acting in the hypothalamus, failure to initiate the release of a secondary 
factor, or altered chemoreceptor reflex sensitivity is not known. 
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3.2 INTRODUCTION 
Intermittent hypoxia (IH) is a major pathophysiological consequence of 
obstructive sleep apnea, a condition during which there is the episodic closures 
of the airway during sleep. A substantial reduction in pulmonary oxygen tension 
is observed during IH resulting in hypoxemia (Dempsey et al., 2010; Simon and 
Collop, 2012). As a result of this whole-body hypoxic insult, several physiological 
systems are altered, including the cardiovascular (Levy et al., 2012; Freet et al., 
2013) and respiratory (Debevec and Mekjavic, 2012; Dempsey et al., 2012) 
systems. It has been shown that alterations to the endocrine system are also 
induced by both sustained hypoxia and IH (Dempsey et al., 2010; Moreau and 
Ciriello, 2013; Reinke et al., 2011; Tschop et al., 2000). In particular, studies in 
both humans and experimental animal models have shown plasma leptin 
concentration to be elevated following IH (Messenger et al., 2012; Moreau and 
Ciriello, 2013; Tschop et al., 2000), and this is often associated with alterations in 
body energy balance (Moreau and Ciriello, 2013; Tschop et al., 1998). Leptin is 
an important modulator of satiety. Released by white adipocytes, the 16-kDa 
protein hormone signals arcuate nucleus of the hypothalamus (ARC; Satoh et al., 
1997). Within ARC, leptin increases the activity of pro-opiomelanocortin (POMC) 
neurons, while inhibiting neurons expressing neuropeptide Y (Elmquist et al., 
1998). When activated, POMC neurons mediate satiation and anorexigenic 
responses (Balthasar et al., 2004; Dhillon et al., 2006).   
Recently, we have shown that acute IH can alter central mechanisms important 
for the regulation of body energy balance (Moreau and Ciriello, 2013). This study 
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demonstrated that leptin, a satiety-inducing hormone, released into the 
circulation occurred after acute IH. Subsequently, a reduction in food intake was 
observed, despite an initial loss of body weight. These effects were observed 
concomitant to the induction of the anorexigenic factors phosphorylated signal 
transducer and activator of transcription 3 (pSTAT3), pro-opiomelanocortin 
(POMC), and a reduction of phosphorylated extracellular signal-regulated kinase 
1/2 (pERK1/2) within arcuate nucleus of the hypothalamus (Moreau and Ciriello, 
2013). Whether leptin played a direct role in these observed effects following IH 
is not known.  
Therefore, this study was done to determine whether the effects of acute 
IH on body energy balance and associated hypothalamic feeding pathways are 
initiated as a result of the release of leptin following IH. To determine this, leptin-
deficient rats were exposed to IH or normoxic conditions, and assessed for 
various measures of body weight, behaviors and plasma hormones associated 
with body energy balance and compared to wild type Sprague Dawley rats (WT). 
ARC was also removed to determine potential alterations in signaling in 
hypothalamic feeding pathways. 
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3.3 METHODS AND MATERIAL 
3.3.1 Animals and study design 
Adult male, Sprague-Dawley rats (300-350 g; n=12) were obtained from Charles 
River Canada (Sherbrooke, QC). Adult male, homozygous, leptin-deficient KILO 
rats (250-400 g; n=8; SD-Leptm1sage) were obtained from Sigma Advanced 
Genetic Engineering Laboratories (TGRA3780; Vaira et al., 2012). Rats were 
individually housed at a temperature of 22°C and 60% relative humidity with 
access to food and water available ad libitum, except during the 8 h IH or 
normoxic exposure, in 12h light/dark cycle conditions. Animals were handled in 
accordance with the guidelines set forth by the Canadian Council on Animal Care 
and the Animal Use Committee at the University of Western Ontario. 
 
3.3.2 IH and normoxic exposures 
Animals were assigned to either IH or normoxia group for exposure. Following 
these exposures, physiological measures of body weight and consumatory 
behaviours were measured. Animals were exposed to IH and normoxic 
conditions as previously described (Messenger and Ciriello, 2013; Messenger et 
al., 2012, 2013; Moreau and Ciriello, 2013). In brief, animals were placed in 
chambers consisting of four tubes (10 cm diameter by 35 cm length) and a zero-
pressure escape valve. For IH-exposed animals, a computer that regulated 
solenoid valves altered the input of N2 or room air to generate IH conditions. 
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Animals were exposed to 80s hypoxia (6.5% O2) followed by 120s normoxia. The 
levels of O2 and CO2 were monitored by sensors on the chamber, which relayed 
information back to the computer to ensure proper cycling. Conditions within the 
chamber were isobaric (770 ± 11 mmHg) and eucapnic (<0.1% CO2) (Moreau 
and Ciriello, 2013). Normoxic animals were exposed to only the air input. 
 
3.3.3 Measures of body weight, food intake and water intake 
Animals were weighed immediately before and after IH or normoxic exposure. 
These values were used to calculate body weight changes during the exposure 
period, overnight body weight gain and 24 h body weight change. Furthermore, 
food and water intake were measured over the remaining 16 h following IH or 
normoxic exposure (Moreau and Ciriello, 2013). 
 
3.3.4 Locomotion assay 
Immediately following IH or normoxic exposure (1700 h), animals were placed in 
home cages with access to food and water ad libitum. Animals were placed into 
large cages (60 cm x 40 cm) with a floor 4x5 grid system in the dark (red light on) 
30 min into the dark (active) cycle (1930 h). Over a 5 min period, the number of 
crosses of a line by an animal was determined by two independent, blinded 
observers to determine horizontal locomotion. Simultaneously, vertical 
locomotion was determined by the number of rearing events. An average value 
107 
 
was then calculated from these two observers for both horizontal and vertical 
locomotion (Moreau and Ciriello, 2013). 
 
3.3.5 Plasma collection and enzyme immunoassays 
As previously described (Moreau and Ciriello, 2013), immediately after the cross-
over exposure, rats were immediately sacrificed under equithesin anaesthesia 
(0.3 ml/100 g b.w.; i.p.). Blood samples were collected by cardiac puncture in the 
presence of 7% ethylenediaminetetraacetic acid at a volume of 10 µl/ml blood 
and immediately centrifuged at 10 000 RPM for 10 min at 4 °C to isolate the 
aqueous plasma. This aqueous plasma phase was removed and analyzed using 
enzyme immunoassays for rat leptin (Enzo Life Sciences; Farmingdale, NY) and 
angiotensin II (Phoenix Pharmaceuticals; Burlingame, CA) according to 
manufacturer instructions. Enzyme immunoassay plates were read on a 
SpectraMax M5 plate reader using SoftMax Pro v.5 microplate analysis software 
(Molecular Devices; Sunnyvale, CA).   
 
3.3.6 Tissue collection and preparation 
Immediately after exposure to IH or normoxia, rats were sacrificed under 
equithesin anesthesia (0.3 ml/100 g b.w.; Moreau and Ciriello, 2013) and the 
brains removed and frozen at -80°C until analyzed. Using a circular micropunch 
tool (1 mm internal diameter), 500 µm punches of ARC were taken and 
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immediately homogenized in cold radioimmunoprecipitation assay buffer (50 mM 
Tris, 150 mM NaCl, 1% Triton-X 100, 0.25% sodium deoxycholate, 1 mM NaF, 1 
mM sodium orthovanadate, 25 mM β-glycerophosphate) with protease inhibitor 
cocktail (Roche Applied Science; Laval, QC) by an electric homogenizer (VWR 
International; Radnor, PA). Homogenates were sonicated over three passages 
for 15s each on ice (55%; Sonic Dimembrator Model 150; Fisher Scientific). 
Samples were then rotated for 10 min at 4 °C and centrifuged at 4°C for 20 min 
at 14000 RPM. Protein content of homogenates was quantified using the Bio-
Rad Dc protein assay kit (Bio-Rad Laboratories; Hercules, CA). Protein samples 
were added to 25% sample buffer and 10% reducing buffer (Life Technologies; 
Burlington, ON) and water to a standard protein concentration of 1.67 mg/ml 
(Moreau and Ciriello, 2013; Messenger and Ciriello, 2013). 
 
3.3.7 Western blots 
As previously described (Messenger et al., 2012; Moreau and Ciriello, 2013), 
electrophoresis was carried out using a 10% discontinuous polyacrylamide Bis-
Tris gel (Life Technologies; Burlington, ON), followed by standard protein 
immunoblotting techniques. From each animal, 25 µg of protein of each sample 
was loaded. Electrophoresis was carried out at 200 V and terminated when the 
dye front reached the bottom of the gel. Proteins were transferred to a 
polyvinylidene fluoride membrane using a wet transfer method in the presence of 
methanol and  SDS (50 mM Tris, 40 mM glycine, 0.3% SDS, 20% methanol) and 
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wet transfer apparatus (Mini Trans-Blot Electrophoretic Transfer Cell; Bio- Rad 
Laboratories; Hercules, CA) at 100 V for 2 h. After transfer, the membrane was 
washed in Tris-buffered saline + Tween-20 (TBST; 20 mM Tris-HCl, 0.5 M NaCl, 
0.1% Tween-20; pH 8.0) blocked for 1 h with 5% skim milk made in TBST buffer 
at room temperature. The membrane was then incubated with primary antibodies 
diluted in skim milk over night at 4 °C.  The following day, the membrane was 
washed with TBST before being incubated with horseradish peroxidase-
conjugated secondary antibodies-specific to the appropriate host of the primary 
antibody being analyzed, for 1 h at room temperature. For detection, the 
membrane was washed with TBST, followed by distilled water and then stained 
using a horseradish peroxidase substrate enhanced chemiluminescence system 
(Luminata Forte, EMD Millipore; Billerica, MA). Blots were visualized using a 
VersaDoc imaging system (Bio-Rad Laboratories; Hercules, CA) and analyzed 
using ImageLab v.3.0 (Bio-Rad Laboratories; Hercules, CA). 
 
3.3.8 Antibodies 
The following antibodies were used for western blots: rabbit anti-β-actin-HRP 
(1:50000; A3854, Sigma-Aldrich; St. Louis MO),  chicken anti-ObRB (1:5000; 
CH14104, Neuromics; Edina, MN), rabbit anti-STAT3 (1:2000; #9132, Cell 
Signaling; Boston, MA), rabbit anti-pSTAT3 (Tyr705) (1:1000; #9131, Cell 
Signaling; Boston, MA), rabbit anti-POMC (1:2000; RB-08-0013, RayBiotech; 
Norcross GA), donkey anti-rabbit IgG-HRP (1:10000; 711-035-152, Jackson 
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Immunoresearch; West Grove, PA), donkey anti-chicken IgY-HRP (1:10000; 703-
035-155, Jackson Immunoresearch; West Grove, PA). 
 
3.3.9 Statistics and analysis 
For physiological measures and circulating factors, differences between IH and 
normoxic groups of WT and KILO rats were determined by two-way ANOVA, 
followed by a Bonferroni post-hoc analysis. Differences between IH and normoxic 
exposures were determined within WT and KILO groups for western blots using 
an unpaired, two-tailed Student t-test, and a p-value < 0.05 was taken to indicate 
statistical significance. All values were expressed as mean ± standard error. All 
bar charts were made using GraphPad Prism v.5 graphing software (GraphPad 
Software; La Jolla, CA). 
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3.4 RESULTS 
3.4.1 Food and water intake 
In the 16 h following exposure, WT normoxic animals consumed 30.2 ± 2.3 g of 
food, or 8.6 ± 1.3 g/100 g b.w. whereas WT IH exposed animals consumed less 
food (21.1 ± 2.1 g, or 5.9 ± 0.5 g of food/100 g b.w.). KILO rats exposed to 
normoxia consumed 29.9 ± 1.8 g of food, or 9.4 ± 1.6 g /100 g b.w., while IH 
exposed KILO rats consumed 31.2 ± 2.4 g of food, or 9.6 ± 1.5 g/100 g b.w. For 
both absolute (Fig 3.1a) and standardized food intakes (Fig 3.1b), WT IH 
consumed significantly less food than WT normoxic. In the KILO rats, this effect 
was not observed (Fig. 3.1a-b). There was no significant difference between WT 
normoxic exposed rats and normoxic and IH exposed KILO rats, though these 
relationships were complex as both had an interaction. There were no significant 
differences between any groups for water consumption. 
 
3.4.2 Food conversion efficiency 
WT animals exposed to normoxia had a food conversion efficiency of 0.46 ± 0.13 
g b.w. gain/g food consumed, whereas IH exposed WT rats had food conversion 
efficiency of 1.11 ± 0.15 g b.w. gain/g food consumed. Normoxic KILO rats had a 
food conversion efficiency of 1.00 ± 0.07 g b.w. gain/g food consumed, while 
KILO rats exposed to IH were 1.05 ± 0.05 g b.w. gain/g food consumed. In WT 
animals, IH animals had higher food conversion efficiency, while this difference  
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Figure 3.1 Energy intake and utilization in KILO rats following IH. 
Food intake and food conversion efficiency are altered in WT, but not KILO rats 
exposed to IH. Bar charts indicate total (a) and standardized (b) food intake over 
16h immediately following exposure to IH or normoxia in WT and KILO rats. 
Calculated food conversion efficiency over the same period (c) is also shown. 
NS: non-significant; * p < 0.05 as determined by two-way ANOVA followed by a 
Bonferroni post-hoc analysis. Data are presented as mean ± standard error. n=6 
for WT groups, n=4 for KILO groups. 
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was not observed in leptin-deficient KILO rats. KILO rats did not have 
significantly different food conversion efficiency from WT, though the 
comparisons were complex with a significant interaction being present (Fig 3.1c). 
 
3.4.3 Body weight changes 
Prior to exposure, there were no significant differences (p = 0.99) in body weights 
between KILO IH (380 ± 63 g) and KILO normoxic (380 ± 75 g), and WT IH (365 
± 10 g) and WT normoxic (364 ± 9 g) groups. During the exposure to either IH or 
normoxia, WT IH exposed animals lost approximately 8% of their body weight (-
29.3 ± 1.9 g) and WT normoxic animals lost approximately 3% (-13.8 ± 1.2 g) of 
their body weight. KILO IH animals lost 7% of their body weight (-28.4 ± 1.5 g), 
and normoxic KILO animals lost about 6% of their body weight (-24.5 ± 2.2 g). 
Body weight lost during exposure was significantly higher in WT IH animals 
compared to normoxic controls, though this effect was not observed in KILO 
animals. There was no significant difference between the body weight lost during 
exposure between WT and KILO animals, though a significant interaction was 
found (Fig 3.2a). In the 16 h immediately following the exposures, WT normoxic 
animals had a regained body weight change of 14.1 ± 3.2 g while IH animals 
regained 23.6 ± 4.5 g. KILO normoxic animals regained 29.9 ± 2.0 g overnight 
while the KILO IH animals regained 32.6 ± 2.3 g in the same time period. WT 
animals exposed to IH gained more body weight overnight, while leptin-deficient 
KILO rats did not differ in their response to IH compared to normoxia. KILO 
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animals gained significantly more body weight overnight than WT animals (Fig 
3.2b). The overall change in body weight for the 24h following the initiation of 
exposure was 0.4 ± 3.7 g for WT normoxic, -5.6 ± 2.6 g for WT IH exposed 
animals, 5.4 ± 3.2 g for normoxic KILO and 4.2 ± 3.0 g for IH KILO animals. 
There were no significant differences between IH and normoxic exposed animals 
of either strain though KILO animals gained significantly more body weight 
compared to WT animals over the same time period (Fig 3.2c). 
 
3.4.4 Fat pad mass 
The mass of the epididymal fat pad was 3.1 ± 0.8 g in WT normoxic animals, 2.8 
± 0.6 g in WT IH animals, 15.2 ± 2.6 g in KILO normoxic animals, and 13.2 ± 2.8 
g in KILO IH animals. No differences were observed between IH and normoxia 
exposures in either WT or KILO animals. However, KILO rats did have 
significantly higher fat pad mass compared to WT animals (Fig 3.3a). The 
retroperitoneal fat pad mass of WT normoxic animals was 5.2 ± 1.2 g, 4.8 ± 1.2 g 
in WT IH animals, 24.4 ± 2.9 g in normoxic KILO rats, and 22.2 ± 3.1 g in KILO 
IH animals. There were no statistical differences between normoxia and IH 
exposed animals of either genetic background, although KILO rats had 
significantly larger retroperitoneal fat pads (Fig 3.3b). 
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Figure 3.2 Body weight in KILO rats exposed to IH. 
Body weight is significantly altered following IH in WT, but not KILO rats. Bar 
charts indicating body weight change during exposure (a), overnight body weight 
gain (b), and overall body weight change 24h from baseline (c) in WT or KILO 
animals exposed to normoxia or IH. NS: non-significant; * p < 0.05 as determined 
by two-way ANOVA followed by a Bonferroni post-hoc analysis. Data are 
presented as mean ± standard error. n=6 for WT groups, n=4 for KILO groups. 
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3.4.5 Locomotion 
Horizontal locomotor activity in normoxic WT animals was 112 ± 9 line 
crossings/5 min and in IH WT animals 87 ± 3 line crossings/5 min. In the KILO 
rats exposed to normoxia, animals had horizontal locomotion of 93 ± 7 line 
crossings/5 min while the IH KILO rats had 87 ± 8 line crossings/5 min. WT 
animals exposed to IH had significantly less horizontal locomotor activity. This 
effect of IH was not found in KILO animals (Fig. 3.3c). There were no significant 
differences between WT and KILO animals, though an interaction was observed 
(Fig 3.3c).  
Vertical locomotor activity was measured in normoxic WT animals to be 31 
± 3 rearings/5 min, 28 ± 4 rearings/5 min in IH WT animals, 26 ± 4 rearings/5 min 
in normoxic KILO animals and 23 ± 4 rearings/5 min in IH KILO animals. There 
were no significant differences between or among the groups for vertical 
locomotor activity (Fig 3.3d). 
 
3.4.6 Plasma leptin concentration 
WT rats exposed to normoxia had a circulating leptin level of 3.8 ± 1.0 ng/ml, 
while WT rats had significantly elevated plasma leptin concentrations of 11.1 ± 
1.3 ng/ml following IH exposure. KILO rats exposed to normoxia had leptin 
concentration of 0.2 ± 0.1 ng/ml and IH exposed KILO rats had a similar plasma 
level (0.2 ± 0.1 ng/ml). KILO animals had a significantly lower concentration of  
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Figure 3.3 Fat pad mass and locomotion in KILO rats following IH. 
Fat pad mass and locomotion in WT and KILO animals exposed to either 
normoxia or IH. Bar charts indicating epididymal (a) and retroperitoneal (b) fat 
pad mass in either WT or KILO animals following either normoxia or IH. 
Horizontal (c) and vertical (d) locomotor activities in in WT and KILO animals 
exposed to either normoxia or IH are also displayed. NS: non-significant; * p < 
0.05 as determined by two-way ANOVA followed by a Bonferroni post-hoc 
analysis. Data are presented as mean ± standard error. n=6 for WT groups, n=4 
for KILO groups. 
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leptin than WT animals, regardless of exposure, and there was an interaction 
between both exposure and genetic background of the animals (Fig 3.4a). 
 
3.4.7 Plasma angiotensin II concentration 
WT normoxic animals had an angiotensin II plasma concentration of 0.65 ± 0.20 
ng/ml. WT IH animals had a greater than 2 fold increase in circulating level of 
angiotensin II (1.55 ± 0.17 ng/ml). KILO rats exposed to normoxia had a 
circulating angiotensin II concentration of 0.91 ± 0.10 ng/ml. Similarly, KILO rats 
exposed to IH had a circulating plasma angiotensin II concentration of 0.87 ± 
0.10 ng/ml (Fig 3.4b). 
 
3.4.8 ARC leptin signaling molecules 
Within ARC, the amount of ObRB protein was not different between normoxic 
and IH exposed animals for either WT (p = 0.65; Fig 3.5a) or KILO animals (p = 
0.90; Fig 3.5b). The amount of β-actin protein was not different between 
normoxia exposed and IH exposed WT (p = 0.88) or KILO animals (p = 0.68). 
IH WT animals had significantly more (p = 0.0031) pSTAT3 compared to 
normoxic WT animals (0.78 ± 0.03 A.U. vs. 0.12 ± 0.02 A.U., respectively; Fig 
3.5c). This effect was not observed within the ARC of KILO animals (p = 0.72) 
exposed to normoxia (0.0056 ± 0.0007 A.U.) or IH (0.0060 ± 0.0008 A.U.; Fig  
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Figure 3.4 Plasma hormone concentrations in KILO rats exposed to IH. 
Plasma concentration of leptin and angiotensin II in WT and KILO animals in 
response to either IH or normoxia. Bar charts indicate the plasma concentration 
of leptin (a) and angiotensin II (b) in WT and KILO animals exposed to either IH 
or normoxia. NS: non-significant; * p < 0.05 as determined by two-way ANOVA 
followed by a Bonferroni post-hoc analysis. Data are presented as mean ± 
standard error. n=6 for WT groups, n=4 for KILO groups. 
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3.5d). The total amount of STAT3 protein was not different for either WT (p = 
0.84) or KILO (p = 0.70) animals.  
POMC protein levels were significantly higher (p = 0.022) in ARC of WT 
animals exposed to IH (1.10 ± 0.31 A.U.) compared to normoxia (0.51 ± 0.15 
A.U.; Fig 3.5e). No significant difference (p = 0.43) was observed in POMC 
protein levels within ARC of KILO rats exposed to normoxia (0.034 ± 0.0043 
A.U.) or IH (0.029 ± 0.003 A.U.; Fig 3.5f). 
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Figure 3.5 Leptin signaling molecules in ARC of KILO rats exposed to IH. 
Representative blots and bar graphs depicting important leptin signaling 
molecules in ARC of WT and KILO rats. ObRB/β-actin within the ARC of WT (a) 
and KILO rats (b). Note that the amount of ObRB to β-actin protein within the 
ARC is not changed in WT or the KILO rat. (c-d), representative blots and bar 
graphs depicting pSTAT3/STAT3 within ARC of WT (c) and KILO rats (d). Note 
that the amount of pSTAT3 to total STAT3 protein within the ARC is elevated in 
WT, but not the KILO rat. (e-f), representative blots and bar graphs depicting 
POMC/β-actin within ARC of WT (e) and KILO rats (f). Note that the amount of 
POMC to β-actin protein within the ARC is elevated in WT, but not the KILO rat. 
*, p < 0.05 as determined by unpaired, two-tailed t-test. Data are presented as 
mean ± standard error. n=6 for WT groups, n=4 for KILO groups. 
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3.5 DISCUSSION 
This study has shown that the effects of IH previously described (Moreau 
and Ciriello, 2013) on body energy balance, hypothalamic signaling, and 
circulating hormones are mediated by the leptin released in responses to IH as 
the effects were not present in the leptin-deficient KILO rat. This is based on the 
findings that IH in WT animals reduced body weight during exposure, and 
increases overnight regain of the body weight. This effect is concomitant with a 
reduction in food intake and food conversion efficiency, effects not observed in 
the KILO rat. Additionally, elevated circulating angiotensin II and leptin are 
observed following IH exposure in WT animals, but these effects were not 
observed in KILO animals, suggesting that the absence of leptin in response to 
IH in KILO rats is important in the release of angiotensin II into the circulation in 
response to IH. Finally, in ARC, activation of downstream pSTAT3 and increased 
POMC were found following IH in WT animals. However, these differences are 
not observed in ARC of the leptin-deficient KILO animal. Taken together, these 
findings suggest that leptin released into the circulation is essentially for body 
energy balance and hypothalamic signaling in response to IH. 
 In an earlier study, significant reduction in body weight during 8h IH and a 
subsequent significant increase in body weight regain in the 16 h immediately 
following exposure has been described (Moreau and Ciriello 2013). As a result, 
the 24 h body weight change was not different between IH and normoxic 
exposed animals. As previously argued (Moreau and Ciriello, 2013), the loss of 
body weight due to exposure of IH is likely not due to a reduction in specific 
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adipose depot tissue mass, although it may be a cumulative effect from all 
sources of adipose tissue. Following chronic IH, a reduction in adipose tissue 
mass and body weight has also been observed (Martinez et al., 2008). Given that 
leptin deficient animals exposed to IH failed to lose more body weight during 8h 
IH suggests that the mechanisms resulting in weight loss during IH are 
dependent on the presence of leptin released into the circulation during IH 
(Messenger et al., 2012; Moreau and Ciriello, 2013).  
   Circulating leptin can reduce food intake by acting on neurons within 
ARC (Satoh et al., 1997). Once bound to the ObRB, leptin causes 
autophosphorylation of JAK2 and subsequent homodimerization of pSTAT3 
(Banks et al., 2000; Kloek et al., 2002; White et al., 1997). pSTAT3 then acts to 
regulate transcription of various genes, including Pomc (Banks et al., 2000). After 
acute IH, plasma leptin concentrations were increased and increased levels of 
pSTAT3 and POMC were observed in ARC as previously described (Moreau and 
Ciriello, 2013). In the absence of leptin, as in the present study, these changes in 
anorexigenic signaling molecules are not altered in response to IH. This suggests 
the activation of satiety signals in ARC due to IH is dependent upon the presence 
of leptin. This effect may not be direct, as other systems have been shown to 
increase activation of pSTAT3 and POMC within ARC (Anderson et al., 2003; 
Zhang et al., 2011). However, if they were responsible for the observed changes, 
they must ultimately fall under the control of leptin, as these changes are 
abolished in the leptin-deficient KILO rat.   
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An increase in circulating angiotensin II concentration was also observed 
in WT animals following IH. Unexpectedly, this effect was abolished in the KILO 
rat. This suggests that the release of angiotensin II following IH is dependent on 
leptin signaling. The mechanism by which leptin may contribute to the elevation 
of angiotensin II is not known, but may involve actions of leptin in the brainstem 
(Ciriello, 2013) or at the level of the carotid body (Messenger et al., 2012) to 
increase peripheral chemoreceptor sensitivity (Ciriello and Moreau, 2013), which 
in turn may increase renal sympathetic nerve activity (Ciriello, 2013), a known 
stimulus for the renin-angiotensin hormonal pathway (Froeschl et al., 2013).  
In conclusion, this study has shown that leptin plays an essential role in 
mediating the effects of acute IH on changes to body energy balance, and 
related hormonal secretion and molecular alterations within ARC. Taken 
together, these data suggest that leptin may be an essential mediator of the 
physiological response to hypoxia. 
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CHAPTER 4 
 
CHRONIC INTERMITTENT HYPOXIA INDUCES LEPTIN 
RESISTANCE 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been submitted to the Journal of 
Neuroendocrinology JNE-13-0165-OA, October 28, 2013. 
134 
 
4.        CHAPTER 4 
4.1 CHAPTER SUMMARY 
Obstructive sleep apnea (OSA) is strongly correlated with the presence of 
obesity and it has been determined that patients with OSA experience weight 
gain, in addition to elevated leptin concentrations. Chronic intermittent hypoxia 
(CIH) is a major pathophysiological manifestation of OSA, and acute IH has 
recently been shown to alter body energy balance. Therefore, this study set out 
to determine the relationship of body energy balance and leptin signaling in CIH. 
To examine this, Sprague-Dawley rats were exposed to 95 days of CIH or 
normoxic control conditions, and were assessed for daily measures of body 
weight, food intake, and food conversion efficiency. Towards the end of the 
study, leptin sensitivity, locomotor activity and circulating leptin was determined 
within animals. Following the study period, fat pads and arcuate hypothalamic 
nuclei (ARC) were isolated. ARC were assessed for factors associated with leptin 
signaling. CIH animals increased their food intake over the study period, whereas 
normoxic animals reduced this value. Normoxic animals had a reduced daily 
body weight change over the study period, whereas this value was not different 
in CIH animals. Epididymal fat mass and food conversion efficiency was less in 
CIH animals. Following peripheral leptin injection, normoxic animals reduced 
food intake, whereas CIH animals did not. Basal concentrations of leptin were not 
different between the groups, but were elevated in CIH when normalized for 
epididymal fat mass. Within ARC, CIH animals had elevated SOCS3 protein. 
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This study suggests that CIH, as seen in OSA, can induce a state of leptin 
resistance. 
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4.2 INTRODUCTION 
Obesity is an energy balance disorder that affects a large number of 
individuals within society (Ogden et al., 2013). This disease is associated with a 
positive energy balance, whereby individuals do not utilize as many calories as 
consumed throughout the day. The caloric imbalance observed in obesity is 
believed to be the result of leptin resistance, which is considered to be the 
primary risk factor for both obesity and overweight (Morris et al., 2010). During 
leptin resistance, the satiety and anorexigenic effects of leptin are lost, thus 
promoting dysregulation of caloric consumption, preventing negative feedback 
onto energy storage sites such as the adipose tissue (Kalra et al., 1998). As a 
result, hyperphagia persists, resulting in an increased deposition of adipose 
tissue mass (Lin et al., 2000). The resultant increase in adipose tissue causes an 
elevation in circulating leptin concentrations, potentially furthering the resistance 
to leptin (Scarpace et al., 2002). 
Hyperphagia and obesity are caused by a reduced expression of leptin 
signaling molecules such as the long-form leptin receptor (ObRB) in the ARC 
(Gong et al., 2008). Once leptin binds ObRB, phosphorylation and 
homodimerization of signal transducer and activator of transcription 3 (STAT3) 
occurs (Vaisse et al., 1996). Activation by phosphorylation of extracellular 
regulated kinase 1/2 (ERK1/2) also occurs (Banks et al., 2000). The translocation 
of pSTAT3 to the nucleus induces the transcription and production of pro-
opiomelanocortin (POMC), a major effector for satiety, and suppressor of 
cytokine signaling 3 (SOCS3; Banks et al., 2000; Munzberg et al., 2003; Bates et 
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al., 2003), a negative regulator of ObRB (Bjorbak et al., 2000). Another important 
negative regulator of leptin signaling is protein tyrosine phosphatase 1B (PTP1B; 
Sahu, 2004). Leptin resistance is associated with a decrease in activity of leptin 
within the arcuate nucleus of the hypothalamus (ARC; Ladyman and Grattan, 
2004; Munzberg et al., 2004). The mechanisms that drive leptin resistance are 
not known, but may occur at the blood-brain barrier leptin transport system, such 
as the short forms of the leptin receptor (ObR100; Banks et al., 1999), at the 
level of the receptor (Rahmouni et al., 2008) or post-receptor signaling (Cheng et 
al., 2002; Mori et al., 2004), including changes in the down-stream melanocortin 
system (Marsh et al., 1999). 
Obesity is a major risk factor for the development of obstructive sleep 
apnea (Peppard et al., 2000), which is a sleep-related breathing disorder 
characterized by nocturnal intermittent hypoxia. Patients with obstructive sleep 
apnea have elevated leptin levels, and a greater disposition to weight gain 
(Phillips et al., 2000). Recently, we have demonstrated that acute intermittent 
hypoxia alters energy balance, increases plasma leptin levels and activates 
leptin-related signaling mechanisms within ARC (Moreau and Ciriello, 2013). 
Taken together, these results would suggest that chronic intermittent hypoxia 
(CIH) may induce a state of leptin resistance. To test this possibility, experiments 
were done in which leptin resistance was determined by the effects of acute 
leptin injections on food intake, altered energy balance, and concomitant 
alterations in ARC after exposure to long term CIH. 
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4.3 METHODS AND MATERIAL 
4.3.1 Animals  
Experiments were done in adult male Sprague-Dawley rats (360-400 g) 
individually housed in a room maintained at a temperature of 22°C and 60% 
relative humidity. All animals had access to food and water ad libitum, except 
during the 8h of intermittent hypoxic or normoxic exposure, in 12h light/dark cycle 
conditions. Animals were randomly assigned to either CIH (n=8) or normoxia 
(n=8) groups and exposed to the corresponding conditions for 95 days. Animals 
were handled in accordance with the guidelines set forth by the Canadian 
Council on Animal Care and Use Committee at the University of Western 
Ontario.   
 
4.3.2 CIH and normoxic exposures 
Animals were exposed to CIH and normoxic conditions as previously described 
(Moreau and Ciriello, 2013; Messenger and Ciriello, 2013; Messenger et al., 
2012, 2013). Briefly, animals were placed in chambers each consisting of four 
tubes (10 cm diameter by 35 cm length) and a zero-pressure escape valve. For 
CIH-exposed animals, a computer that regulated solenoid valves altered the 
input of N2 or room air to generate CIH conditions. Animals were exposed to 80s 
hypoxia (6.5% O2) followed by 120s normoxia. The levels of O2 and CO2 were 
monitored by sensors on the chamber, which relayed information back to the 
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computer to ensure proper cycling. Conditions within the chamber were isobaric 
(770 ± 11 mmHg) and eucapnic (<0.1% CO2). Normoxic animals were exposed 
to only the air input. 
 
4.3.3 Measurement of body weight, food and water intake 
Each day throughout the study, animals were weighed immediately before and 
after CIH or normoxic exposure. These values were used to calculate body 
weight changes during the exposure period, overnight body weight gain and 24h 
body weight change. Additionally, food and water were measured over the 16h 
immediately following CIH or normoxic exposure on each day.  
 
4.3.4 Locomotion assay 
Immediately following CIH or normoxic exposure on days 91 and 92, animals 
were returned to their home cages and were allowed access to food and water 
ad libitum. Thirty min into the dark (active) cycle (1930 h), animals were placed 
into large cages (60 cm x 40 cm) with a floor 4x5 grid system in the dark (red 
light on). Over a 10 min period, the number of crosses of a line by an animal was 
determined by two independent observers blinded to their exposure regime to 
determine horizontal locomotion (Moreau and Ciriello, 2013). Simultaneously, 
vertical locomotion was determined by the number of rearing events. An average 
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value was then calculated from these two observers for both horizontal and 
vertical locomotion (Moreau and Ciriello, 2013). 
 
4.3.5 Leptin resistance assay  
Following CIH or normoxic exposure on days 93 and 94, animals were placed 
into their home cages with ad libitum access to food and water. At the beginning 
of the dark cycle (1900 h), animals were randomly assigned to vehicle or leptin 
groups, and injected (i.p.) with either 0.4 mg/kg carrier-free recombinant rat leptin 
(598-LP; R&D Systems, Minneapolis, MN) dissolved to 1 mg/ml in 20 mM Tris 
HCl (pH = 8.0), or vehicle. Food intake measurements were taken at 1, 2, 3 and 
14h after the leptin injection. Animals were exposed to CIH or normoxic 
conditions the next day, and then were crossed-over to be injected with opposite 
injectate (i.e. vehicle instead of leptin and vice versa), such that each animal 
received an injection of both the vehicle and leptin for comparisons. 
 
4.3.6 Plasma collection and enzyme immunoassays 
The day following exposure, animals were immediately sacrificed under 
equithesin anesthesia (0.3 ml/100 g b.w.; i.p.) (Moreau and Ciriello, 2013). Blood 
samples were collected by cardiac puncture in the presence of 7% 
ethylenediaminetetraacetic acid at a volume of 10 µl/ml blood. This blood was 
immediately centrifuged at 10 000 RPM for 10 min at 4°C to isolate the aqueous 
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plasma. This aqueous plasma phase was removed and stored frozen at -80 °C 
until analyzed for hormone content. Plasma samples were analyzed using 
enzyme immunoassay for rat leptin (Enzo Life Sciences; Farmingdale, NY) 
according to manufacturer instructions. Enzyme immunoassay plates were read 
on a SpectraMax M5 plate reader using SoftMax Pro v.5 microplate analysis 
software (Molecular Devices; Sunnyvale, CA).   
 
4.3.7 Tissue collection and preparation 
Following exposure to CIH or normoxia, animals were sacrificed under equithesin 
anesthesia and the brains immediately removed and frozen at -80°C. Using a 
circular 1 mm (internal diameter) micropunch tool, 500 µm punch-outs of ARC 
were taken and immediately homogenized in cold radioimmunoprecipitation 
assay buffer (50 mM Tris, 150 mM NaCl, 1% Triton-X 100, 0.25% sodium 
deoxycholate, 1 mM NaF, 1 mM sodium orthovanadate, 25 mM β-
glycerophosphate) with protease inhibitor cocktail (Roche Applied Science; 
Laval, QC) by an electric homogenizer (VWR International; Radnor, PA). 
Homogenates were then sonicated over three passages for 15s each on ice 
(55%; Sonic Dimembrator Model 150; Fisher Scientific). Samples were then 
rotated for 10 min at 4°C and centrifuged at 4°C for 20 min at 14000 RPM. 
Protein content of homogenates was quantified using the Bio-Rad Dc protein 
assay kit (Bio-Rad Laboratories; Hercules, CA). Protein samples were added to 
25% sample buffer and 10% reducing buffer (Life Technologies; Burlington, ON) 
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and water to a standard protein concentration of 1.67 mg/ml (Messenger and 
Ciriello, 2013; Moreau and Ciriello, 2013).  
 
4.3.8 Western blots 
Electrophoresis was carried out using a 10% discontinuous polyacrylamide Bis-
Tris gel (Life Technologies; Burlington, ON), followed by standard protein 
immunoblotting techniques (Messenger et al., 2013; Moreau and Ciriello 2013). 
For each animal, 25 µg of protein of each sample was loaded. Electrophoresis 
was carried out at 200 V and terminated when the dye front reached the bottom 
of the gel. Proteins were transferred to a polyvinylidene fluoride membrane using 
a wet transfer method in the presence of methanol and  SDS (50 mM Tris, 40 
mM glycine, 0.3% SDS, 20% methanol) and wet transfer apparatus (Mini Trans-
Blot Electrophoretic Transfer Cell; Bio- Rad Laboratories; Hercules, CA) at 100 V 
for 2h. After transfer, the membrane was washed in Tris-buffered saline + 
Tween-20 (TBST; 20 mM Tris-HCl, 0.5 M NaCl, 0.1% Tween-20; pH 8.0) blocked 
for 1 h with 5% skim milk made in TBST buffer at room temperature. The 
membrane was then incubated with primary antibodies diluted in skim milk over 
night at 4°C.  The following day, the membrane was washed with TBST before 
being incubated with horseradish peroxidase-conjugated secondary antibodies-
specific to the appropriate host of the primary antibody being analyzed, for 1h at 
room temperature. For detection, the membrane was washed with TBST, 
followed by distilled water and then stained using a horseradish peroxidase 
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substrate enhanced chemiluminescence system (Luminata Forte, EMD Millipore; 
Billerica, MA). Blots were visualized using a VersaDoc imaging system (Bio-Rad 
Laboratories; Hercules, CA) and analyzed using ImageLab v.3.0 (Bio-Rad 
Laboratories; Hercules, CA).  
 
4.3.9 Antibodies 
For western blots the following antibodies were used: rabbit anti-β-actin-HRP 
(1:50000; A3854, Sigma-Aldrich; St. Louis MO),  rabbit anti-ObR (1:1000; 
OBR12-A, Alpha Diagnostics International; San Antonio, TX) chicken anti-ObRB 
(1:5000; CH14104, Neuromics; Edina, MN), rabbit anti-STAT3 (1:2000; #9132, 
Cell Signaling; Boston, MA), rabbit anti-pSTAT3 (Tyr705) (1:1000; #9131, Cell 
Signaling; Boston, MA), rabbit anti-ERK1/2 (1:2000; #9102, Cell Signaling; 
Boston, MA), rabbit anti-pERK1/2 (Thr202/Tyr204) (1:1000; #9101, Cell 
Signaling; Boston, MA), rabbit anti-POMC (1:2000; RB-08-0013, RayBiotech; 
Norcross GA), rabbit anti-SOCS3 (1:1000; ab16030, Abcam; Cambridge, MA), 
goat anti-PTP1B (1:500; sc-1718, Santa Cruz Biotechnology; Dallas, TX), donkey 
anti-rabbit IgG-HRP (1:10000; 711-035-152, Jackson Immunoresearch; West 
Grove, PA), donkey anti-chicken IgY-HRP (1:10000; 703-035-155, Jackson 
Immunoresearch; West Grove, PA), donkey anti-goat IgG-HRP (1:10000; 705-
035-003, Jackson Immunoresearch; West Grove, PA). 
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4.3.10 Statistics and analysis 
Differences between and within CIH and normoxic groups at week 1 and week 
13 of physiological variables, as well within basal plasma leptin concentrations of 
fasted and non-fasted animals, were determined by two-way ANOVA with a 
repeated measure between the exposure time groups, followed by Bonferroni 
post-hoc analysis. Western blot analyses and fat pad mass between CIH and 
normoxic groups were compared using an unpaired, two-tailed t-test. For leptin 
resistance assays, a paired two-tailed t-test was used to compare vehicle 
injection to leptin injection within CIH and normoxic groups. For all statistical 
analyses, a p-value < 0.05 was taken to indicate statistical significance. All 
values are expressed as mean ± standard error. All charts were made using 
GraphPad Prism v.5 graphing software (GraphPad Software; La Jolla, CA). 
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4.4 RESULTS 
4.4.1 Body weight changes 
Prior to exposure, body weights between CIH (385.5 ± 9.9 g) and normoxic 
(386.5 ± 10.5 g) groups were not significant different (p = 0.95). Average body 
weight after the first week CIH exposure was 386 ± 11.3 g, while the normoxic 
animals weighed an average of 402.4 ± 9.6 g. After the thirteenth week of 
exposure, CIH animals weighed 584.8 ± 12.2 g and normoxic animals weighed 
635.6 ± 21.8 (Fig 4.1a). There was both a significant effect of the duration of 
exposure and exposure type on body weight (Fig. 4.1a-d). After the first week of 
exposure, CIH exposed animals lost on average approximately 6% of their body 
weight (-23.7 ± 1.9 g), whereas normoxic controls lost about 3% of their body 
weight (-12.6 ± 0.7 g; Fig. 4.1b). After the thirteenth week of exposure, CIH 
animals lost an average of 5% of body weight (-31.8 ± 3.2 g) and normoxic 
animals lost about 2% of body weight during exposure (-11.9 ± 2.2 g; Fig 4.1b). 
There was a significant effect of exposure between CIH and normoxic groups. In 
addition, the CIH group lost significantly more body weight on average after 13 
weeks of exposure compared to the first week, but no effect of exposure length 
on normoxic animals was observed. In the 16h following exposure after the first 
week, CIH animals gained an average of 25.9 ± 1.5 g and normoxic animals 
gained 18.0 ± 0.6 g. After 13 weeks, CIH animals gained an average of 32.0 ± 
3.2 g and normoxic animals gained 12.8 ± 2.0 g overnight (Fig 4.1c). CIH animals 
gained significantly more weight overnight than normoxic animals, and this 
overnight body weight gain increased over the length of exposure. On the other 
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hand, normoxic animals had decreased overnight body weight gain over the 
same time period. Average daily body weight change after the first week for CIH 
animals was 2.1 ± 0.5 g, while normoxic animals gained an average of 5.5 ± 0.4 
g. After 13 weeks, CIH animals had an average daily body weight change of -1.1 
± 0.8 g, while normoxic animals had 0.46 ± 0.77 g (Fig 4.1d). There was a 
significant effect of exposure on daily body weight change, with CIH animals 
gaining less weight daily. The effect of exposure length on daily body weight 
change is complex as normoxic exposed animals reduce their daily body weight 
change, while CIH animals do not significantly alter this response.   
 
4.4.2 Fat pad mass changes 
Epididymal fat pad mass was significantly reduced (p = 0.024) in CIH exposed 
animals (6.1 ± 1.1 g) compared to those exposed to normoxia (10.1 ± 0.8 g) (Fig. 
4.1e). Although no differences (p = 0.17) were observed in retroperitoneal fat pad 
mass between CIH (8.4 ± 1.7 g) and normoxic animals (12.0 ± 1.8 g), a trend 
towards a decrease was also observed (Fig. 4.1f). These effects were observed 
even when accounting for total body weight. Epididymal fat of CIH animals (1.08 
± 0.14 g/100 g b.w.), was significantly less (p = 0.028) than normoxic animals 
(1.60 ± 0.11 g/100 g b.w.). Retroperitoneal fat was not different (p = 0.15) 
between CIH (1.48 ± 0.23 g/100 g b.w.) and normoxic animals (1.89 ± 0.24 g 
/100 g b.w.). 
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Figure 4.1 Effect of CIH on body weight changes and fat pad mass. 
Bar charts summarizing the changes body weight (a), body weight change during 
8h IH exposure (b), 16 h post-exposure overnight body weight gain (c), and daily 
change in body weight between animals exposed to CIH or normoxia averaged 
for over week 1 and week 13 (d). Bar charts summarize epididymal (e) and 
retroperitoneal (f) fat pad mass after 13 weeks of CIH or normoxia exposure. 
Note that body weight, body weight changes and adipose tissue mass are altered 
by CIH. Data are shown as mean ± standard error. *, p < 0.05 (determined by 
two-way ANOVA followed by a Bonferroni post-hoc analysis for body weights, 
and as determined by an unpaired, two-tailed Student’s t-test for fat pad mass). n 
= 8 per group. 
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4.4.3 Food intake 
In the 16h following daily exposure after the first week, CIH animals consumed 
an average of 25.2 ± 1.0 g of food while the normoxic animals consumed 31.4 ± 
0.8 g of food (Fig. 4.2a). Following 13 weeks of exposure, CIH animals 
consumed a daily average of 27.5 ± 0.7 g of food, representing an increase of 
approximately 9%, and normoxic animals consumed 27.9 ± 1.1 g of food, 
representing a decrease of approximately 11% (Fig 4.2a).  
 
4.4.4 Food conversion efficiency 
Food conversion efficiency was 1.04 ± 0.08 g b.w. gain/g food in CIH exposed 
animals and 0.59 ± 0.03 g b.w. gain/g food in normoxic animals after the first 
week. After week 13, CIH animals had a food conversion efficiency of 1.08 ± 0.04 
g b.w. gain/g food, and normoxic animals were 0.44 ± 0.04 g b.w. gain/g food 
(Fig 4.2b). There was an effect of exposure for CIH to increase food conversion 
efficiency, while the relationship of exposure length and exposure interacted to 
produce a complex relationship whereby there was no alteration within CIH 
animals over the exposure time, but significantly reduced food conversion 
efficiency in normoxic animals over the time period.  
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4.4.5 Locomotion changes 
Horizontal locomotor activity was not different (p = 0.66) between CIH and 
normoxic control rats (301.2 ± 25.8 line crosses/10 min and 295.6 ± 26.1 line 
crosses/10 min, respectively; Fig 4.2c). Vertical locomotor activity was not 
different (p = 0.25) between CIH and normoxic rats (83.5 ± 15.8 rears/10 min and 
72.4 ± 12.3 rears/10 min, respectively; Fig 4.2d).  
 
4.4.6 Plasma leptin concentrations 
Plasma concentrations of leptin during fasting conditions following 95 days CIH 
had 1.2 ng/ml of leptin in their plasma, while normoxia animals had 1.5 ± 0.3 
ng/ml of leptin. When these plasma levels are normalized to epididymal fat 
content in each animal, CIH exposed animals had a significantly elevated (p = 
0.036) plasma leptin than normoxic controls (0.41 ± 0.08 ng/ml/g fat compared to 
0.23 ± 0.06 ng/ml/g fat, respectively; Fig 4.2e). Furthermore, a similar finding is 
observed if the plasma leptin levels are compared to both epididymal and 
retroperitoneal fat pads.  
 
4.4.7 Leptin resistance induced by CIH 
In animals exposed to normoxia, food intake 1 h after acute leptin injection was 
significantly (p = 0.012) reduced compared to vehicle injected controls (Fig.  
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Figure 4.2 Changes in food intake and energy expenditure following CIH. 
Bar charts showing food intake (a) and food conversion efficiency (b) over the 
16h after 1 week or 13 week exposure to CIH or normoxia. In addition, (c-d) 
show that both horizontal (c) and vertical (d) locomotion were not changed by 
CIH at the 13 week time-point. Bar chart (e) also shows plasma leptin levels 
normalized for epididymal fat pad mass. Note that CIH causes changes in food 
intake and body energy utilization without changing locomotor activity. 
Furthermore, basal plasma leptin levels are elevated when fat pad mass is taken 
into account. Data are shown as mean ± standard error. *, p<0.05 (determined by 
two-way ANOVA followed by a Bonferroni post-hoc analysis for food intake, food 
conversion efficiency, leptin concentration, and as determined by an unpaired, 
two-tailed Student’s t-test for locomotor activities and normalized leptin) n = 4 per 
group. 
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4.3a). On the other hand, in the CIH exposed animals, food intake was not 
altered at this time point (Fig. 4.3a). Similarly, at 2h and 3h after acute leptin 
injection, food intake was significantly (2h, p = 0.0092; 3h, p = 0.015) reduced 
after acute leptin injections in the normoxic controls compared to vehicle injected 
animals, but was not altered in the CIH exposed animals (Fig. 4.3b-c). These 
values were not altered at the 14h time point (Fig. 4.3d). Furthermore, neither 
vehicle, nor leptin injections in animals exposed to CIH or normoxia altered food 
intake from total food intake values over the 16h measured on a daily basis. 
 
4.4.8 Protein expression of leptin receptors after CIH 
As shown in Figure 4.4, within ARC, CIH did not alter (p = 0.85) the protein 
expression of the long-form leptin receptor (ObRB) compared to normoxia (0.17 
± 0.02 A.U. and 0.16 ± 0.02 A.U., respectively; Fig 4.4a). IH also did not alter (p = 
0.46) protein expression of the short form leptin receptor ObR100 compared to 
normoxic exposed animals (0.22 ± 0.03 A.U. and 0.24 ± 0.01 A.U., respectively; 
Fig 4.4b). 
 
4.4.9 Proteins associated with leptin signaling within ARC 
Within the ARC, CIH did not alter pSTAT3 protein expression as a function of 
total STAT3 (p = 0.46) compared to normoxic controls (0.15 ± 0.02 A.U. and 0.13 
± 0.02 A.U., respectively; Fig 4.5a), and did not change total STAT3 protein  
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Figure 4.3 CIH induces resistance to leptin 
Bar charts showing cumulative food intake at 1h (a), 2h (b), 3h (c) and 14h (d) 
post-injection (i.p.) of either 0.4 mg/kg leptin or vehicle treatment. Note that leptin 
induces satiety in normoxic animals, but not in the CIH exposed animals. Data 
are presented as mean ± standard error. *, p < 0.05 (determined by a paired, 
two-tailed Student’s t-test between vehicle and leptin treatments). n = 8 per group 
and injection. 
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Figure 4.4 Effect of CIH on ObR in ARC 
Representative blots and bar graphs depicting ObRB/β-actin protein expression 
(a) and ObR100/β-actin protein expression (b). Note that leptin receptor isoforms 
are not altered in ARC following CIH exposure. Data are shown as mean ± 
standard error. n = 8 per group. 
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expression (p = 0.39). Protein expression levels of POMC were found to be 
significantly less (p = 0.045) in CIH (0.41 ± 0.02 A.U.) exposed animals 
compared to normoxia animals (0.53 ± 0.06 A.U.; Fig 4.5b). Protein expression of 
total ERK1/2 was significantly less (p = 0.0045) in CIH animals (5.72 ± 0.34 A.U.) 
compared to ARC of normoxia animals (7.62 ± 0.38 A.U.; Fig 4.5c). However, a 
significant increase (p = 0.001) in the proportion of ERK1/2 that was 
phosphorylated was observed in CIH animals (0.12 ± 0.01 A.U.) compared to 
normoxic control animals (0.043 ± 0.010 A.U.; Fig 4.5d).  
 
4.4.10 Protein markers associated with leptin resistance within ARC 
Within ARC, CIH significantly increased (p = 0.022) the expression of SOCS3 
protein compared to normoxic controls (0.20 ± 0.03 A.U. and 0.12 ± 0.01 A.U., 
respectively; Fig 4.6a). On the other hand, no significant difference (p = 0.56) in 
PTP1B protein expression was observed between CIH (0.038 ± 0.004 A.U.) and 
normoxic animals (0.041 ± 0.005 A.U.; Fig 4.6b). 
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Figure 4.5 Leptin signaling proteins in ARC following CIH 
Representative blots and bar charts depicting (a) pSTAT3/STAT3 protein 
expression, (b) POMC protein expression, (c) total ERK1/2 protein expression, 
and (d) pERK1/2 / ERK1/2 protein expression in ARC. Note that CIH alters leptin 
signaling protein expression within ARC. Data are presented as mean ± standard 
error. *, p < 0.05 (determined by an unpaired, two-tailed Student’s t-test). n = 8 
per group. 
 
 
 
 
 
 
160 
 
 
 
 
 
 
 
 
 
161 
 
 
 
 
 
 
Figure 4.6 Effect of CIH on negative regulators of leptin signaling in ARC. 
Representative blots and bar charts depicting inhibitors of leptin signaling 
SOCS3 (a) and PTP1B (b) protein expressions within ARC. Note that CIH alters 
SOCS3, but not PTP1B protein expression in the ARC after 13 weeks exposure. 
Data are presented as mean ± standard error. *, p < 0.05 (determined by an 
unpaired, two-tailed Student’s t-test). n = 8 per group. 
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4.5 DISCUSSION 
This study has demonstrated that 13 weeks of continuous exposure to 
intermittent hypoxia induces a state of leptin resistance. Animals exposed to CIH 
have increased food intake over the study period, where normoxic controls 
reduce their level of consumption over the same period. This occurs alongside a 
significant reduction in daily body weight change by controls, while no change is 
observed in CIH animals. Epididymal fat pad mass is significantly less at the end 
of the study in CIH compared to normoxic animals. Direct measure of the effect 
of leptin on food intake indicated a state of leptin resistance in CIH animals, while 
normoxic animals responded normally to acute administration of leptin. Basal 
plasma leptin concentrations normalized to epididymal fat mass were was 
significantly higher in CIH exposed animals compared to normoxic controls. 
These changes are concomitant with a lower protein amount of ERK1/2 and 
POMC in ARC, while pERK1/2 and SOCS3 were elevated between CIH and 
normoxic groups.  
In a recent study, we have described the acute effect of intermittent 
hypoxia on body energy balance (Moreau and Ciriello, 2013). Each bout of 
exposure to intermittent hypoxia induced a loss of body weight, which was 
abrogated following non-hypoxic conditions as a result of reduced locomotion 
and altered body energy utilization. In this study, after 13 weeks of CIH, body 
weight loss during exposure increases, as opposed to no difference observed 
within the normoxic animals. It is likely that this effect could was due to a 
potentiation of the peripheral chemoreceptor reflex on sympathetic flow, 
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independent of a change in respiration (Prabhakar et al., 2005, 2009; Dick et al., 
2007; Xing and Pilowsky, 2010). This conclusion is supported by the finding that 
CIH has long-term effects on sympathetic outflow (Zoccal et al., 2007, 2008). 
Given the observed reduction of epididymal fat pad mass, it may be suggested 
that the break-down of adipose tissue contributes to the body weight loss, a 
finding also reported by others (Martinez et al., 2008; Drager et al., 2011), 
although this may not be the primary mediator of the decreased body weight 
observed following acute intermittent hypoxia (Moreau and Ciriello, 2013).  
Overnight food intake was observed in animals exposed to CIH during the 
first week compared to normoxia. This acute effect was also observed following 
only 8h of exposure to intermittent hypoxia (Moreau and Ciriello, 2013) and has 
been reported in humans exposed to chronic hypoxia (Tschop et al., 1998). 
However, by the thirteenth week food intake between CIH and normoxic animals 
was not significantly different. In fact, food intake over this time course was 
reduced in normoxic controls, but was increased in CIH exposed animals. The 
increased food intake could be suggestive in the CIH exposed animals of a 
potential manifestation of leptin resistance (Kalra et al., 1998; Trujillo et al., 
2011). Similarly, food conversion efficiency, an indirect measure of whole-body 
energy utilization, was reduced in normoxic animals over the exposure period. 
This is suggestive of increased body energy utilization. This change was not 
observed in CIH animals, suggesting their body energy metabolism was not 
changing in a way concurrent to normoxic control animals. Along the exposure 
length in the CIH animals, food conversion efficiency was elevated compared to 
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normoxic animals, suggestive of reduced body energy utilization. Although the 
long-term effects that food conversion efficiency will have on pre-disposition to 
weight gain is not well understood, a reduction in metabolic function is associated 
with weight gain in humans (Houmard, 2008). Whether the lack of increase in 
body energy utilization is due to leptin resistance in CIH animals is not known, 
but it is possible that given that leptin augments metabolic activities mediated in 
part by the sympathetic nervous system (Harris, 2013), and plasma leptin levels 
are elevated following a bout of intermittent hypoxia (Moreau and Ciriello, 2013), 
CIH may contribute to leptin resistance. In support of this suggestion, leptin 
resistance was measured directly by a repeated comparison to leptin and vehicle 
treatment in CIH and normoxia exposed animals. It was found that in normoxic 
animals, acute leptin injections caused a significant reduction in food intake in the 
first three hours. However, in the CIH exposed animals, leptin did not induce a 
satiating effect when compared to vehicle injections.  
Leptin resistance is followed by the development of weight gain and 
hyperphagia (Kalra et al., 1998; Trujillo et al., 2011). Due to the complex 
interaction of CIH and this leptin resistant state on body weight, it may be 
suggested that the effects on body weight may not yet have taken hold in these 
CIH exposed animals for a long enough period to induce a significant weight gain 
as recently reported (Guo et al., 2013).  An alternate explanation may be that in 
this model, due to its anorexigenic effects through increased sympathetic activity, 
an increase in body weight may not be easily demonstrated until animals are 
exposed to longer periods of CIH, despite evidence that CIH causes a wide 
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range of metabolic pathophysiologies including dyslipidemia, high blood pressure 
and insulin resistance (Polotsky et al., 2003; Zoccal et al., 2007; Drager et al., 
2011).  It should also be kept in mind that there are individuals that suffer from 
the metabolic syndrome that are not obese, and CIH, as a result of obstructive 
sleep apnea, can worsen their metabolic profile (Kono et al., 2007).  
Another major effect of leptin resistance is chronic hyperleptinemia. 
Fasting leptin concentrations in the CIH animals were not different compared to 
normoxic controls. However, given that CIH animals had less body weight and 
epididymal fat pad mass, it suggested that the observed levels of leptin in the 
CIH animals were in fact elevated compared to normoxic controls. When fat 
mass was taken into account, it was found that CIH animals had significantly 
higher plasma leptin concentrations than their normoxic counterparts. It should 
be noted that the epididymal fat mass is thought to be the largest producer of 
leptin in the rat (Zheng et al., 1996). Previous reports by us (Messenger et al., 
2012; Moreau and Ciriello, 2013) and others (Polotsky et al., 2003; Li et al., 
2006) have shown that acute short-term intermittent hypoxia can increase 
plasma leptin concentrations. This elevated leptin release immediately following 
bouts of intermittent hypoxia on a daily basis may contribute to the development 
of the leptin resistance observed in the 13 week exposed CIH animals.  
Following CIH, within ARC, no alterations were observed in the protein 
expression of either the long- or short form leptin receptors. While the precise 
mechanism surrounding leptin resistance is not understood, it has been 
suggested that a reduction in ObRB may prevent appropriate leptin signaling 
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(Schwartz et al., 1997). From these data, it appears that this may not be the 
mechanism driving the leptin resistance in this model. Similar suggestions have 
been made regarding ObR100, where a reduction in this protein would prevent 
sufficient transport of leptin across the blood-brain barrier (Banks et al., 2001). 
CIH animals were found not to have altered ObR100 protein expression in ARC. 
However, it should be kept in mind that these do not take into account changes in 
affinity for the receptor (Mooradian et al., 2000), or changes in receptor 
localization (Gan et al., 2012).  
Within ARC, it was observed that CIH animals had less POMC protein 
expression than normoxic control animals. Consistent with this finding, a 
reduction in POMC within ARC has been shown to be associated with 
hyperphagia (Richard et al., 2011). This could be the result of reduced signaling 
in leptin resistance, or could function as a mediator of the resistance itself. Also 
within ARC, SOCS3 protein was found to be higher in CIH than normoxic 
animals. An increase in SOCS3 would prevent activation of the leptin receptor 
signaling cascade (Bjorbak et al., 2000), and preventing downstream activation 
of factors associated with the effect of leptin, such as POMC (Banks et al., 2000). 
SOCS3 overexpression has previously been shown to occur in leptin resistant 
states, and experimentally can increase food intake (Bjørbaek et al., 1998; Reed 
et al., 2010).  
Taken together, these data have demonstrated for the first time that 
exposure to CIH can induce a state of leptin resistance. This pathophysiological 
state is associated with increased energy balance. Furthermore, this leptin 
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resistant state is associated with an increased protein expression of SOCS3 and 
with a concomitant reduction in POMC protein expression within ARC. These 
findings suggest a possible link between patients exposed to CIH, such as 
obstructive sleep apnea and the development of obesity and metabolic disorders. 
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CHAPTER 5 
 
INTERMITTENT HYPOXIA INDUCES CHANGES IN PROTEIN EXPRESSION 
OF NEUROPLASTICITY MARKERS IN THE NUCLEUS OF THE SOLITARY 
TRACT 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been submitted for publication to Experimental 
Neurology, EX-NR-13-844, November 16, 2013. 
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5.         CHAPTER 5 
5.1 CHAPTER SUMMARY 
Intermittent hypoxia (IH) has been shown to alter the response of neurons in 
nucleus of the solitary tract (NTS) to cardiovascular inputs. The mechanisms 
involved in these effects may involve pre- and/or post-synaptic neuroplasticity 
alterations in NTS. To investigate this possibility, Sprague-Dawley wild-type rats 
were exposed to 1, 7 or 95 days of IH or normoxia. Additionally, to determine 
whether leptin exerted an effect on the 1 day changes to IH, leptin-deficient 
(KILO) rats were exposed to IH or normoxia. Arterial pressure (AP) was also 
measured at these time intervals in conscious wild-type animals. Additionally, at 
each time point protein was extracted from NTS and analyzed by western blot for 
the expression of brain-derived neurotrophic factor (BDNF), tropomyosin receptor 
kinase B (TrkB), synaptophysin and growth-associated protein-43 (GAP-43). AP 
was not different between the IH and normoxic animals at 1 or 7 days. However, 
after 95 days of IH, AP was significantly elevated compared to normoxic controls. 
After 1 day IH, TrkB protein expression in NTS was higher while synaptophysin 
was lower than normoxic wild-type rats. No changes were found in TrkB protein 
expression in KILO rats after 1 day IH, although synaptophysin protein 
expression was decreased. BDNF and GAP 43 protein expression levels were 
not altered in any group following 1 day IH or normoxia. After 7 days of IH, BDNF 
and TrkB protein expression was found to be elevated in NTS compared to 
normoxic controls. After 95 days of IH expression of BDNF, synaptophysin, and 
GAP-43 proteins were less abundant in NTS than in normoxic controls. These 
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results suggest that neuroplasticity changes occurring within NTS may be 
associated with the development of autonomic dysregulation often seen in 
patients with chronic obstructive sleep apnea, including elevated blood pressure. 
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5.2 INTRODUCTION 
 Obstructive sleep apnea is a chronic, progressive disease that is 
characterized by episodic closures of the upper airway during sleep (Dempsey et 
al., 2010). One of the physiological consequences of obstructive sleep apnea is 
intermittent hypoxia (IH; Freet et al., 2013). IH has previously been shown to 
activate peripheral carotid chemoreceptors (Cooper et al., 2005). These 
specialized cells respond to lowered blood oxygen tension and in response 
increase afferent neural activity to the nucleus of the solitary tract (NTS), the 
primary site of peripheral chemoreceptor afferent termination (Ciriello et al 1994). 
It has previously been shown that chronic intermittent activation of the carotid 
chemoreceptor pathway can result in sympathetic long-term facilitation (Dick et 
al., 2007; Xing and Pilowsky, 2010), which plays an important role in the 
exaggerated sympathetic responses seen by further chemoreceptor activation 
(Xing and Pilowsky 2010).  
IH may also induce alterations in the sensitivity of the baroreceptor reflex 
(Bonsignore et al., 2002; Carlson et al., 1996). Intermittent apneas have been 
shown to reset the baroreceptor reflex to a higher level (Monahan et al., 2006; 
Prabhakar and Khumar, 2010) suggesting a possible interaction between 
activation of the chemoreceptor reflex and a depression of the baroreceptor 
reflex (Cooper et al., 2005; Somers et al., 1991) during IH. Although the central 
mechanisms that may induce sympathetic long-term facilitation and baroreceptor 
reflex depression are not known, they may be important in the development and 
maintenance of hypertension observed in individuals suffering from chronic 
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obstructive sleep apnea. We have recently demonstrated that IH can increase 
plasma leptin concentration (Messenger et al., 2012; Moreau and Ciriello, 2013). 
Circulating leptin has been shown to potentiate the chemoreceptor reflex (Ciriello 
and Moreau, 2013; Ciriello and Moreau, 2012) and inhibit the baroreceptor reflex 
(Arnold et al., 2009; Ciriello, 2013a, 2013b) at the level of the NTS. Interestingly, 
the NTS region has been identified as one of the few neurogenic sites within the 
central nervous system (Bauer et al 2005; Chigr et al 2009), and the NTS has a 
high level of expression of factors associated with neuroplasticity including the 
neurite outgrowth protein brain-derived neurotrophic factor (BDNF) and its 
receptor tropomyosin receptor kinase B (TrkB), growth-associated protein-43 
(GAP-43), and the synaptogenic marker synaptophysin (Jin et al., 2010; 
Korshunova and Mosevitsky, 2010; Moyse et al., 2006). Leptin has been shown 
to affect neuroplasticity and synaptogenesis within extra-hypothalamic regions of 
the brain (Harvey, 2013; Shanley et al., 2001; Wayner et al., 2004). Previous 
studies have suggested BDNF, TrkB, GAP-43 and/or synaptophysin may be 
important in mediating alterations associated with activity-dependent functional 
changes in cardiovascular afferents that terminate within NTS (Martin et al 2009).  
 This study was designed to investigate whether neuroplasticity occurred 
within NTS in response to acute (1 day), short term chronic (7 days) and long 
term chronic (95 days) IH and whether changes in mean arterial pressure (MAP) 
and heart rate (HR) occurred that may be associated with chronic IH. Finally, the 
role of leptin in the neuroplastic alterations in NTS following acute IH was also 
determined in the leptin deficient KILO rat (Vaira et al., 2012).  
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5.3 METHODS AND MATERIAL 
5.3.1 Animals 
Adult, male Sprague-Dawley rats (300-350 g; n=36) were purchased from 
Charles River Canada and served as wild-type control animals (WT). Adult, male, 
homozygous, leptin-deficient KILO rats (250-400 g; n=8; SD-Leptm1sage) were 
obtained from SAGE Laboratories (TGRA3780; Vaira et al., 2012). Animals were 
housed singly at a temperature of 22°C and 60% relative humidity with access to 
food and water available ad libitum, except during the daily 8 h IH or normoxic 
exposure, in 12h light/dark cycle conditions. All experimental procedures were 
done in accordance with the guidelines on the use and care of laboratory animals 
as set by the Canadian Council on Animal Care and approved by the Animal 
Care Committee at The University of Western Ontario.  
 
5.3.2 IH or normoxic exposure 
Animals were exposed to 8 h (0900-1700) of IH or normoxia each day as 
previously described (Messenger et al., 2012, 2013; Moreau and Ciriello, 2013). 
WT rats were exposed for 1-day, 7-days or 95-days of IH or normoxia. KILO rats 
were exposed only for 1-day of IH or normoxia. In brief, animals were placed in a 
chamber consisting of four tubes (10 cm diameter x 35 cm length) with a zero-
pressure escape valve. For IH-exposed animals, a computer that regulated 
solenoid valves altered the input of N2 or room air to generate IH conditions. 
Animals were exposed to 80s hypoxia (6.5% O2) followed by 120s normoxia. The 
levels of O2 and CO2 were monitored by sensors in the chamber, which relayed 
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information back to the computer to ensure proper cycling. Conditions within the 
chamber were isobaric (770 ± 11 mmHg) and eucapnic (<0.1% CO2). Normoxic 
animals were exposed to same conditions except that only room air was cycled 
(Messenger et al., 2012, 2013; Moreau and Ciriello, 2013). 
 
5.3.3 Hemodynamic recordings 
Following exposure to IH or normoxia at 1 day, 7 days and 95 days, WT animals 
had their systolic, diastolic and MAP and HR measured using the non-invasive 
tail cuff method (CODA System; Kent Scientific; Torrington, CT). This approach 
has been previously validated with direct hemodynamic measures (Feng et al., 
2008).  
 
5.3.4 Tissue collection and preparation 
Following exposure to IH or normoxia, animals were sacrificed under equithesin 
anesthesia (0.3 ml/100 g b.w.; Moreau and Ciriello, 2013) and the brains 
removed and frozen at -80°C until analyzed. Using a circular 1 mm (internal 
diameter) micropunch tool, 500 µm bilateral punches of NTS from each animal 
were taken and immediately homogenized in cold radioimmunoprecipitation 
assay buffer (50 mM Tris, 150 mM NaCl, 1% Triton-X 100, 0.25% sodium 
deoxycholate, 1 mM NaF, 1 mM sodium orthovanadate, 25 mM β-
glycerophosphate) with protease inhibitor cocktail (Roche Applied Science; 
Laval, QC) using an electric homogenizer (VWR International; Radnor, PA). 
Homogenates were then sonicated over three passages for 15s on ice (55%; 
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Sonic Dimembrator Model 150; Fisher Scientific). Samples were then rotated for 
10 min at 4 °C and centrifuged at 4°C for 20 min at 14000 RPM. Protein content 
of homogenates was quantified using the Bio-Rad Dc protein assay kit (Bio-Rad 
Laboratories; Hercules, CA). Protein samples were added to 25% LDS sample 
buffer and 10% reducing buffer (Life Technologies; Burlington, ON), and water to 
a standard protein concentration of 1.67 mg/ml (Messenger et al., 2013).  
 
5.3.5 Western blots 
Electrophoresis was carried out using a 10% discontinuous polyacrylamide Bis-
Tris gel (Life Technologies; Burlington, ON), followed by standard protein 
immunoblotting techniques (Messenger et al., 2013). For each animal, 25 µg of 
protein of each sample was loaded. Electrophoresis was carried out at 200 V and 
terminated when the dye front reached the bottom of the gel. Proteins were 
transferred to a polyvinylidene fluoride membrane using a wet transfer method in 
the presence of methanol and  SDS (50 mM Tris, 40 mM glycine, 0.3% SDS, 
20% methanol) and wet transfer apparatus (Mini Trans-Blot Electrophoretic 
Transfer Cell; Bio- Rad Laboratories; Hercules, CA) at 100 V for 2 h. After 
transfer, the membrane was washed in Tris-buffered saline + Tween-20 (TBST; 
20 mM Tris, 0.5 M NaCl, 0.1% Tween-20; pH 8.0) blocked for 1 h with 5% skim 
milk made in TBST buffer at room temperature. The membrane was then 
incubated with primary antibodies diluted in skim milk over night at 4 °C.  The 
following day, the membrane was washed with TBST before being incubated with 
horseradish peroxidase-conjugated secondary antibodies-specific to the 
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appropriate host of the primary antibody being analyzed, for 1 h at room 
temperature. For detection, the membrane was washed with TBST, followed by 
distilled water and then detected using a horseradish peroxidase substrate ECL 
chemiluminescence system (Luminata Forte, EMD Millipore; Billerica, MA). Blots 
were visualized using a VersaDoc imaging system (Bio-Rad Laboratories; 
Hercules, CA) and analyzed using ImageLab v.3.0 (Bio-Rad Laboratories; 
Hercules, CA).  
 
5.3.6 Antibodies 
For western blots, the following antibodies were used: rabbit anti-β-actin-HRP 
(1:50000; A3854, Sigma-Aldrich; St. Louis MO), rabbit anti-TrkB (1:1000; sc-
8316, Santa Cruz Biotechnology; Dallas, TX), mouse anti-synaptophysin (1:1000; 
ab8049, Abcam; Cambridge, MA), rabbit anti-GAP-43 (1:1000; #8945, Cell 
Signaling Technology; Danvers, MA), rabbit anti-BDNF (1:1000; sc-20981, Santa 
Cruz Biotechnology; Dallas, TX), donkey anti-rabbit IgG-HRP (1:10 000; 711-
035-152, Jackson Immunoresearch; West Grove, PA), donkey anti-mouse IgG-
HRP (1:5000; 715-035-151, Jackson Immunoresearch; West Grove, PA).  
 
5.3.7 Statistics and analysis 
All values are expressed as mean ± standard error. Differences between IH and 
normoxic groups were determined by unpaired, two-tailed Student t-test. A p-
value < 0.05 was taken to indicate statistical significance. All bar charts were 
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made using GraphPad Prism v.5 graphing software (GraphPad Software; La 
Jolla, CA). 
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5.4 RESULTS 
5.4.1 AP following exposure to IH 
Following 1 day and 7 days of IH, systolic (Fig. 5.1a), diastolic (Fig. 5.1b), MAP 
(Fig. 5.1c), and HR (Fig. 5.1d) were found not to be altered compared to 
normoxic controls at the same time points. After 95 days of IH, animals had a 
significantly higher (p = 0.030) systolic blood pressure, compared to normoxic 
controls (152 ± 6 mmHg vs. 130 ± 8 mmHg, respectively; Fig. 5.1a). Additionally, 
these animals had significantly elevated diastolic blood pressure (p = 0.05; IH, 
113 ± 6 mmHg vs. normoxic controls, 99 ± 4 mmHg; Fig 5.1b). As a result, MAP 
was significantly elevated within these animals (p = 0.026; IH, 124 ± 6 mmHg vs. 
normoxic controls, 107 ± 4 mmHg; Fig 5.1c). On the other hand, no differences 
(p = 0.13) were observed in HR between the normoxic control and IH groups 
(400 ± 12 bpm vs. 419 ± 12 bpm, respectively; Fig. 5.1d). Figure 5.1e also shows 
that the gain as measured by the MAP level compared to HR was decreased at 
95 days following IH compared to normoxic controls. 
 
5.4.2 BDNF protein expression in NTS following IH  
BDNF protein expression was found not to be different (p = 0.42) in NTS 
between IH and normoxic WT after 1 day exposure (Fig. 5.2a). Following 7 days 
of IH exposure, there was 53% increase (p = 0.0062) in BDNF protein expression 
in NTS compared to normoxic WT (Fig 5.2b). On the other hand, after 95 d of IH 
exposure, there was 34% less BDNF protein expression in NTS compared to 
normoxic WT (p = 0.008; Fig 5.2c). 
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Figure 5.1 Effect of IH on hemodynamic variables 
Bar chart showing arterial pressure and heart rate changes following 1, 7 and 95 
days of exposure to IH or normoxia. Shown are: (a), systolic pressure, (b), 
diastolic, (c) mean arterial pressure and (d) heart rate in the conscious rat. In 
addition, (e) shows the effect of IH on heart rate in relation to the level resting 
arterial pressure (Gain; bpm/mmHg). Note that systolic, diastolic and mean blood 
pressures and gain are significantly (*, p<0.05) altered after 95 days of IH 
exposure. n=7 for all the 1 and 7 days groups and n=8 for the 95 day groups. 
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Figure 5.2 NTS expression of BDNF following IH 
Representative western blots and bar charts indicating the change in protein 
expression of BDNF determined by western blot in the same NTS samples at 1 
day (a), 7 days (b) and 95 days (c) after IH or normoxic exposure. Note that 
BDNF protein expression is elevated after 7 days of IH exposure and then 
reduced after 95 days of IH exposure. *, p<0.05 determined by two-tailed, 
unpaired Student t-test. n=7-8. 
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5.4.3 TrkB protein expression in NTS following IH  
After 1 day of IH, there was a significant elevation in protein expression of both 
the short (gp95) and long (gp145) isoforms of the TrkB neurotropic receptor in 
the NTS region of WT (Fig 5.3a).  The gp95 isoform was increased (p = 0.028) by 
about 28% in IH compared to normoxic controls (Fig. 5.3). Over the same time 
period in the NTS, the gp145 isoform was also increased (p = 0.018) by about 
166% in IH compared to normoxic controls (Fig. 5.3a). The ratio of gp145:gp95 
isoform was 100% higher (p = 0.012) in IH compared to normoxic control NTS in 
WT (Fig. 5.3d).  
 Following 7 days of IH (Fig 5.3b), gp95 was significantly higher (p = 0.043) 
from normoxic controls in NTS, with about 43% more gp95 protein expression in 
IH animals. The gp145 isoform was also significantly greater (p = 0.038) by about 
52% in IH compared to normoxic controls (Fig. 5.3b). The ratio of gp145:gp95 
isoform was not significantly different (p = 0.39) in IH compared to normoxic 
control (Fig. 5.3d). 
 After 95 days of IH (Fig 5.3c), gp95 was significantly lower (p = 0.013) by 
approximately 52% compared to normoxic control animals, while the gp145 
isoform was not different (p = 0.27). The gp145:gp95 ratio was also not different 
(p = 0.29) between 95 d IH exposed and 95 d normoxic animals (Fig. 5.3d). 
 
5.4.4 Synaptophysin protein expression in NTS following IH  
The expression of the synaptic marker protein synaptophysin was significantly 
lower (p = 0.042) by about 16% in NTS after 1 day IH exposure compared to  
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Figure 5.3 NTS expression of TrkB isoforms following IH 
Representative western blots and bar charts indicating the change in protein 
expression of gp95 (a), gp145 (b) and the ratio of gp145:95 (c) TrkB isoforms in 
NTS following 1 day (a), 7 days (b), and 95 days (c) IH or normoxic exposure. 
(d), the ratio of gp145:gp95 TrkB isoforms. Note that both TrkB isoforms are 
increased after acute and short term exposure to IH. However, after 95 days IH 
exposure, only the gp95 isoform is reduced. Differences were determined 
between IH and normoxia within isoform and ratio of each group. *, p<0.05 as 
determined by two-tailed, unpaired Student t-test. n=7-8. 
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normoxic control WT (Fig 5.4a). On the other hand, no differences were found in 
synaptophysin protein expression (p = 0.34) between IH and normoxic controls in 
the NTS region following 7 days of exposure (Fig 5.4b), although there was a 
trend towards a decrease. After 95 days, there was about 42% less expression 
(p = 0.0029) of the synaptophysin protein in NTS of the IH animals compared to 
normoxic WT animals (Fig 5.4c). 
 
5.4.5 GAP-43 protein expression in NTS following IH  
GAP-43 protein was not different in NTS between IH and normoxic WT rats at 1 
day (p = 0.42) and at 7 days (p = 0.48) exposure (Fig 5.5a-b). Following 95 days, 
GAP-43 protein expression was reduced by about 34% (p = 0.045) in NTS of the 
IH exposed animals compared to the normoxic animals (Fig 5.5c). 
 
5.4.6 Changes in neuroplastic markers in NTS of KILO rats following IH  
To determine whether leptin contributed to the changes observed in the 
neuroplastic markers in NTS, leptin deficient rats (KILO rat) were exposed to 
acute (1 day) IH. IH failed to induce any changes in BDNF in the KILO (p=0.44) 
or WT rat (Fig. 5.6a).  Similarly, in the KILO rat, acute IH did not induce changes 
in TrkB isoforms (Fig. 5.6b) which were present in the WT rat. Neither gp95 (p = 
0.27; Fig. 5.3b), gp145 (p = 0.20) nor the ratio of gp145:gp95 TrkB isoforms (p = 
0.44) were altered in NTS of the KILO rats following IH exposure. On the other 
hand, 1 day exposure of KILO rats to IH induced a lower (p = 0.043) protein 
expression of synaptophysin in NTS by about 26% compared to normoxic KILO  
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Figure 5.4 NTS expression of synaptophysin following IH. 
Representative western blots and bar charts showing changes in protein 
expression of synaptophysin in NTS after 1 day (a), 7 days (b) and 95 days (c) of 
exposure to IH or normoxic. Note the synaptophysin decreases in response to 
acute/short term and long term IH exposure. *, p<0.05 as determined by two-
tailed, unpaired Student t-test. n=7-8. 
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Figure 5.5 NTS expression of GAP-43 following IH. 
Representative western blots and bar charts showing the change in protein 
expression of GAP-43 in NTS at 1 day (a), 7days (b) and 95 days (c) after IH or 
normoxic exposure. Note that at only 95 days of IH exposure is GAP-43 altered 
in NTS. *, p<0.05 as determined by two-tailed, unpaired Student t-test. n=7-8.  
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controls (Fig. 5.6c). IH as previously shown induced a decrease in synaptophysin 
protein expression in the WT rat after 1 day exposure. Acute IH exposure in the 
KILO rat did not induce changes in GAP-43 (p = 0.44; Fig. 5.6d). 
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Figure 5.6 Effect of IH in KILO rats on neuroplastic markers in NTS. 
Representative western blots and bar charts showing the change in protein 
expression of BDNF (a), TrkB (b), synaptophysin (c)m and GAP-43 in NTS at 1 
day IH exposure in WT and KILO-/- rats. Note that the lack of leptin abolishes the 
TrkB effects to IH (b), but not those associated with synaptophysin (c) after IH. In 
addition, note that the lack of leptin does not induce changes in BDNF nor GAP-
43 after IH. *, p<0.05 as determined by two-tailed, unpaired Student t-test. n=4-8. 
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5.5 DISCUSSION 
 This study has demonstrated that both acute and long term IH exposure 
induces changes in neuroplasticity markers in NTS. In addition, some of these 
changes observed following acute IH exposure were due to leptin signaling in 
NTS as they were not observed in the leptin deficient rats. Finally, long term 
exposure to IH induced an increase in MAP, but not HR, suggesting that some of 
the neuronal plasticity changes observed in NTS may be associated with the 
hypertension resulting from long term activation of peripheral chemoreceptors. 
BDNF protein expression levels were elevated in NTS following 7 days of 
IH exposure. On the other hand, after 95 days of IH exposure, BDNF levels were 
found to be lower than those of animals exposed to normoxia. These changes 
suggest an initial elevated responsiveness of the BDNF-TrkB system, whereas 
this effect is diminished over long-term exposure to IH as gp145:gp95 
normalizes, and BDNF ligand is reduced. The neurotrophin BDNF has been 
demonstrated in NTS cardiovascular afferent synapses (Martin et al., 2009), and 
has been suggested to be released in response to activation of the carotid 
chemoreceptor reflex (Chavez-Valdez et al., 2012; Montero et al., 2012). BDNF-
containing terminal boutons come in close apposition to second-order neurons 
shown to express its receptor, TrkB (Kline et al., 2010). Within NTS, BDNF has 
been reported to modulate glutamatergic neurotransmission and thus altering 
cardiovascular responses (Clark et al., 2011).  
It was found that the TrkB receptor isoforms within NTS increased in 
response to acute and short term IH exposure, whereas after 95 day IH 
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exposure, the gp95 isoform was decreased. The gp145 TrkB subunit is 
considered the full-length isoform of the receptor, whereas gp95 TrkB is a 
truncated version lacking an intracellular kinase domain (Klein et al., 1990; 
Middlemas et al., 1991). The gp95 TrkB acts as a dominant negative receptor 
inhibiting the responsiveness of the full-length gp145 TrkB to stimulation by 
BDNF (Haapasalo et al., 2001). Due to the dominant negative nature of the gp95 
TrkB isoform, the ratio of gp145:gp95 may be an important indicator of BDNF-
TrkB signaling capability (Haapasalo et al., 2001). This ratio was found to be 
higher in animals exposed to 1 day IH, but not different following 7 or 95 days of 
exposure. As BDNF-TrkB signaling plays an important role in long-term 
neuroplastic alterations such as neurite outgrowth (Hartnick et al., 1996; Hu et 
al., 2005) and synaptogenesis (Seil and Drake-Baumann, 2000; Hu et al., 2005), 
it is likely that these changes begin within the first day of IH exposure and 
diminish over time once neuroplasticity has been induced. The finding that BDNF 
protein expression decreases after long term exposure is consistent with a recent 
study by Chavez-Valdez and colleagues (2012) demonstrating a decrease of 
NTS BDNF content following hyperoxia in juvenile rats. 
TrkB may also mediate the effects of hormonal signaling molecules such 
as leptin within NTS (Spaeth et al., 2012) and other brain regions (Liao et al., 
2012). The changes in TrkB isoforms observed following acute IH were not seen 
in NTS of leptin-deficient KILO rats. This observation, coupled with the earlier 
finding that plasma leptin levels are elevated after acute IH (Messenger et al., 
2012; Moreau and Ciriello, 2013) suggests that leptin is important for the 
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increase in TrkB. Although the importance of leptin over longer periods of IH 
exposure is not known and warrants further study, on the basis of the finding that 
TrkB protein expression remains elevated compared to normoxic controls after 
short term IH exposure suggests that it may continue to signal TrkB. 
Interestingly, the decrease in TrkB after 95 days of IH exposure is also consistent 
with the finding of decreased plasma levels of leptin observed in these animals 
after long term IH exposure (unpublished observations). 
We observed reduced synaptophysin during exposure to IH and reduced 
GAP-43 protein expression only following 95 days of IH. The reduction in 
synaptophysin in NTS following 1 day exposure of IH was not due to leptin 
signaling as it was still observed within the leptin deficient animals. This suggests 
that these alterations in synaptophysin expression may be due to activity-
dependent signaling (Li et al., 2002) or a direct effect of hypoxia (Ding et al., 
2009). Synaptophysin is a marker for synapses and synaptic strength, and has 
been used for the quantification of synapses (Calhoun et al., 1996). On the other 
hand, GAP-43 is an important mediator of neurite outgrowth (Jap Tjoen San et 
al., 1991), neuronal regeneration (Meiri et al., 1988) and a marker of the pre-
synaptic terminals (Eastwood et al., 2007). Consistent with the findings in this 
study, it has recently been shown that IH exposure reduces afferent 
neurotransmission in the intermediate and caudal NTS (Almado et al., 2012). It 
was also determined that this synaptic depression was the result of a loss of 
active synapses (Almado et al., 2012). Thus, the reduction in synaptophysin and 
GAP-43 observed in this study could be interpreted to suggest a reduction in 
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NTS active synapses, synaptic strength and afferent neurites. Although it would 
be expected that chemoreceptor afferent activity would be elevated following IH, 
the depression of neurotransmission may be selectively related to reduced 
baroreceptor reflex activity and output observed in animals exposed to chronic IH 
(Lai et al., 2006). Consistent with this suggestion, it was found that after chronic 
IH, the animals exhibited an elevated MAP and a decreased HR response to the 
elevated arterial pressure further suggesting an impairment of the baroreceptor 
reflex. 
In conclusion, the present results support the notion that the NTS complex 
functions as an important site of integration of afferent inputs. The IH induced 
changes observed in neuroplastic molecules including BDNF-TrkB, 
synaptophysin and GAP-43 suggest this integration is dynamic, and may be 
altered over acute, short- and long-term IH and at least the short term effects 
appear to be dependent on leptin. The direct contribution of these alterations to 
cardiovascular changes observed are not known, but do appear to be associated 
with hypertension and possibly baroreceptor reflex resetting.  
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CHAPTER 6 
 
EFFECTS OF ANGIOTENSIN II ON LEPTIN AND DOWNSTREAM LEPTIN 
SIGNALING IN THE CAROTID BODY DURING ACUTE INTERMITTENT 
HYPOXIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been submitted for publication to Neuroscience 
NSC-13-1392, October 8, 2013. 
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6.     CHAPTER 6 
6.1 CHAPTER SUMMARY 
Angiotensin II (ANG II) is known to promote leptin production and 
secretion. Although ANG II type 1 receptors (AT1R) and leptin are expressed 
within the carotid body, it is not known if AT1R and leptin are co-expressed in the 
same glomus cells nor if these peptides interact to alter the carotid body function. 
This study was done to investigate whether ANG II altered leptin signaling in the 
carotid body during acute intermittent hypoxia (IH). Rats were treated with 
captopril or the AT1R blocker losartan in the drinking water for 3 days prior to 
being exposed to IH (8h) or normoxia (8h). IH induced increases in plasma ANG 
II and leptin compared to normoxic controls. Captopril treatment abolished the 
plasma leptin changes to IH, whereas losartan treatment had no effect on the IH 
induced increase in plasma leptin. Additionally, carotid body glomus cells 
containing both leptin and the long form of the leptin receptor (OB-Rb) were 
found to co-express AT1R protein, and IH increased the expression of only AT1R 
protein within the carotid body in both captopril and non-captopril treated 
animals. On the other hand, losartan treatment did not alter AT1R protein 
expression to IH. Additionally, captopril and losartan treatment eliminated the 
elevated carotid body leptin protein expression, and the changes in 
phosphorylated signal transducer and activator of transcription 3 protein, the 
short form of the leptin receptor (OB-R100), suppressor of cytokine signaling 3, 
and phosphorylated extracellular-signal-regulated kinase 1/2 protein expression 
induced by IH. However, captopril elevated the expression of OB-Rb protein, 
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whereas losartan abolished the changes in OB-Rb protein to IH.  These findings, 
taken together with the previous observation that ANG II alters carotid body 
chemosensitivity, suggest that the increased circulating levels of ANG II and 
leptin induced by IH act at the carotid body to alter leptin signaling within the 
carotid body which in turn may influence chemoreceptor function.  
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6.2 INTRODUCTION 
The carotid body is a highly vascularized organ located bilaterally at the 
bifurcations of the common carotid arteries (Heymans et al., 1930; Nurse, 2005). 
The carotid body, composed of specialized oxygen-sensing type-I glomus cells, 
signals carotid sinus nerve endings that transmit the afferent information to the 
nucleus of the solitary tract (Ciriello et al., 1994), activating homeostatic 
mechanisms involving respiratory, cardiovascular and hormonal systems 
(Schultz and Li, 2007; Kumar, 2009).  
There are now considerable data suggesting that substances within the 
circulation gain access to carotid body glomus cells and alter their excitability 
(Allen 1998; Chen et al., 2005; Leung et al., 2000, 2003; Nurse & Piskuric, 2012; 
Peng et al., 2006). One vasoactive compound shown to alter the discharge of 
carotid body afferent fibers independent of its circulatory effects is angiotensin II 
(ANG II) (Allen 1998; Leung et al., 2000). The carotid body has been shown not 
only to contain ANG II binding sites (Allen, 1998), but to also possess its own 
intrinsic renin-angiotensin system (RAS) (Lam & Leung, 2002), suggesting that 
ANG II within the carotid bodies may act in an autocrine/paracrine manner. Key 
elements of the RAS, including protein and mRNA of angiotensinogen as well as 
mRNA of angiotensin I converting enzyme (ACE) have been localized to the 
type-I glomus cells (Lam & Leung, 2002). A role for ANG II in chemosensitivity is 
supported by the finding that gene expression for the ANG II type 1 receptor 
(AT1R) is up-regulated in the carotid bodies during chronic hypoxia (Leung et al., 
2000; Fung et al., 2002), and this increased expression of the AT1R is associated 
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with the increased sensitivity of carotid chemoreceptors (Leung et al., 2000; Fung 
et al., 2001, 2002). In addition, administration of the ANG II type 1 receptor 
(AT1R) antagonist losartan abolishes these effects on chemoreceptors (Allen, 
1998; Leung et al., 2000), including the increased intracellular calcium levels in 
type-I cells induced by ANG II (Fung et al., 2001). Consistent with these results, 
a recent study has demonstrated that signaling through the AT1R is critical for 
carotid chemoreceptor sensitivity and signal transduction of the carotid 
chemoreceptor reflex during hypoxia (Marcus et al., 2010). 
The increases in intracellular calcium induced by ANG II suggest that 
through activation of the AT1R, ANG II may impact vesicle secretion from type-I 
glomus cells and therefore promote the release of other potential modulators 
involved in chemoreceptor function and for the signal transduction of glomus 
cells to the carotid sinus nerve (Gomez-Nino et al., 1990; Eyzaguirre and Zapata, 
1968; Bock, 1980). One possibility may be that ANG II may signal changes in 
leptin signaling within the carotid body as ANG II signaling is known to affect 
leptin production and secretion in other tissues such as ventricular myocytes, 
bone marrow and adipocytes (Cassis et al., 2004; Danser et al., 1999; 
Haznedaroglu and Buyukasik, 1997; Haznedaroglu et al., 1996; Rajapurohitam et 
al., 2006, 2012). Leptin is a 16 kDa protein product of the obese gene and is 
produced in proportion to, and secreted primarily, but not exclusively, by 
adipocytes (Lonnquist et al., 1995; Caro et al., 1996). Circulating leptin is thus an 
indicator of body fat content and acts as a satiety hormone, as well as increasing 
energy expenditure to balance body energy stores (Lonnquist et al., 1995; Caro 
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et al., 1996). Leptin signals primarily through the long-form leptin receptor (OB-
Rb), although 6 splice variants of the leptin receptor exist (OB-Ra-OB-Rf) of 
which only a few have known functions (Lee et al., 1996; Wang et al., 1996). 
Leptin has been shown to possess a signaling capability within the carotid body 
(Messenger et al., 2012; Messenger and Ciriello, 2013), and both circulating and 
carotid body protein expression levels of leptin have been found to increase in 
response to acute intermittent hypoxia (IH) and chronic intermittent hypoxia 
challenge (Messenger et al., 2012; Messenger and Ciriello, 2013), although its 
function within carotid body glomus cells remains unclear. The discovery of 
leptin, as well as four leptin receptor isoforms within carotid body glomus cells 
(Messenger et al., 2012, 2013; Porzionato et al., 2011), as well as the finding that 
circulating leptin induces phosphorylated signal transducer and activator of 
transcription 3 (pSTAT3) and immediate early gene Fra-1/2 expression within 
glomus cells (Messenger et al., 2012) is suggestive of a role in chemosensitivity 
for the adipokine. 
ANG II has been shown to be released and is required along with 
increased sympathetic nerve activity for the chronic hypertension in both human 
and the animal model of obstructive sleep apnea (Fletcher et al., 1999, 1992a/b; 
Moller et al., 2003; Yuan et al., 2004). In addition, in the animal model of 
obstructive sleep apnea, circulating and carotid body leptin is elevated 
(Messenger et al., 2012; Messenger and Ciriello, 2013; Moreau and Ciriello, 
2013), a finding consistent with clinical data (Phillips et al., 2000; Harsch et al., 
2003). However, it is not known whether ANG II may affect leptin signaling in the 
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carotid body, which in turn may contribute to altered sensitivity within the 
chemoreceptor reflex pathway (Ciriello and Moreau, 2012, 2013). Therefore, this 
study was done to determine: (1) whether, selective chronic inhibition of ACE by 
captopril or the selective blockade of the AT1R by losartan had an effect on 
circulating levels of leptin during IH; (2) whether glomus cells expressing the 
AT1R co-express leptin and the OB-Rb, and whether AT1R levels in carotid 
bodies are altered following exposure to IH; (3) whether chronic inhibition of ACE 
or the AT1R alters leptin, leptin receptor or downstream mediators of the OB-Rb 
signaling within the carotid body.   
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6.3 METHODS AND MATERIAL 
6.3.1 General animal procedures 
Experiments were done in male Sprague–Dawley rats (Charles River Canada, 
St. Constant, Canada) weighing 250-350 g. All animals were housed under 
controlled conditions with a 12 h light/dark cycle. Food and water were available 
ad libitum. All experimental procedures were done in accordance with the 
guidelines on the use and care of laboratory animals as set by the Canadian 
Council on Animal Care and approved by the Animal Care Committee at the 
University of Western Ontario. 
 
6.3.2 Angiotensin converting enzyme inhibition 
Inhibition of angiotensin converting enzyme was performed by administration of 
captopril (Sigma-Aldrich, St. Louis, MO) in the drinking water (2 mg/ml) of each 
animal three days prior to IH (n=7) or normoxic conditions (n=7). Captopril was 
freshly dissolved daily in the drinking water which was monitored daily and it was 
calculated that the animals received 146 ± 6 mg/kg/day of captopril. At this dose, 
ACE inhibition has been shown to occur (Schiffrin & Genest, 1982; Ferrone & 
Antonaccio, 1979). 
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6.3.3 Selective blockade of AT1R 
Selective blockade of the AT1R was accomplished by the administration of 
losartan (Merck, Whitehouse Station, NJ) in the drinking water (0.12 mg/ml) of 
each animal three days prior to AIH (n=7) or normoxic conditions (n=7). Losartan 
was freshly dissolved daily in the drinking water which was monitored daily and it 
was calculated that the animals received 14.2 ± 0.7 mg/kg/day of losartan. At this 
dose, AT1R blockade has been shown to occur (Boustany et al., 2005; Kline & 
Liu, 1994). 
 
6.3.4 Induction of IH 
IH or normoxia was induced in the captopril or losartan treated animals described 
above and in a separate set of animals that were not treated with the drugs (IH, 
n=11; normoxia, n=11) as previously described (Messenger et al., 2012; 
Messenger and Ciriello, 2013; Moreau and Ciriello, 2013). Animals were exposed 
to the 8h IH or the normoxic stimuli each day of the experimental period during 
daylight hours (900h-1700h). 
 
6.3.5 Plasma collection and immunoassays 
Measurement of plasma levels of leptin and ANG II were made immediately after 
the exposure of the animals to IH or the normoxic stimuli (Messenger et al., 
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2012; Messenger & Ciriello 2013; Moreau and Ciriello, 2013). Blood samples 
were collected by cardiac puncture in 7% ethylenediaminetetraacetic acid at a 
volume of 10 µl/ml blood. The blood was immediately centrifuged at 10 000 RPM 
for 10 min at 4 °C to isolate the aqueous plasma. This aqueous plasma phase 
was removed and stored frozen at -80 °C until analyzed for hormone content. 
Plasma samples were analyzed using enzyme immunoassays for rat leptin (inter-
assay variability: 6.5% intra-assay variability: 7.1%; Enzo Life Sciences; 
Farmingdale, NY), and rat ANG II (inter-assay variability: <15%; intra-assay 
variability: <10%; Phoenix Pharmaceuticals, Burlingame, CA) according to 
manufacturer instructions. Enzyme immunoassay plates were read on a 
SpectraMax M5 plate reader using SoftMax Pro v.5 microplate analysis software 
(Molecular Devices; Sunnyvale, CA). 
 
6.3.6 Carotid body protein extracts and immunoblot analysis 
Carotid body protein extracts were obtained following bilateral carotid body 
excision from the normoxia- or IH-exposed animals as described previously 
(Messenger et al., 2012; Messenger & Ciriello 2013). In brief, the carotid bodies 
(bilaterally) from each animal were snap frozen, pooled together, homogenized in 
200µl of RIPA buffer solution (150 mM NaCl, 1 mM NaF, 1 mM NaVO4, 0.5 mM 
β-glycerophosphate, 1mM EDTA, 1% Triton-X 100, 50mM Tris-HCL at pH of 7.5) 
with a protease inhibitor cocktail (Roche Diagnostics, Laval, QC, Canada) and 
sonicated. The homogenate was centrifuged at 4°C for 15 min at 2100 RPM. The 
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supernatant was retained and then centrifuged a second time at 4°C for 20 min 
at 13200 RPM. The resultant supernatant was retained as the protein 
preparation. Equal concentrations of extracted proteins normalized by 
colorimetric DC assay (Bio-Rad laboratories, Hercules, CA) underwent gel 
electrophoresis in 10% Bis-acrylamide gel (Life Technologies Inc., Carlsbad, CA) 
and transferred onto a polyvinylidene fluoride membrane. Blots were probed 
using: polyclonal rabbit anti-AT1R (1:1000; Cat. # sc-1173; Santa Cruz 
Biotechnology Inc., Dallas, TX), anti-AT2R (1:1000; Cat. # sc-7420; Santa Cruz), 
polyclonal rabbit anti-leptin (1:1000, Cat. # sc843; Santa Cruz Biotechnology 
Inc.), polyclonal rabbit anti-OB-R (1:1000, Cat. # OBR12-A; Alpha Diagnostics 
International Inc., San Antonio, TX), affinity purified polyclonal chicken anti-OB-
Rb (1:1000, Cat. # CH14104; Neuromics, Edina, MN), polyclonal rabbit anti-
SOCS3 (1:1000, Cat. # ab16030; Abcam Inc., Cambridge, MA), monoclonal 
rabbit anti-STAT3 (1:2000, Cat. # 4904S; Cell Signaling Technology), polyclonal 
rabbit anti-pSTAT3 (1:1000, Cat. #9131S; Cell Signaling Technology, Danvers, 
MA), monoclonal rabbit anti-ERK1/2 (1:1000, Cat. # 4695S; Cell Signaling 
Technology), monoclonal rabbit anti-pERK1/2 (1:1000, Cat. # 4376S; Cell 
Signaling Technology), and monoclonal horseradish peroxidase-conjugated β-
actin (1:50000, catalog no. A3854, Sigma-Aldrich) diluted in 5% milk-Tris-
buffered saline-Tween 20 buffer and with horseradish peroxidase conjugated 
donkey anti-rabbit IgG, donkey anti-goat, or donkey anti-chicken IgG (1:10000, 
catalog # 711- 035-152, 705-035-003 or 703-035-155, respectively; Jackson 
ImmunoResearch Laboratories, West Grove, PA) diluted in 5% milk-1X Tris-
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buffered saline-Tween 20 buffer as the secondary antibody. Immunoreactive 
bands were visualized using an enhanced chemiluminescence detection system 
(Millipore Canada Ltd, Toronto, ON, Canada).  
 
6.3.7 Immunofluorescence 
Immediately after the application of the 8h IH or normoxic stimuli, the animals 
(IH, n=3; normoxia, n=3) were anesthetized with 0.3 ml/100g equithesin and 
perfused transcardially using 500 ml ice-cold phosphate buffered saline (PBS; 
0.1M, pH 7.4) followed by 4% paraformaldehyde in 0.1 M PBS (Messenger et al., 
2012; Messenger & Ciriello 2013). The carotid arteries at their bifurcations, along 
with the attached carotid bodies were removed bilaterally, and stored overnight in 
Zamboni’s fixative at 4 ºC. The following day the tissues were gradually 
dehydrated through a series of alcohols, and placed in xylene followed by 
paraffin wax. Serial transverse sections were cut at 6 µm on a RM 2155 
microtome (Leica Microsystems Inc., Buffalo Grove, IL), floated in a warm water 
bath and mounted on double-gelatinized glass microscope slides and placed on 
a slide warmer. Tissue sections were later de-paraffinized in xylene and 
rehydrated using graded alcohol solutions. For each animal, 1 in every 5 slides 
was stained with thionin to identify the region of the carotid body and blood 
vessels. Additionally, adjacent sections to those stained for thionin from the 
normoxic and IH-exposed animals were rinsed in PBS and processed for double-
immunofluorescence (Vectastain Elite ABC Kit, Cat. # PK6100; Vector 
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Laboratories, Burlingame, CA) for leptin, Ob-Rb and AT1R. Sections underwent 
an antigen-retrieval protocol using a citrate buffer (10 mM sodium citrate/0.05% 
Tween; pH 6.0) heated to 90-95ºC in a microwave for 15 min and then were 
rinsed in PBS before being placed in 5% normal goat serum ((Cat. # S-1000; 
Vector Laboratories) in PBS containing 0.3% Triton X-100 for 30 min (Messenger 
et al., 2012). The sections were later rinsed in PBS and placed overnight (12 h) 
into a primary polyclonal rabbit anti-leptin (Cat. # sc843; Santa Cruz 
Biotechnology Inc.; 1:1000 in PBS/0.3% Triton X-100) or affinity purified 
polyclonal chicken anti-OB-Rb (1:1000, Cat. # CH14104; Neuromics) at room 
temperature. Sections were then rinsed in PBS and incubated in goat biotinylated 
anti-rabbit IgG (Cat. # BA-1000; Vector Laboratory) diluted 1:500 in PBS/ 0.3% 
Triton X-100 for 1 h. Following PBS rinses, sections were placed in Streptavidin 
Alexafluor-488 (Cat. # S11223; Life Technologies) diluted 1:100 for 1 h. 
Following PBS rinses, sections were exposed to an avidin containing solution for 
15 min followed by a biotin containing solution for an additional 15 min 
(Avidin/Biotin blocking kit, Cat. # SP-2001; Vector Laboratories) to block non-
specific binding sites. Sections were then rinsed in PBS and incubated overnight 
at room temperature in primary polyclonal rabbit anti-AT1R (Cat. # sc-1173; 
Santa Cruz Biotechnology Inc.) diluted 1:1000 in PBS/0.3% Triton-X 100 and 5% 
normal goat serum. Following PBS washes, the sections were placed in goat 
biotinylated anti-rabbit IgG diluted 1:500 in PBS/ 0.3% Triton X-100 or goat 
biotinylated anti-chicken IgY (Vectastain Elite ABC Kit) diluted 1:200 in PBS/ 
0.3% Triton X-100 for 1 h. Sections were rinsed in PBS and placed in 
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Streptavidin Texas Red (Code: RPN1233; GE Healthcare, Baie d’Urfe, QC, 
Canada) diluted 1:100 for 1 h. Following PBS rinses, sections were placed in 
100% ethanol containing 5% glacial acetic acid on dry ice for 10 min. Sections 
were then immediately cover-glassed using Fluoromount mountant. 
 
6.3.8 Statistical analysis 
Statistical comparisons between the normoxia and IH exposed animals were 
made using a two-tailed, unpaired Student t-test. In all comparisons, a minimum 
p-value of < 0.05 was taken to indicate statistical significance (GraphPad Prism; 
GraphPad Software, San Diego, CA, USA).  
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6.4 RESULTS 
6.4.1 Plasma ANG II and leptin levels following captopril or losartan 
treatment 
IH significantly increased plasma ANG II (p < 0.002) (Fig. 6.1a) levels about 3 
fold above those found in the normoxic controls. Plasma leptin (Fig. 6.1b) levels 
were also significantly increased in IH exposed animals by approximately 6 fold 
(p < 0.01) above those found in the normoxic controls. Following captopril 
treatment, no differences were found between the IH and normoxic controls in 
both ANG II and leptin levels within the plasma. Following losartan treatment 
ANG II levels were found not to be different between the normoxic controls and 
IH exposed animals (Fig. 6.1a), whereas the increased levels of leptin induced by 
IH was not affected by the selective blockade of AT1R with losartan (Fig. 6.1b).  
 
6.4.2 Leptin, OB-Rb and AT1R co-expression in carotid body 
Figure 6.2 shows the effect of IH on leptin, OB-Rb and AT1R immunoreactivity 
within glomus cells of the carotid body. Glomus cells expressed low levels of 
leptin (Fig. 6.2a), OB-Rb and AT1R (Fig. 6.2b) immunofluorescence under 
normoxic conditions. However, following exposure to IH, carotid body glomus 
cells exhibited an elevated immunofluorescence associated with leptin (Fig. 
6.2c), ObRB (Fig. 6.2e), and AT1R (Fig. 6.2d and 6.2f).  Figure 6.2 also shows  
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Figure 6.1 Change in plasma levels of ANG II and leptin following IH. 
Bar charts showing the effect of IH on plasma levels of ANG II (a), and leptin (b) 
compared to levels observed in normoxic controls under sham (non-captopril 
treatment), and captopril and losartan treatment. Note that plasma ANG II (a) and 
leptin (b) are significantly elevated following IH in the non-captopril treated 
(sham) group compared to normoxic group. Additionally, note that captopril and 
losartan prevented the rise in ANG II to IH. Furthermore, note that while captopril 
blocked the rise in leptin to IH, this increase in leptin to IH was not affected by 
losartan treatment. Values are shown as means ± S.E. *p < 0.01. 
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Figure 6.2 Leptin, ObRB and AT1R in glomus cells in the carotid body. 
Fluorescent photomicrographs of the carotid body showing glomus cells 
immunoreactive to leptin (a,c), Ob-Rb (e) and angiotensin type-1 receptor (AT1R; 
b,d,f) following exposure to IH (c,d,e,f) or normoxia (a,b). Note that cells 
immunoreactive to leptin and Ob-Rb also contain immunoreactivity to AT1R. 
Calibration marks indicate 25 µm. 
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that AT1R immunoreactivity is co-localized within the same glomus cells of the 
carotid body that express leptin and Ob-Rb immunoreactivity.  
 
6.4.3 Effect of IH on AT1R and AT2R in carotid body 
Figure 6.3 shows the effect of IH on AT1R and AT2R protein expression in the 
carotid body. When exposed to IH, the expression of AT1R was significantly 
increased by about 33 % (Fig. 6.3a). However, the protein expression of AT2R 
was not different following IH exposure (Fig. 6.3b). This same pattern was 
evident in animals that were treated with captopril (Fig. 6.3c-d). However, 
following losartan treatment, neither AT1R nor AT2R protein expression was 
altered in the carotid body after IH exposure (Fig. 6.3e-f). 
 
6.4.4 Effect IH in animals treated with captopril or losartan on leptin within 
the carotid body 
As previously reported by Messenger and Ciriello (2013), IH induced an increase 
in the leptin protein expression in the carotid body. Figure 6.6 shows the effect of 
captopril treatment on carotid body leptin protein levels following normoxia (Fig. 
6.4a) or IH (Fig. 6.4b) exposure. In normoxic animals (Fig. 6.4a), captopril 
treatment lowered leptin levels to about 50% of non-captopril treated animals. In 
the IH animals, captopril (Fig. 6.4b) lowered leptin levels within the carotid body  
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Figure 6.3 Effect of IH on AT1R and AT2R within carotid body. 
Western blots showing the effect of IH on AT1R (a) and AT2R (b) the protein 
expression in the carotid bodies. Note that AT1R protein levels are significantly 
elevated following IH, whereas levels of the AT2R are not altered in the carotid 
bodies (a-b). These effects on the AT1R were maintained after captopril 
treatment (c-d). However, losartan treatment eliminated the effects of IH on AT1R 
protein expression (e), and did not alter AT2R (f) protein expression. *, 
significantly different from normoxic control animals. 
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Figure 6.4 Carotid body leptin protein following IH. 
Western blots showing changes in leptin protein expression within the carotid 
body following IH with or without captopril (Capt; a-c) or losartan (Los; d) 
treatment. Note that captopril treatment lowered leptin levels within the carotid 
body in both normoxic (Norm) (a) and the IH (b) group. In addition, the decrease 
in leptin following captopril treatment was greater in the IH group compared to 
the normoxic group (c).  A similar decrease in leptin protein expression is 
observed following losartan treatment (d). *, significantly different from non-
captopril IH treated animals. 
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to about 58%, of those levels found within the IH non-captopril treated animals. In 
addition, when the effects of captopril (Fig. 6.4c) in the normoxic animals were 
compared to those in the IH animals, it was found that captopril lowered the 
leptin levels of the IH animals to about 60% of the normoxic captopril animals 
(Fig. 6.4c). Similarly, losartan significantly lowered carotid body leptin protein 
expression to IH (Fig. 6.5d; Table 6.1).   
 
6.4.5 Effect of IH on OB-Rb and OB-R100 protein expression within the 
carotid body following captopril or losartan treatment 
Captopril treatment in either the normoxic controls (Fig. 6.5a) or the IH exposed 
(Fig. 6.5c) animals resulted in a lower carotid body OB-Rb (Fig. 6.5a and 6.5c) 
protein levels (31% and 44%, respectively) compared to normoxic controls, while 
the protein expression levels of  OB-R100 (Fig. 6.5b and 6.5d) were increased to 
about 100% and 140% above the levels within the non-treated normoxic (Fig. 
6.5b) and IH (Fig. 6.5d) animals, respectively. Additionally, when the effects of 
captopril in the normoxic animals were compared to those of the IH animals (Fig. 
6.6a), it was found in the IH animals that captopril raised the expression levels of 
the OB-Rb protein to about 140% more than the normoxic controls. On the other 
hand, no differences were found with the expression of the OB-R100 protein (Fig. 
6.6b) between normoxic- and IH-captopril treated animals. In contrast, both OB-
Rb and OB-R100 protein expression were not altered in the IH group compared to 
the normoxic controls after treatment with losartan (Table 6.1).  
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Table 6.1 The effect of captopril or losartan treatment on ANG II receptors 
and leptin signaling molecules in the carotid body following IH. 
________________________________________________________________________ 
 
Treatment IH 
IH + 
Captopril 
IH + 
Losartan 
Protein 
 
(p value) (p value) (p value) 
  
  
 AT1R 
 
↑ 0.0129 ↑ 0.0138 0.9201 
AT2R 
 
0.4406 0.3641 0.4634 
Leptin 
 
↑ * ↓ 0.05 ↓ 0.0452 
OB-Rb 
 
↓* ↑ 0.0348 0.5232 
OB-
R100 
 
↑ * 
0.2471 
0.7864 
pSTAT3 
 
No Change * 0.2219 0.8345 
pERK1/2 
 
↑ * 0.246 0.2093 
SOCS3 
 
↑ * 0.28 0.3421 
________________________________________________________________________ 
All p values are in comparison to normoxic controls with captopril or losartan 
treatment. *, adapted from Messenger and Ciriello, 2013. 
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Figure 6.5 ObR isoforms following Capt in carotid body. 
Western blots showing changes in OB-Rb (a-b) and OB-R100 (c-d) protein within 
the carotid body following IH and captopril treatment. Note that captopril 
treatment lowered Ob-Rb protein levels within the carotid body in both normoxic 
(Norm) (a) and the IH (b) group. On the other hand, the protein levels of OB-R100 
were increased in both the normoxic (c) and the IH (d) groups. *, significantly 
different from non-captopril treated animals within each group. 
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Figure 6.6 ObR isoforms following Capt: IH vs. normoxic groups. 
Western blots showing changes in OB-Rb (a) and OB-R100 (b) protein within the 
carotid body following captopril treatment in both the normoxic and IH groups. 
Note that the protein level of Ob-Rb was significantly (*) lower in the IH animals 
compared to the normoxic animals (a) treated with captopril. 
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6.4.6 Effect of captopril or losartan on STAT3, pSTAT3, SOCS3 and pERK 
1/2 in the carotid body after IH 
Figures 6.7-6.11 summarize the effects of captopril treatment on carotid body 
protein expression of STAT3 (Figs. 6.7a-b and 6.8a), pSTAT3 (Figs. 6.7c-d and 
6.8b), SOCS3 (Fig. 6.9a-c), and pERK 1/2 (Figs. 6.10 and 6.11a-c; Table 6.1) in 
normoxic and IH exposed animals. Captopril treatment in normoxic animals 
resulted in decreased STAT3 protein expression (Fig. 6.7a) to about 47% of non-
treated group, whereas no differences were found between IH-exposed animals 
(Fig. 6.7b) or between normoxic and IH animals treated with captopril (Fig. 6.8a) 
or losartan (Table 6.1). Captopril treatment in normoxic and IH exposed animals 
also decreased pSTAT3 (52% and 49% of non-captopril treated animals, 
respectively) protein expression (Fig. 6.7c-d). However, STAT3 and pSTAT3 
protein levels in the IH-captopril treated animals were not different from those in 
the normoxic-captopril treated animals (Fig. 6.8; Table 6.1). Similarly, pSTAT3 
protein levels in the IH-losartan treated animals were not different from those in 
the normoxic-losartan treated animals (Table 6.1). 
Captopril treatment in normoxic and IH exposed animals increased 
SOCS3 protein expression within the carotid body (Fig. 6.9a-b). In normoxic 
animals, captopril increased the expression of SOCS3 protein by almost 1036% 
(Fig. 6.9a), while in the IH exposed animals captopril increased the expression of 
SOCS3 protein by about 2490% (Fig. 6.9b). However, the protein expression 
level of SOCS3 in the IH captopril treated animals compared to the normoxic 
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captopril treated animals was not different (Fig. 6.9c; Table 6.1). Similarly, 
SOCS3 protein levels in the IH-losartan treated animals were not different from 
those in the normoxic-losartan treated animals (Table 6.1). 
ERK1/2 and pERK1/2 protein levels were decreased (to about 48% and 
42% of non-captopril treated animals, respectively) following captopril treatment 
(Fig 6.10a and 6.10c).  On the other hand, neither ERK1/2 or pERK1/2 protein 
levels in the IH captopril treated animals were different from those in the non-
captopril treated IH exposed group (Fig, 6.10b and 6.10d) or from the normoxic 
captopril treated groups (Fig. 6.11). Similarly, ERK1/2 and pERK1/2 protein 
levels in the IH-losartan treated animals were not different from those in the 
normoxic-losartan treated animals (Table 6.1). 
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Figure 6.7 Changes in STAT3 following Capt 
Western blots showing changes in STAT3 (a-b) and pSTAT3 (c-d) protein within 
the carotid body following IH and captopril treatment. Note that captopril 
treatment significantly (*) lowered STAT3 protein levels within the carotid body 
only in normoxic (Norm) group (a). However, pSTAT3 levels were significantly (*) 
lower in both the normoxic (c) and the IH (d) groups after captopril treatment. 
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Figure 6.8 Changes in STAT3 following Capt: IH vs. normoxic groups 
Western blots showing changes in STAT3 (a) and pSTAT3 (b) protein within the 
carotid body following captopril treatment in both the normoxic and IH groups. 
Note that the protein level of pSTAT3 was significantly (*) lower in the IH animals 
compared to the normoxic animals (b) treated with captopril. 
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Figure 6.9 Changes in SOCS3 following IH and Capt treatment. 
Western blots showing changes in SOCS3 protein expression within the carotid 
body following IH and captopril treatment. Note that captopril treatment 
significantly (*) elevated SOCS3 protein levels within the carotid body in the 
normoxic (Norm) (a) and IH group (b). However, SOCS3 levels were significantly 
(*) lower in the IH captopril treated group compared to the normoxia captopril 
treated group (c). 
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Figure 6.10 Changes in ERK1/2 following IH and Capt treatment 
Western blots showing changes in ERK 1/2 (a-b) and pERK 1/2 (c-d) protein 
within the carotid body following IH and captopril treatment. Note that captopril 
treatment significantly (*) lowered ERK 1/2 and pERK 1/2 protein levels within the 
carotid body only in normoxic (Norm) group (a and c).  
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Figure 6.11 Changes in ERK1/2 following Capt: IH vs. normoxic groups 
Western blots showing changes in ERK 1/2 (a) and pERK 1/2 (b) protein within 
the carotid body following captopril treatment in both the normoxic and IH groups. 
Note that the protein levels were not altered in either group treated with captopril. 
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6.5 DISCUSSION 
These data provide the first direct evidence that ANG II plays an important 
role in the regulation of leptin not only within the carotid body, but also within the 
circulation during IH, and that within the carotid body ANG II through activation of 
AT1R contributes to changes in downstream leptin signaling during IH. These 
conclusions are based on the findings that within the carotid body, cells that 
expressed leptin and the OB-Rb also expressed the AT1R. Additionally, inhibition 
of ANG II by blocking ACE following captopril treatment decreased leptin not only 
within the carotid body, but also the plasma levels of leptin during IH. 
Furthermore, the decrease in available leptin to the carotid body was 
accompanied by an increase in the OB-Rb protein expression in captopril treated 
animals, but no change in the losartan treated animals. This coupled with the 
lower carotid body levels of leptin during IH in the captopril and losartan treated 
animals suggests a dampening of the entire leptin signaling system within the 
carotid body by the lack of ANG II and activation of AT1R. This suggestion is 
consistent with the observation that both captopril and losartan treatment 
resulted in an inhibition of the downstream mediators of leptin signaling within the 
carotid body following IH. Finally, contrary to the increase in OB-Rb protein 
expression levels following captopril treatment, OB-R100 protein levels in the 
carotid body were increased suggesting either an increase in transport of leptin 
out of cells or an increase in leptin degradation within the cells. Taken together, 
these data can be interpreted to suggest that ANG II effects on carotid body 
chemosensitivity may be mediated in part through the activation of the carotid 
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body leptin system, and that ANG II signaling is also critical for the maintenance 
of circulating levels of leptin in normoxia and during IH.  
The finding that ANG II influences leptin activity and requires functional 
leptin receptors is supported by the observation that AT1R blockade results in a 
decreased body mass index and food intake, but has no effect in obese Zucker 
rats with a genetic mutation in the leptin receptor (Muller-Fielitz et al., 2011). In 
addition, it has been shown that the brain RAS facilitates renal and brown 
adipose tissue sympathetic nerve responses to leptin (Hilzendeger et al., 2012). 
However, the finding that plasma leptin levels induced by IH are not altered after 
losartan treatment, whereas carotid body leptin is inhibited suggests that not all 
leptin effects are mediated by the selective activation of the ANG II AT1R. 
The finding of a decrease in circulating leptin following ANG II inhibition is 
consistent with earlier data suggesting that ANG II signaling stimulates not only 
leptin production, but also leptin secretion (Cassis et al., 2004; Premaratna et al., 
2012). Considering that the main production/secretion site of leptin into the 
plasma is adipose tissue (Lonnquist et al., 1996; Caro et al., 1996), this study 
provides further supports the suggestion that the leptin system may be in part 
under the control of ANG II. This latter suggestion is also consistent with the 
observation in a mouse model deficient in the AT1Ra isoform, in which plasma 
leptin concentrations were found to be reduced when compared to wild-type 
(Kaneko et al., 2011).  
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Carotid body leptin levels were also found to be decreased in animals 
treated with captopril during both normoxia and IH conditions. This finding is 
similar to that observed within adipocytes taken from rats treated with captopril, 
in which both circulating leptin and leptin release was decreased (Cassis et al., 
2004). Additionally, incubation of adipocytes with ANG II resulted in an up-
regulation of leptin mRNA, as well as leptin secretion (Cassis et al., 2004) while 
in ventricular myocytes, ANG II promotes de novo synthesis and secretion of 
leptin (Rajapurohitam et al., 2006). Furthermore, blocking OB-Rs in these 
cardiomyocytes prevented the hypertrophic effects ANG II normally has on these 
cells suggesting that leptin may mediate effects normally attributed to direct ANG 
II action (Rajapurohitam et al., 2012). Finally, in human vascular smooth muscle 
cells, it has been previously found that increased ANG II results in increased 
leptin protein and mRNA expression (Shyu et al., 2012). Thus, it is not 
unreasonable to suggest that leptin may be involved in mediating some of the 
changes in carotid body chemosensitivity normally attributed to ANG II (Gomez-
nino et al., 1990; Eyzaguirre and Zapata, 1968; Bock, 1980).  
Interestingly, the increased leptin protein and mRNA expression observed 
in human vascular smooth muscle cells as a result of the elevated ANG II has 
been attributed to increases in reactive oxygen species (Shyu et al., 2012). The 
IH induced changes in the carotid body chemosensitivity have been suggested to 
be related to an enhanced reactive oxygen species production (Pawar et al. 
2009; Iturriaga et al., 2009). In addition, the IH effects associated with increases 
in superoxide have been shown to be blocked by losartan, a specific AT1R 
254 
 
blocker (Marcus et al., 2010). Therefore, taken together, these data suggest a 
possible mechanism by which ANG II signaling may modulate ROS activity and 
subsequently leptin activity within the carotid body. 
Captopril treatment in both normoxia and after IH reduced protein levels of 
OB-Rb compared to their respective controls. This finding suggests that ANG II 
plays an important role in the regulation of Ob-Rb, although due to the low levels 
of available leptin both locally and from the circulation following captopril 
treatment, ligand-induced endocytosis seems unlikely (Bennett et al., 1998; 
Uotani et al., 1999). The short-form leptin receptor displayed increased levels of 
protein expression in the carotid bodies following captopril-treated animals in 
both the normoxic and IH conditions. Generally, OB-Ra is believed to be involved 
in leptin transport, specifically across the blood-brain barrier (Banks et al., 1996; 
Golden et al., 1997; Bjorbaek et al., 1998). One potential explanation may be that 
the reduced leptin availability stimulates OB-Ra protein expression to aid in leptin 
secretion from glomus cells. Additionally, the OB-Ra has been suggested to 
function in the degradation process of leptin (Iida et al., 1996; Merabet et al., 
1997; Sharma et al., 1997) and may provide one mechanism through which the 
decreases seen in carotid bodies occurs. However, the functional significance of 
ANG II effects on Ob-Ra is unknown.  
The lower protein levels of leptin and OB-Rb in the carotid bodies after 
captopril treatment is consistent with the decreases in activation of STAT3. In 
normoxic and IH conditions, captopril treatment reduced pSTAT3 levels, a 
downstream signaler involved in OB-Rb activation (Elmquist et al., 1997; 
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Fruhbeck, 2006; Wang et al., 1998; Huo et al., 2006, 2007). The down-regulation 
of both the ligand and the receptor would be expected to result in a decrease in 
activation of the signaling pathway (Elmquist et al., 1997; Fruhbeck, 2006; Wang 
et al., 1998; Huo et al., 2006, 2007). One other potential explanation for the 
decrease in pSTAT3 levels found in captopril treated animals is the decrease in 
ANG II levels as ANG II signaling, through AT1R, can activate the JAK/STAT 
pathway resulting in phosphorylation of STAT3 (Ji et al., 2012; Omura et al., 
2001). However, it has also been shown that leptin injections resulted in up-
regulation of pSTAT3 protein expression (Messenger et al., 2012), and thus this 
decrease after ANG II inhibition most likely occurs at least in part through 
decreased leptin signaling. 
Consistent with the decrease in pSTAT3 is the concomitant rise in SOCS3 
levels.  SOCS3 acts as a negative feedback loop on JAK/STAT signaling 
(Bjorbaek et al., 2000; Fruhbeck et al., 2006). The decrease in pSTAT3 
accompanied by the SOCS3 rise would be expected in the IH condition, which 
has previously been shown to stimulate the JAK/STAT pathway (Messenger et 
al., 2012; Messenger & Ciriello, 2012). In some cell types, ANG II has been 
known to stimulate the JAK/STAT pathway which results in increased SOCS3 
expression (Calegari et al., 2003; Ji et al., 2012; Omura et al., 2001). However, 
as to the reason why such a profound increase was found in both the normoxic 
and IH condition is unknown.  
In addition to the JAK/STAT pathway, OB-Rb signaling can also activate 
the MAPK cascade (Bjorbaek et al., 1997; Banks et al., 2000) and thus activation 
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of ERK1/2 is an indicator of pathway activation. In normoxic animals, captopril 
treatment resulted in a decrease in pERK1/2 protein levels, however no changes 
were observed in the IH animals. This finding suggests during IH, other 
mechanisms in addition to leptin (Bjorbaek et al., 1997; Banks et al., 2000) or 
ANG II (Li et al., 1998; Nakai et al., 2012) may activate ERK1/2.  
In summary, this study has demonstrated that the RAS modulates the 
leptin system not only in the circulation, but also within the chemosensitive 
carotid body. Inhibition of ANG II by ACE results in a dampening effect on 
circulating leptin levels as well as local carotid body leptin protein levels. There is 
also a decrease in the OB-Rb and downstream indicators of OB-Rb activation, 
and this appears to be mediated through an interaction with the activation of the 
AT1R. Angiotensin signaling through the AT1R is critical for this chemosensitivity 
by the carotid bodies (Marcus et al., 2010), and given its co-localization with OB-
Rb and leptin within the glomus cells suggests that AT1R has a stimulatory effect 
on the carotid body leptin system and ANG II chemosensitive role may be 
mediated in part through leptin signaling.  
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7.         CHAPTER 7 
7.1 SUMMARY OF MAJOR FINDINGS 
This thesis examined the effects of intermittent hypoxia (IH) exposure on 
physiological responses related to energy balance and cardiovascular regulation 
in rats. Physiological alterations were observed following both acute and chronic 
exposure to IH, and included changes in neural pathways associated with these 
physiological systems. The role of leptin signaling in these pathways was an 
underlying theme, and was altered in both acute and chronic models, an 
important factor in mediating many of the observed effects. 
In Chapter 2 of this thesis, I wanted to evaluate alterations in body energy 
balance associated with exposure to acute IH. This study was performed given 
that chronic models of IH have significant, detrimental metabolic alterations and 
that OSA patients also present with altered metabolism and body energy balance 
(Martinez et al., 2008; Dempsey et al., 2010). The role of leptin in these major 
changes was also determined using a leptin-deficient transgenic rat in Chapter 3. 
These KILO animals have the leptin gene removed through zinc-finger nuclease 
technology (Vaira et al., 2012). Body energy balance is significantly altered in 
wild-type rats exposed to IH, displaying a negative body energy balance, 
including body weight loss likely due to decreased food intake. Interestingly, the 
body energy expenditure appeared to be reduced in these animals, given that 
food conversion efficiency and locomotion were both decreased compared to 
normoxic controls. These alterations were associated with a significant elevation 
in circulating leptin, concomitant with reduced adipose leptin content. Circulating 
266 
 
adiponectin was reduced, whereas adipose adiponectin content was elevated. 
Leptin:adiponectin ratio was elevated in animals exposed to IH, as a result. The 
ARC of animals was isolated and protein expression of pSTAT3 was shown to be 
higher in animals exposed to IH, suggestive of activation of a cytokine receptor 
dependent on the JAK2/STAT3 signaling pathway. POMC was also higher in the 
ARC of IH animals, and this was mirrored by an increased number of POMC 
cells expressing immediate early gene product immunoreactivity. When leptin-
deficient KILO rats were used, none of these differences were observed between 
IH and normoxic exposed animals, suggesting that leptin is a necessary 
component of mediating the body energy balance phenotype in animals exposed 
to IH. 
Since the role of leptin in mediating the effects of IH on body energy 
balance appeared to be critical, we looked at the role of chronic IH in body 
energy balance and whether a state of leptin resistance could potentially be 
induced in Chapter 4. Certainly animals exposed to 95 days of IH had reduced 
body weight compared to controls, but by the end of the study period, animals 
exposed to IH were gaining no more body weight than at the start of the period, 
compared to a reduction in body weight gain in controls, an effect mirrored by 
energy utilization. These changes were concomitant to an elevation in food 
intake in CIH animals over the study period, whereas normoxic animals had a 
significant reduction in food intake over the same time. This may be suggestive 
of a physiological manifestation of leptin resistance. Leptin sensitivity was 
measured directly, and it was shown that CIH animals were resistant to leptin 
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compared to normoxic controls. Animals had elevated leptin/epididymal fat pad 
mass, an important factor given the alterations observed in body energy balance. 
No changes in locomotion were observed. CIH animals exhibited no differences 
in the protein expression level of neither ObRB, nor ObR100, nor pSTAT3, 
though pERK1/2 was curiously elevated. POMC protein was decreased and 
SOCS3 increased in the ARC, suggesting that leptin resistance may occur 
following CIH through SOCS3 induction, and POMC is reduced as a result of the 
decreased leptin signaling. This study suggests that IH may be able to induce a 
state of positive body energy balance over long-term exposures. 
In Chapter 5, the role of acute, short-term and chronic IH on hemodynamic 
measures were assessed and associated with neuroplastic alterations within the 
NTS region of the brainstem. Hypertension without concomitant alterations in 
heart rate was observed in animals following 95 days of IH, but not at any other 
time point. The basal gain of the baroreflex was also reduced following this 
exposure. It was observed that specific alterations in the TrkB-BDNF signaling 
system change over time, which may be the result of differential leptin signaling. 
Interestingly, the amount of synaptophysin within the NTS region was reduced 
following IH, indicative of a loss of synapses within the region. However, in acute 
IH this effect was still observed in KILO leptin-deficient animals, suggesting leptin 
does not play a role in this effect. The neurite growth factor GAP-43 was reduced 
following CIH, suggesting a potential reduction in cardiorespiratory afferent 
neurites or potential for neurite sprouting within the NTS region. We believe this 
may be a novel mechanism mediating hypertension following IH, an effect 
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supported by other groups observing a reduction in glutamatergic synapses 
following IH (Almado et al., 2012). 
Finally in Chapter 7, the role of angiotensin II in mediating leptin signaling 
within the carotid body following IH was assessed. This was done by exposing 
animals to acute IH following angiotensin converting enzyme (ACE) inhibition or 
blockade of the type 1 angiotensin II receptor (AT1R), and served as a follow-up 
to initial findings describing the effects of acute IH on leptin signaling in the 
carotid body (Messenger and Ciriello, 2013). Here, we show that leptin protein 
within the carotid body is reduced in animals exposed to IH compared with 
controls in both conditions of reduced angiotensin II signaling. The treatments 
also prevented all the alterations observed in leptin signaling within the carotid 
body following IH under sham conditions, suggesting that angiotensin II plays a 
critical role in mediating the effect of leptin at the carotid body during IH. 
Likewise, it was observed that circulating leptin concentrations were not different 
in IH animals following ACE inhibition, but were elevated during AT1R blockade 
following IH, similar to sham animals. This suggests that leptin secretion 
following IH is dependent on angiotensin II acting through non-AT1Rs. 
 
7.2 LIMITATIONS AND FUTURE STUDIES 
The animal model of IH used in these studies under both acute and chronic 
exposures is a sleep-independent model, which is applied during the rest phase 
of the sleep/wake cycle of the rats used. Due to the sleep-independent nature of 
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this exposure, it could be that for some short periods of time animals were being 
exposed to IH while actually awake. The effect this may have on the outcomes of 
these studies is not known, but may be negligible since studies using IH 
exposure during an aroused state in humans showed effects consistent with that 
observed in patients with obstructive sleep apnea (OSA; Louis and Punjabi, 
2009). Likewise, alterations in oxygen availability in patients with OSA may 
persist throughout the waking hours (Shiota et al., 2013).  
 In addition to potential inconsistencies of hypoxia between the model of IH 
utilized and OSA, it has previously been shown that rodents exposed to IH 
experience an elevated ventilator response, resulting in eucapnea and no 
alterations in intrathoracic pressure (Fletcher et al., 1992). In patients with OSA, 
both hypercapnemia and reductions in intrathoracic pressure similar to that seen 
in the Muller manoeuvre have been noted during apnea (Dempsey et al., 2010). 
This is the result of difference between the inductions of IH experimentally and 
clinically. In the model of IH, environmental oxygen levels are altered, but the 
airway of the animal or subject remain intact. This occurs without a change in 
environmental pressure or carbon dioxide, and thus breathing is free to go 
unimpeded and without any change in carbon dioxide within the lungs. In 
contrast, a reduction in airway flow during OSA results in reduced gas exchange 
and unsuccessful attempts to breathe during apnea (Dempsey et al., 2010). 
Since these models do not mimic OSA, but rather the specific IH component of 
OSA, is precisely the reason that models of IH are not described as models of 
OSA, and so differences between the model and the disease are important to 
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take into consideration. Despite this, it is believed that the cardiovascular and 
metabolic responses in OSA are largely due to the observed IH. The 
neurocognitive components appear to be largely due to disruption in sleep 
architecture and IH. Interestingly, it has been determined in rodent models that 
hypercapnea does not alter responses to IH (Dempsey et al., 2010). 
 Despite the overwhelming contributions of IH in exploring mechanistic and 
causal roles of OSA-induced IH to other disease states, there are other 
unresolved issues in modelling OSA with current IH models. The most important 
of which, is the sudden nature of IH exposure. OSA is a chronic, progressive 
disease that can persist for a significant portion of an individual’s life. Most 
current models of CIH involve exposing rodents to IH with an apnea-hypopnea 
index (AHI) within the moderate-severe range immediately. This massive change 
in oxygen availability is likely a massive insult to the homeostasis of an animal, 
and does not mimic what is observed in OSA. In an attempt to resolve this issue, 
I have proposed a model of CIH that includes a progressive component, 
increasing hypoxic exposure to a plateau level that coincided with that normally 
exposed in our CIH model. This so-called ramped IH model consists of starting 
animals with an AHI of 1 event/h, with progressive steps of AHI by 1 event/h 
every four days. Animals are then exposed to CIH in the plateau phase for 28 
days, for a total hypoxic exposure of 96 days (on par with our 95 day CIH model). 
I believe this model will allow for appropriate adaptation in neural signaling 
networks, such as the carotid body afferent system and sympathetic and phrenic 
efferent systems. This model must be further studied to validate these claims, 
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and determine the appropriateness for use in better modelling the chronic, yet 
dynamic exposure to IH experienced in OSA. On this topic, it may also be 
advisable that models of CIH be utilized for longer time periods. Given that 
rodents exposed to 95 days IH developed leptin resistance and had small initial 
alterations in food intake and body weight changes, it would be better suited to 
observe these models over long periods of time to determine the 
pathophysiological manifestation of obesity and/or metabolic syndrome. As well 
other, currently unstudied pathologies and their association to CIH such as heart 
failure and sudden cardiac death could also be studied over longer exposure 
times.   
 
7.3 SIGNIFICANCE OF RESEARCH AND CONCLUSIONS 
OSA represents a significant disease burden to both patients and healthcare 
systems globally. Given the associations of OSA with other diseases such as 
obesity and cardiovascular disease, the time has come to determine the true role 
OSA has in mediating mechanisms that lead to, and are part of, these deadly 
disease states. Understanding the factors that link these diseases is important for 
1) an understanding of the importance of diagnosing and treating OSA, 2) 
mechanisms which may be targeted by OSA treatment, 3) the development of 
novel treatment approaches to OSA, and 4) the development of novel treatment 
approaches for OSA-related pathologies. 
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 Clinical studies have shown that obesity is an important risk factor for the 
development of OSA, and patients with OSA tend to gain weight compared to 
normal individuals (Phillips et al., 2000). Likewise, OSA patients have more 
trouble losing weight than normal individuals. These findings form the basis for a 
bidirectional relationship between OSA and body weight gain. For the first time, 
body energy balance within animals has been assessed in a model of CIH. My 
study has shown that a primary and potentially causative hallmark of obesity is 
induced by CIH. In this study, leptin resistance occurs despite a reduction in body 
weight gain, though is accompanied by an increase in food intake over the 
exposure time, compared to controls. This may provide a mechanism by which 
body weight gain and obesity could be induced by the CIH observed in patients 
with OSA. Likewise, most of the short-term effects of IH on body energy balance 
are due to leptin signaling. This is concomitant to the finding that hypoxia and 
OSA in humans increases circulating leptin. Acute IH causes changes such as 
an alteration in leptin:adiponectin ratio, which is believed to be an important 
variable in cardiovascular disease development (Kappelle et al., 2012), though 
this measure has not been assessed in OSA patients. 
 Another common comorbidity with OSA is hypertension. My studies 
suggest a potential novel mechanism by which neuroplastic alterations in the 
nucleus of the solitary tract is associated with hypertension in animals exposed to 
IH. The development of hypertension in patients with OSA is often described as 
resistant in nature. This suggests that classical mechanisms of blood pressure 
elevation, which are largely targeted by drugs, are not likely the mechanisms 
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mediating the hypertension-inducing effects of OSA. Instead, new approaches to 
hypertension must be addressed in complicated forms of secondary resistant 
hypertension, such as the one induced by the CIH model. It cannot be ruled out 
that selective leptin resistance, which permits the activity of the hypertensive 
effects but inhibits the satiety effects of leptin, played a role in mediating this 
hypertension. Likewise, the alterations observed in neuroplastic markers, 
especially considering that leptin deficient animals do not develop the same 
alterations in some of the markers of neuroplasticity, may also be the result of 
leptin acting selectively in this area to drive blood pressure. Nonetheless, these 
potential pathways warrant a closer look in additional studies to determine the 
role of these changes following IH in hypertension. 
 Finally, in Chapter 4 of this thesis I have shown that leptin signaling 
pathways within the carotid body are regulated by the AT1R, while the IH-
dependent release of leptin is regulated by angiotensin II through non-AT1R. The 
clinical relevance of this data is not obvious, but these effects may be important 
in suggesting a role for a complex interaction between leptin and angiotensin II 
both peripherally and specifically within the carotid body. The functional effects of 
this interaction are unknown, but it is known that angiotensin II is an important 
modulator of the carotid chemoreceptor reflex (Marcus et al., 2010), and so leptin 
may interact with this to potentiate hypoxic responses. This is important, as data 
suggest a potentiation of carotid body signaling and sympathetic nervous drive 
following exposure to IH (Dick et al., 2007). 
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Collectively, the studies in this thesis provide many new avenues for 
research into cardiometabolic diseases associated with IH exposure, presumably 
to determine mechanism of diseases associated with OSA. Addressing these 
mechanisms may provide novel therapeutic targets in addressing the disease 
burden associated with OSA. This disease burden will become increasingly 
important as OSA increases in prevalence within our population. 
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